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Abstract 
The Leucine Rich Repeat kinase 2 (LRRK2) G2019S mutation is the most 
common genetic cause of Parkinons's disease (PD) which is clinically and 
pathologically indistinguishable from idiopathic PD. The effects of the G2019S 
mutation were explored in primary fibroblasts and SHSY5Y cells expressing wild type 
or G2019S LRRK2. LRRK2 was predominantly in the cytosol and small vesicular 
fraction of lymphoblasts and SHSY5Y cells with some localized to the mitochondria in 
overexpressing cells. While we could detect LRRK2 in various mouse and marmoset 
brain regions LRRK2 protein levels were higher in fibroblast and lymphoblast 
cultures. LRRK2 cellular distribution, mRNA and protein expression were not 
affected by the mutation.  
Mitochondrial abnormalities are a common feature in PD. To determine 
whether mitochondrial function is compromised in mutant cells, a detailed 
bioenergetic assessment was carried out on both G2019S cell models. An increase in 
basal and oligomycin inhibited respiration rates, reduced mitochondrial membrane 
potential and cellular ATP levels was observed for G2019S fibroblasts with similar 
changes observed in the neuroblastoma G2019S model. Respiratory rates and 
membrane potential were restored with LRRK2 kinase inhibition. Our data is 
consistent with reversable uncoupling of oxidative phosphorylation. 
Investigating transcriptional levels of mitochondrial uncoupling proteins 
(UCP) identified a G2019S dependent increase in UCP2 and 4 in fibroblasts and 
SHSY5Y cells. Upstream of this transcriptional event, an interaction between LRRK2 
and the negative regulator of PGC1α expression, HDAC5 was investigated for both 
the wild type and G2019S protein. 
We have identified a role for endogenous LRRK2 in regulating mitochondrial 
bioenergetics with a kinase dependent gain of function for the G2019S mutation 
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consistent with partial uncoupling of oxidative phosphorylation. LRRK2 G2019S 
enhanced the HDAC5 association which may be responsible for increased PGC1α 
expression and the downstream UCP transcription linked with the observed 
mitochondrial phenotype.  
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Chapter 1: Introduction 
1.1.1 Basal Ganglia and Parkinson’s Disease 
Parkinson’s disease (PD) is the second most common neurological disorder 
affecting approximately 2% of the population over the age of 60 and 4% over 80 
years [1]. Clinical motor PD abnormalities are thought to result predominantly from 
the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). 
Dopamine (DA) is a catecholamine, and the primary function of this modulatory 
neurotransmitter is to serve as the reinforcement signal for the learning and 
maintenance of adaptive behaviours. Introducing a stimulus to the striatum, nigral 
dopamine regulates striatal output to the thalamus through the intricate circuitry of 
the basal ganglia [2] (Fig 1.1, adapted from [3]).The pathophysiology and resulting 
clinical manifestation in PD is thought to arise as a result of striatal dopamine 
depletion, increased neuronal activity in the output nuclei of the basal ganglia and 
inhibition of thalamocortical responses. Suppression of thalamic neurons is required 
to maintain control of unwanted physical movements. Typical symptoms of 
hypokinesia, akinesia and bradykinesia develop due to this shift in basal ganglia 
function towards inhibitory cortically aided movements. The resulting loss of 
regulatory control leads to deterioration of simultaneous and repetitive movements 
with a decrease in amplitude of repetitions [4]. Tremor and rigidity seem to result 
from altered oscillatory activity in the basal ganglia circuitry, due to 
desynchronization of positive and negative regulatory pathways [5]. At the time of 
clinical manifestation it has been estimated that about 50-80 % of nigral 
dopaminergic neurons have been lost potentially accounting for the motor deficit. 
As well as regulation of motor function, the basal ganglia have been 
proposed to have a role in cognitive control [6], potentially explaining the cognitive 
malfunction in later stages of PD, although this could also be due to spread of PD 
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pathology to cortical areas (section 1.1.2). Cognitive symptoms are linked to the 
deterioration of cortical neurons in progressive disease stages. As well as motor and 
cognitive defects, affected subjects often develop autonomic disturbances. 
Gastrointestinal, cardiovascular and urogenital systems, under the control of 
cholinergic, noradrenergic and serotonergic nuclei can suffer, emphasising the 
contribution of other cell populations to the disease [5].  
 
 
1.1.2 Pathology in PD 
The pathological hallmarks of Parkinson’s disease are Lewy bodies and 
dystrophic neurites. Lewy bodies are proteinaceous, cytoplasmic inclusion 
composed primarily of aggregated α-synuclein protein and positively 
immunoreactive for ubiquitin [7] while dystrophic neurites appear as damaged 
projections of affected cells. According to the Braak hypothesis of PD transmission, 
the progressive pathology in PD is thought to occur as a result of pathological spread 
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from the brain stem to cortical regions potentially accounting for the motor deficit 
and delayed cognitive decline. This transmission has been subdivided into six stages, 
characterized by the appearance and spread of the neuropathological hallmarks (Fig 
1.2, adapted from [8]). Pathology is initially confined to the olfactory bulb and lower 
brainstem regions, spreading up to the locus coeruleus in stage II of PD. Clinical 
symptoms are thought to occur in stage III where Lewy neurites, α-synuclein 
aggregates and Lewy bodies can be detected in SNpc. Stage IV comes with nigral cell 
loss and spread to the hippocampal and basal forebrain areas. Neocortical Lewy 
body pathology occurs in stage V, confined primarily to the temporal regions and 
continues to spread in stage VI of the disease [5].  
Pathological diagnosis in PD requires depigmentation of the substantia nigra 
as a result of neuronal cell loss and presence of Lewy bodies in post mortem brain 
tissue to accompany the clinical motor abnormalities [9]. However, ‘parkinsonian’ 
phenotypes are not solely restricted to PD with features of idiopathic parkinsonism 
(IPD) found in a wider spectrum of movement disorders [10]. Furthermore, a clinical 
diagnosis of PD does not always correlate with the pathological requirements. In 
particular, juvenile onset recessive forms of the disease (section 1.2) present with 
more atypical clinical features that closely resemble dystonia [11]. In these cases, 
disease progression is slow and pathology variable. Autosomal dominant PD (section 
1.2.) can differ in pathology even between family members carrying the same 
genetic mutation with Lewy body positive cases reported as well as those with tau, 
β-amyloid deposits (hallmark of Alzheimer’s disease (AD)) and ubiquitin positive 
inclusions [12]. Variable neuropathology in PD indicates the potential involvement of 
multiple cellular pathways in the disease pathogenesis which may or may not 
converge to produce a common clinical phenotype. 
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1.2 Causative factors in PD 
The etiology of the disease is unknown. Idiopathic forms of PD are thought 
to result from variable contributions of genetic and environmental origin, with rare 
cases caused solely by one or the other factors. Gene linkage analyses and positional 
cloning have identified specific mutations which confer a familial link in 
approximately 10 % of all PD cases [13]. The genes identified can be subdivided into 
two groups based on their inheritance pattern; autosomal dominant and autosomal 
recessive.  
1.2.1.1 Autosomal dominant PD genes: α-synuclein 
 The genetic link between α-synuclein and Parkinson’s disease was first 
identified in 1996 for a large Greek/Italian kindred with a mean age of onset of 55 
years [14]. A year later, the G209C mutation (A53T) was described in the α-synuclein 
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gene located on chromosome 4 for this cohort [15]. Additional familial linkages in 
the α-synuclein gene were found as point mutations at positions 88 (G to C 
substitution, A30P mutation) in a German kindred and position 188 in a Spanish, 
Basque family (G to A substitution, E46K mutation) [16]. In addition, families carrying 
duplications (French cohort) [17] and triplications (Iowa cohort) [18] of the α-
synuclein gene have been reported suggesting that cellular levels of the protein 
correlate with PD onset, progression and severity. Furthermore, genome-wide 
association studies generated from large cohorts of idiopathic PD patients suggest 
that α-synuclein sequence polymorphisms are a risk factor for the disease, in 
support of the gene linkage data [19-21].  
Inherited α-synuclein mutations result in similar clinical phenotypes of L-
dopa responsive parkinsonism but appear more aggressive when compared to 
idiopathic cases. Clinical features and pathology of point mutation and duplication 
α-synuclein cases fall into the spectrum of PD variations, clinically diagnosed as 
dementia with Lewy bodies (DLB) due to their progressive cognitive deficits [16, 22]. 
Lewy body pathology was identified for each familial α-synuclein case.  
α-synuclein is an intrinsically disordered 14 kDa protein highly abundant in 
the brain [23, 24]. Structurally, α-synuclein is capable of conformational changes 
which govern its membrane binding properties and aggregation propensity [25, 26].  
1.2.1.2 Autosomal dominant PD genes: Leucine Rich Repeat Kinase 2 
Sequence analysis of large Japanese families identified a heritable 
component in the PARK8 locus on chromosome 12 (12p11.2-q13.1) [27]. 
Subsequently, Leucine Rich Repeat Kinase 2 (LRRK2) pathogenic mutations within 
linked families were mapped for North American (R1441C) and European (Y1699C) 
kindreds as well as a small German family (I2020T) [28]. In parallel, families and 
sporadic PD cases from the Basque country in Spain were identified to harbour 
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LRRK2 R1441G mutations while British families were linked to Y1699C substitutions 
by the same group [29].  
Subsequent identification of the G2019S mutation spurred interest in the PD 
research field due to its high frequency in specific populations and association with 
the ‘classical’, late onset sporadic PD. First reports of G2019S came from two 
unrelated Caucasian families of North American-British and Ashkenazi Jewish 
ancestry [30]. Reports of 13 individuals from a variety of ethnic backgrounds (North 
America, Norway, Ireland and Poland) sharing a common disease associated 
phenotype, confirmed G2019S occurence in sporadic PD [31]. Population studies 
determined greatest G2019S prevalence in the Ashkenazi Jew and North African 
Arabs, identified in 27.9 %, and 30 % of all PD cases from these regions respectively 
[32, 33] with lower incidence in North American (7 % [34]) and European (6.6 % [35]) 
cohorts. In control groups, the highest frequency of G2019S was reported in Israel 
(2.4 %) and Arab Berber Tunisians (2 %) [32, 36]. Haplotype analysis of 
demographically distinct populations identified a common ancestrial founder [37]. 
More recently LRRK2 has been implicated in the disease through genome-wide 
association studies of idiopathic PD patients in the UK and Japanese cohorts [19, 20].  
In humans and rodents a paralogous gene to LRRK2 has been identified 
sharing 26 % sequence identity termed Leucine Rich Repeat Kinase 1 [38]. However, 
PD associated mutations in the LRRK1 gene have not been described. 
The number of reported autopsies for all the mutant LRRK2 PD cases totals 
38 [12]. Lewy bodies and dopaminergic cell loss have been identified in association 
with all established pathogenic mutations. Lewy bodies are generally described in 
the brain stem, cortex and the limbic system. A number of studies reported pure 
nigral degeneration free from Lewy bodies associated with LRRK2 [39] however, 
these cases are rare. Additional features include neurofibrillary tangles with the 
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degree of plaques and tangles in G2019S cases ranging from levels compatible with 
normal ageing to densities observed in demented Alzheimer’s disease patients [40]. 
Clearcut tauopathies have been noted for some R1441C and G2019S cases [12]. 
Although heterogeneity can be observed in mutant LRRK2 PD, in general, 
pathological hallmarks are comparable to those found in idiopathic disease [41]. 
1.2.1.3 Autosomal recessive PD genes: Parkin 
Japanese families found to contain deletions in the PARK2 gene on 
chromosome 6, led to the discovery of parkin as a causative risk gene for autosomal 
recessive juvenile PD [42]. Loss of parkin protein function due to autosomal 
recessive familial gene deletions have been found in European families however, 
missense mutations, resulting in partial or complete loss of function, are more 
common among the Caucasian haplotypes [43]. Single allele mutations, inherited in 
an autosomal dominant manner have also been identified and seem to infer a risk 
factor for the disease [44]. 
Unlike sporadic PD, PD cases associated with loss of parkin function have an 
early onset and slow disease progression with good responses to dopamine 
replacement therapy [42-44]. Furthermore autopsies of parkin PD patients rarely 
show evidence of Lewy body pathology suggesting a distinctive cause for this 
subtype of PD [45]. 
The 50 kDa protein encoded by the parkin gene is a ubiquitin protein ligase 
with a RING finger domain [42]. 
1.2.1.4 Autosomal recessive PD genes: PINK1 
First identified in three consanguineous Sicilian families, loss of function 
mutations in the Phosphatase and Tensin (PTEN) induced kinase (PINK1) gene 
located on chromosome 1 were shown to cause autosomal recessively inherited PD 
[46]. Subsequently, the PINK1 homozygous L347P and a compound heterozygous 
 36 
 
G240L/L489P were identified in Filipino families [47]. Mutations in PINK1 are 
infrequent when compared to familial parkin cases. Similar to parkin, heterozygous 
PINK1 mutations have been identified as a risk factor for PD [48]. In addition, PINK1 
mutations have been found in sporadic PD subjects [49].  
Clinical features of PINK1 PD present with early onset parkinsonism with 
slow disease progression, good levodopa response and bradykinetic symptoms 
mimicking that of parkin PD. Although only a few cases have been presented at 
autopsy, PD patients with PINK1 mutations have been described with Lewy body 
deposits [50].  
Intracellular proteolytic processing of full length 63 kDa PINK1 generates 
two additional forms of the protein; 54 kDa and 10 kDa respectively [51]. The 
enzymatic domain in PINK1 has putative kinase characteristics although 
physiological phosphorylation substrates have not yet been identified.  
1.2.1.5 Autosomal recessive PD genes: DJ1 
PD associated mutations in DJ1 were first identified in the PARK7 gene, 
located on chromosome 1 in two consanguineous families from Italy and the 
Netherlands. Patients from the Dutch family carried a gene deletion while Italian 
subjects encoded a single base substitution (L166P) resulting in a loss of function 
protein [52]. DJ1 mutations are rare in PD, however, the clinical phenotype of DJ1 
patients resemble those found in other early onset, recessively linked PD cases [45]. 
No neuropathology in PARK7 cases has been reported to date.  
The 20 kDa DJ1 protein exists as a dimer formed by a disulphide bond 
between two monomeric molecules. The potential for free radical oxidation of DJ1 
cysteine residues labelled the protein as a redox sensing molecule [53].  
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1.2.1.6 Autosomal recessive PD genes: Glucocerebrosidase 
The glucocerebrosidase (GCase) gene located on 1q21-22, spanning 11 
exons, has been reported to have >300 mutations associated with Type 1-3 
Gaucher’s disease, a lysosomal storage disorder. In addition, heterozygous 
mutations within the GCase are the most common risk factor for sporadic 
Parkinson’s disease [54]. Mutation penetrance can vary between ethnic groups 
observed at high frequency for Ashkenazi Jews [55] and low frequency in European 
cohorts [56]. Initially regarded as a risk factor rather than a mendelian form, 
identification of familial links has provided the criteria to label GCase as an 
autosomal recessive PD gene [57, 58]. 
Clinically, parkinsonian symptoms in GCase PD cases occur with early onset 
relative to idiopathic disease and typical Lewy body pathology has been described 
for the limited number of cases inspected at autopsy [59]. 
The GCase protein, synthesised in endoplasmic reticulum (ER) 
polyribosomes is targeted to the lysosome following peptide cleavage and N linked 
glycosylation. Polyubiquitination of GCase facilitates ER exit. In the lysosomal 
compartment, GCase functions to break down the lipid glucoceramide into glucose 
and ceramide [60]. Some of the most common GCase mutations are reported to trap 
GCase in the ER depleting the lysosomal GCase pool [61].  
1.2.2 PD genetic models 
The discovery of familial PD genes led to the development of genetic PD 
animal models in an attempt to recapitulate the clinical features and pathology of 
PD and dissect the mechanism of disease pathogenesis. Although α-synuclein 
transgenic mouse models have frequently been shown to develop motor 
abnormalities correlating with a reduction in dopamine transmission and α-
synuclein positive inclusions, these protein aggregates were reported to be distinct 
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from Lewy bodies described in PD patients [62-65]. In addition, dopaminergic 
neuronal loss was not observed in the animals. Defects in mitochondrial morphology 
and mitochondrial dysfunction have been described in two studies [66, 67] 
suggesting a potential role of mitochondria in the α-synuclein pathology and motor 
disturbances associated with α-synuclein over-expression in mice. Although 
C.elegans and D.melanogaster lack α-synuclein orthologues, over-expression of the 
human wild type and mutant α-synuclein protein in flies has shown to result in age 
dependent motor abnormalities, dopamine depletion and the formation of α-
synuclein positive aggregates [68, 69]. Slowness of movement has been described in 
C.elegans over-expressing wild type and mutant α-synuclein consistent with a 
perturbation in dopaminergic function [70, 71] and correlating with the loss of 
dopaminergic neurons [71] however, α-synuclein aggregates were not reported.  
Recessive PD has been modelled in animals through deletions of DJ1, PINK1 
and parkin genes. Although PINK1, parkin and DJ1 knockout mice have signs of 
abnormal dopamine metabolism, nigral dopaminergic cell death is not a feature and 
Lewy bodies have not been observed in these animals [72-74]. Drosophila 
melanogaster models of loss of PINK1 and parkin function have revealed motor 
defects and dramatic defects in mitochondrial morphology in energy intensive 
tissues [75] as well as degeneration of dopaminergic neurons [76]. Although DJ1 
knockout flies also show mitochondrial structural alterations, these appear to be 
distinct from those identified in PINK1 and parkin knockouts [77]. Mild 
mitochondrial abnormalities have been observed in PINK1 and parkin knockout mice 
however these features are less pronounced than the corresponding fly models [78].  
Although none of the animal models recapitulate the full pathological 
spectrum of PD, some overlapping features indicate the involvement of distinctive 
cellular pathways in the disease pathogenesis. In particular, the pathways involved 
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in α-synuclein synthesis and degradation mediating steady state levels of the 
protein, synaptic function regulating dopamine metabolism and mitochondrial 
function contributing to cellular energy homeostasis. 
1.2.3 Environmental factors in PD 
Familial mutations account for about 10 % of all PD cases suggesting 
additional factors may be involved in the disease pathogenesis. Population based 
studies have shown that head trauma may accelerate PD onset [79] while meta 
analysis [80] of studies in humans and rodents [81] have demonstrated a protective 
role for cigarette smoking and neuroprotection from nicotine. Studies looking at 
physical activity, caffeine use and non steroidal anti inflammatory drugs have all 
shown negative correlations with respect to the disease [82-84]. In addition, 
exposure to environmental toxins and pesticides has been shown to correlate with 
sporadic forms of PD [85, 86]. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
was identified to induce Parkinsonian like symptoms and pathology in humans and 
non-human primates [85, 87]. Chronic, systemic administration of the pesticide 
rotenone in rodents led to the development of PD like symptoms and α-synuclein 
aggregates [88]. Paraquat, a quaternary ammonium herbicide, structurally 
resembles MPTP and resulted in selective loss of dopaminergic neurons, dopamine 
depletion and α-synuclein aggregation in rodents [89, 90]. The subsequent 
characterization of the molecular mechanisms associated with these compounds 
further emphasised the role of mitochondrial function in PD pathogenesis. The link 
between mitochondrial dysfunction and α-synuclein aggregation in toxic animal and 
human PD models was also noted. 
1.2.4 Mitochondria 
Mitochondria are double membrane bound organelles consisting of a 
relatively permeable, cholesterol rich outer membrane and an impermeable, protein 
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rich inner membrane. The outer membrane houses different families of proteins 
facilitating mitochondrial import, organelle dynamics and apoptotic cascades. The 
cristae folds of the inner membrane allow for high concentrations of proteins 
involved in processes such as oxidative phosphorylation to meet the metabolic 
demands of the cell. The mitochondrial matrix incorporates mitochondrial 
transcriptional machinery working in concert with nuclear genes to regulate 
mitochondrial function. In addition, the mitochondrial matrix facilitates the 
tricarboxylic acid cycle (TCA) supplying reducing equivalents to the electron 
transport chain (ETC).  
In terms of mitochondrial involvement in PD pathogenesis, a considerable 
amount of attention has been focused on the mitochondrial respiratory chain. 
Structurally, the mitochondrial respiratory chain consists of 5 multi subunit 
complexes where Complexes I, III, IV and V span the inner mitochondrial membrane 
while Complex II contacts the membrane at the matrix side (Fig 1.3, adapted from 
[91]). Reducing equivalents (NAD(P)H and FADH2) from the TCA and β-oxidation 
function as electron donors feeding into Complexes I and II. Redox cofactors bound 
to their respective enzymes transfer electrons to the mobile electron carrier 
coenzyme Q 10 which in turn is oxidised by Complex III to allow for electron transfer 
to cytochrome C. Shuttling of reduced cytochrome C to Complex IV facilitates the 
reduction of oxygen by this enzyme. Electron transfer by Complexes I, III and IV 
results in the movement of protons [H+] across the inner membrane to the inter- 
membrane space. The generated proton gradient is referred to as the mitochondrial 
membrane potential. The thermodynamic tendency of [H+] to flow back into the 
matrix generates energy, the driving force for Complex V (ATP synthase complex). 
Respiratory chain defects often lead to reduced electron flow, mirrored by a drop in 
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the mitochondrial membrane potential and a build-up of reducing equivalents, a 
source of potentially damaging reactive oxygen species (ROS). 
 
 
 
The reduction of oxygen by one electron at a time produces a range of 
relatively stable intermediates. One electron reduction generates the superoxide 
anion (O2
.-) and spontaneous or enzyme induced dismutation of O2
.- produces 
hydrogen peroxide (H2O2) which in turn may be partially reduced to hydroxyl radicals 
(OH.-). OH.- can be re-reduced by O2
.- propagating the process [92]. Hydroxyl radicals 
can directly lead to lipid peroxidation and react with nucleic acids of mitochondrial 
DNA to cause DNA damage. The superoxide anion, although relatively non-toxic can 
react with nitric oxide (NO.-) to generate the highly reactive peroxynitrate (OONO-), 
damaging to lipids and DNA. 
   
 42 
 
1.2.4.1 Mechanism of action of mitochondrial toxins 
MPTP selectivity for dopaminergic neurons is conferred by its affinity for the 
dopamine transporter (DAT) [93]. Lipophilic properties target it to the mitochondrial 
matrix where MPTP is metabolized by the enzyme monoamine oxidase B (MAO-B) to 
MPP+. MPP+ blocks electron transfer through Complex I of the ETC by adhering in 
close proximity to the coenzyme Q 10 binding site [94]. Additional effects on TCA 
cycle enzymes results in an energy crisis believed to lead to acute dopaminergic cell 
death.  
Rotenone is a well characterized inhibitor of mitochondrial Complex I. 
Similar to MPTP, its lipophilic nature allows it to cross the blood brain barrier, 
cellular membranes and accumulate in the mitochondria. Unlike MPTP, rotenone 
uptake is not restricted to dopaminergic neurons however, the enhanced 
vulnerability of these neurons to rotenone toxicity links mitochondrial function to 
PD pathology. Rotenone induced Complex I inhibition has been reported to enhance 
ROS production implicating ROS in the disease mechanism. 
Paraquat uptake is not mediated by DAT hence the molecular selectivity for 
dopaminergic neurons is different to that of MPTP [95]. Paraquat is believed to kill 
cells through failure of antioxidant defences and oxidative damage to cytosolic 
proteins rather than the primary defect in Complex I function as is the case for 
rotenone and MPP+ [96], further emphasising the role of ROS in disease 
pathogenesis. 
1.2.4.2 Electron transport chain and PD 
The link between mitochondrial toxins and PD pathology led to the 
identification of mitochondrial respiratory defects in idiopathic PD patients. Complex 
I functional abnormalities were identified in the substantia nigra of IPD subjects and 
confirmed by multiple groups [97-100]. Altered Complex I enzyme assembly has 
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been reported in IPD patient brains [101]. Subsequently, Complex II defects were 
reported as well as Complex II in combination with Complex III or Complex IV 
abnormalities of mitochondria extracted from skeletal muscle, lymphocytes and 
patelets of PD subjects [102-106]. Although substantial variability was reported 
between groups, the association between respiratory chain defects and disease 
were consistent.  
Oxidative stress was another prominent feature identified in PD patient 
brain tissue similar to the effects observed in rotenone and paraquat models. 
Increased levels of lipid oxidation [107], oxidative protein damage [108, 109] and 
oxidative DNA damage [108, 110] have been reported in the SNpc of idiopathic PD 
patients. Oxidative stress has also been noted in peripheral tissues [110-114] 
suggesting that increased ROS generation is not restricted to the affected brain 
areas. 
Respiratory chain defects have also been noted in genetic models of PD.  
Primary cells from recessive PD patients as well as DJ1, PINK1 and parkin knockout 
models show evidence of respiratory chain abnormalities, particularly in Complex I 
activity [115-122] and increased levels of oxidative stress [118, 120, 121]. α-
synuclein association with the inner mitochondrial membrane, specifically Complex I 
of the ETC is believed to modulate the bioenergetics changes associated with 
reduced activity of Complex I and increased levels of oxidative stress in α-synuclein 
over-expressing primary neurons [123]. Furthermore, the mitochondrial association 
and Complex I inhibition is thought to be exacerbated by the toxic oligomeric and 
aggregated α-synuclein [124], further emphasising the link between α-synuclein 
aggregation and PD pathogenesis. 
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1.2.4.3 Mitochondrial turnover and dynamics 
Discovery of the functional roles of the recessively linked PD proteins, PINK1 
and parkin, has led to the mechanistic insight into a novel pathway linking the 
fundamental processes involved in mitochondrial homeostasis- mitochondrial 
dynamics and turnover. 
Mitochondria are now recognised as dynamic structures continuously 
undergoing fission and fusion events. The structural re-organisation of the 
mitochondrial network involves both the inner and outer mitochondrial membranes. 
Mitochondrial fusion events can dilute out mitochondrial DNA mutations and 
metabolic insufficiencies [125]. Outer membrane fusion events require the action of 
mitofusin 1 and 2 (Mfn) proteins while the inner membrane is fused through the 
action of Optic Atrophy 1 (Opa1) protein. Fission of both membranes is facilitated by 
mitochondrial recruitment of the cytosolic proteins dynamin like protein 1 (DLP1) 
and mitochondrial fission protein (Fis1). Oligomerization of DLP1 forms membrane 
boundaries and allows for mitochondrial budding and fragmentation [126]. 
Mitophagy is the process by which the mitochondrial network gets 
degraded. Parkin has been shown to be involved in the removal of damaged 
mitochondrial structures [127]. Depolarization of the mitochondrial membrane in 
response to chemical uncoupling or electron transport chain inhibitors results in 
parkin targeting from its native cytosolic location to the damaged regions of the 
mitochondrial outer membrane [128]. At the outer membrane, parkin promotes 
ubiquitin mediated degradation of the mitofusins and is thought to induce 
mitophagy by localized prevention of mitochondrial fusion events [129]. Isolated 
mitochondrial fragments targeted for mitophagic removal are subsequently 
incorporated into double membrane vesicles and shuttled to the lysosome for 
proteolytic processing [126]. PD linked parkin mutations interfere with various 
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aspects of this mechanism, affecting parkin translocation, ubiquitin ligase activity 
and mitophagic membrane formation [130].  
Functionally PINK1 has been shown to act upstream of parkin in the 
pathway of mitochondrial turnover. PINK1 contains a mitochondrial localization 
motif importing the protein in a membrane potential dependent mechanism where 
it is rapidly cleaved by mitochondrial proteases generating the truncated PINK1 
forms [131]. Mitochondrial depolarization leads to the accumulation of full length 
PINK1 at the outer surface, believed to act as the signal for parkin recruitment [132]. 
Mutations in PINK1 tend to either destabilize the protein structure or occur in the 
enzymatic domain, leading to a loss of function phenotype [46, 47].  
The ETC and mitochondrial morphology defects described for PD linked 
PINK1 and parkin mutations are thought to result from insufficient removal of 
damaged organelles [129, 133]. In addition, parkin is believed to mediate GCase 
polyubiquitination in the ER and facilitate GCase exit [134]. Excessive parkin 
occupancy of trapped mutant GCase is believed to deplete the pool required for 
mitophagy resulting in the build up of damaged organelles [134]. Altered 
mitochondrial membrane binding properties of α-synuclein mutants are thought to 
account for the mitochondrial fragmentation in cells [135, 136]. α-synuclein 
membrane binding could thus influence mitochondrial fusion by interfering with the 
mitochondrial fission fusion machinery. Hence dysregulation of mitophagy has been 
linked to most of the genetic PD models and appears to contribute to PD 
pathogenesis. 
1.2.4.4 Mitochondrial transcriptional regulation 
In addition to homeostatic maintenance of healthy mitochondria through 
turnover, fission and fusion events, recessive PD proteins have been implicated in an 
upstream pathway of mitochondrial control through transcriptional regulation. 
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Mitochondrial biogenesis is the process by which the mitochondrial pool is 
replenished. The main signalling pathway associated with its induction is regulated 
by the nuclear factor (erythroid-derived 2), kelch-like ECH-associated protein 1 
(Nrf2/Keap1) complex stimulating a battery of approximately 100 genes under the 
inducible control of antioxidant response element (ARE) and myocyte enhancer 
element-2 (MEF2) [137]. In addition to the induction of expression of respiratory 
chain components, transport molecules, proteosomal proteins and chaperones, 
global regulatory factors; peroxisome proliferator-activated receptor gamma 
(PPARγ), retinoid X receptor-alpha (RXRα) and PPARγ co-activator 1 alpha (PGC1α) 
are induced to regulate the expression of mitochondrial lipid pathways integral to 
bioenergetic metabolism [138]. Nuclear transcription is coupled to mitochondrial 
RNA synthesis through the expression of a mitochondrial transcription factor (TFAM) 
[139]. The overall outcome is increased mitochondrial content, cellular respiratory 
capacity and improved maintenance of existing organelles.  
Transcription and replication of mitochondrial DNA was found to be 
enhanced by parkin over-expression [140], while down regulation of PINK1 
correlated with reduced mitochondrial content [122], potentially contributing to the 
bioenergetic defect. A functional association between parkin and TFAM has been 
described in neuroblastoma cells, linking the catabolic and anabolic pathways of 
mitochondrial homeostasis [140] further implicating this pathway in the 
pathogenesis of PD. 
  1.2.4.5 Mitochondria and oxidative stress 
Mitochondria respond to oxidative stress by promoting synthesis of 
antioxidant enzymes. The antioxidant response can be stimulated as part of the Nrf2 
signalling pathway, generally mediated by PGC1α regulated expression [141, 142] of 
antioxidant enzymes such as superoxide dismutase 2 (SOD2), glutathione (GSH) and 
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catalase. The Nrf2/Keap1 complex has been shown to be sensitive to cellular redox 
status governing PGC1α transcription [143]. As well as induction of expression by 
Keap1/Nrf2, PGC1α transcription is negatively regulated by nuclear levels of histone 
deacetylase 5 (HDAC5), a transcriptional regulator shuttling between the nucleus 
and cytosol [144]. 
The involvement of this branch of the Nrf2/Keap1 pathway in PD 
pathogenesis is supported by functional association of the downstream PGC1α with 
the recessively linked DJ1 protein [145]. In the nucleus, DJ1 inhibits sumolation of 
pyrimidine tract binding protein-associated splicing factor (PSF), which binds PGC1α 
and mediates its transcriptional activity [145]. DJ1 has been shown to have an 
altered redox state in response to oxidative stress and acidic conditions which may 
in turn influence the protein’s cellular localization with its nuclear translocation 
likely to govern the redox transcriptional response [146]. PD linked DJ1 mutations 
can affect protein cellular distribution and disrupt the PSF modulation resulting in 
reduced transcription of the antioxidant enzymes [147]. In addition, PGC1α levels 
respond to parkin silencing and over-expression potentially as a result of the 
oxidative stress associated with the loss of parkin phenotype [148, 149]. 
Furthermore, increased activity of PGC1α co-regulator PPARγ has been reported to 
be protective against dopaminergic cell loss in PD models [150, 151]. Although 
PGC1α is not regarded as a familial PD protein, polymorphisms in the gene sequence 
link it to sporadic disease [152], further emphasising the role of oxidative stress and 
mitochondria in PD pathogenesis.  
1.2.4.6 Oxidative stress and mitochondrial uncoupling proteins 
In addition to redox maintenance by antioxidant enzymes, ROS levels can be 
regulated through the action of mitochondrial uncoupling proteins (UCPs). This 
family is comprised of five isoforms with structural homology between family 
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members. While UCP2 is expressed ubiquitously, UCP1 is predominantly expressed 
in brown fat, mediating thermogenesis and UCP4 and 5 are the neuronal isoforms 
with poorly defined functional roles. UCP3 is expressed in some but not all tissues 
and the specificity for its distribution has not yet been determined [153]. UCPs exist 
as dimers on the inner mitochondrial membrane forming a pore which allows 
protons to flow into the mitochondrial matrix. Proton flow through the UCP channel 
provides an alternative route from the mitochondrial ATPase and partially dissipates 
the mitochondrial membrane potential in the form of heat release [154, 155]. Mild 
uncoupling of oxidative phosphorylation upregulates ETC function and limits the 
amount of reducing equivalents available for ROS production.  
Regulated transcriptionally [156, 157], translationally [158] and by post 
translational modification [159], UCPs provide a rapid response to the demands of 
the electron transport chain. The UCPs have a relatively short half life of 40 minutes 
with the levels maintained through basal and inducible transcriptional regulation 
[160]. In particular, transcriptional activation occurs by PGC1α mediated activation 
or as part of the nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFκB) pathway [156, 157, 161, 162]. Hence UCP transcription is potentially linked to 
the PD associated parkin and DJ1 proteins.  
Mitochondrial uncoupling proteins have been shown to play a protective 
role in PD models. Neuroprotective properties of UCPs have been demonstrated in 
rodents treated with MPTP where UCP2 over-expression reduced dopaminergic cell 
loss [163]. In addition, chronic MPTP treatment resulted in a time and dose 
dependent induction of UCP2, 4 and 5 in neuronal cells [164]. Mechanistically, 
superoxide generated during respiration can result in lipid peroxidation which in 
turn activates UCP expression to reduce the superoxide production, effects 
presumably exacerbated in MPTP models [165]. Although both neuronal and non 
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neuronal UCPs possess properties that can potentially protect cells against various 
stresses, toxic effects linking UCP over-expression and cell death have been reported 
[166, 167]. 
In addition to the protective role in PD models, a genetic link has been 
reported for the neuronal UCP isoforms and the PD associated DJ1 protein. As well 
as a role in induction of antioxidant enzymes DJ1 has recently been linked to a 
specific function regulating the autonomous pacemaker activity of dopaminergic 
neurons in the SNpc [168]. Pacemaking is unique to SNpc DA neurons and facilitates 
sustained release of dopamine necessary for the proper function of target structures 
in the striatum [169]. Mitochondrial regulation of this function can potentially 
explain the vulnerability of this cell population in PD. Pacemaker activity is regulated 
by long lasting (L) type calcium channels where cytosolic calcium oscillations come at 
a metabolic cost contributed to by oxidative phosphorylation as channel opening 
requires hyperpolarized membrane potentials [170]. Mitochondrial calcium uptake 
is coupled to rapid depolarization and repolarization of mitochondrial membranes 
assumed to be facilitated through the action of UCPs modulating the proton 
gradient [168]. DJ1 knockout animals showed a reduced amplitude and frequency of 
polarization events correlating with reduced expression of UCP mRNA. Furthermore 
superoxides can affect mitochondrial free calcium by regulating the expression of 
UCPs suggesting a potential regulatory loop involving the redox sensing DJ1 protein. 
Of note, mitochondrial calcium dysregulation has been reported in PINK1 knockout 
models suggesting a potential overlap between the recessive PD genes [172]. In 
support of the role of calcium in PD, MPTP and rotenone are associated with 
diminished mitochondrial calcium uptake and increased cytosolic free calcium in 
cultured cells [173-175]. Considering the genetic association between DJ1 and PD, 
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SNpc dopaminergic cell loss and the regulatory control of mitochondrial function, it 
is possible to postulate the involvement of the UCPs in PD pathogenesis. 
1.2.5 Lysosomal function and α-synuclein 
Familial α-synuclein gene duplications and triplications as well as Lewy body 
deposits in PD brains suggest increased levels of α-synuclein protein are a key 
pathological factor in PD. Evidence of the role for mitochondrial dysfunction in α-
synuclein aggregation came from studies identifying α-synuclein aggregates in MPTP 
and rotenone mouse models of PD [176-179].  
Steady state α-synuclein levels are determined by the balance between 
protein synthesis and degradation pathways. Increased α-synuclein mRNA 
expression has been shown in SNpc of IPD patients [180] suggesting increased α-
synuclein expression can potentially increase cellular concentrations of the protein. 
In addition, lysosomal function was determined as the rate limiting step in the 
clearance of protein aggregates [181] suggesting this process may contribute to 
increased α-synuclein levels in cells. α-synuclein degradation involves chaperone 
mediated autophagy (CMA) which requires binding of chaperones to an intrinsic 
pentapeptide motif in α-synuclein and the subsequent receptor mediated 
internalization of the protein into the lysosomal lumen where it is degraded by 
lysosomal proteases [182]. α-synuclein point mutations inhibit CMA [182] and may 
account for the build up in protein levels. 
Inhibition of CMA can stimulate another branch of the lysosomal 
degradation pathway, autophagy, which involves the formation of a double 
membrane vesicle around the target cargo and subsequent fusion with the 
lysosomal membrane [183]. Enhanced autophagy can partially compensate for the 
lack of CMA mediated degradation and has been shown to reduce protein 
aggregation in a number of cellular models of neurodegenerative diseases [184-
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187]. However enhanced autophagy can also induce cell death under stress 
conditions [188]. 
As well as mutant α-synuclein inhibition of chaperone mediated autophagy, 
lysosomal dysfunction has been linked to wild type α-synuclein accumulation.  
Reduced levels of a lysosomal protease, cathepsin D, correlated with increased α-
synuclein accumulation [189]. Clinical features of PD have been noted in patients 
with lysosomal storage disorders accompanied by α-synuclein accumulation in 
neurons and glia [190-192]. In addition, genome-wide association studies linked two 
lysosomal enzymes to an increased risk for developing PD, GCase [54, 193] and a 
lysosomal membrane protein probable cation-transporting ATPase 13A2 (ATP13A2). 
In support of the genetic studies mutant GCase has consistently correlated with α-
synuclein accumulation in cell culture models potentially providing a link to the 
associated Lewy body pathology observed in GCase mutant PD cases [194, 195]. 
ATP13A2 deficiency is associated with impaired lysosomal degradation capacity, α-
synuclein accumulation and toxicity [196, 197].  
Analyses of brain tissue from subjects with lysosomal storage disorders have 
also identified morphologically and biochemically deficient mitochondria [198, 199] 
suggesting mitochondrial function and lysosomal regulation are intrinsically linked. 
As lysosomes are also the final destination for mitophagic cargo, lysosomal 
abnormalitites influence mitochondrial turnover providing a potential link to PINK1 
and parkin mediated mitochondrial regulation.  
1.3 LRRK2 
1.3.1 LRRK2 protein structure 
High incidence of LRRK2 mutations, the pathological and clinical similarities 
with idiopathic disease suggest that LRRK2 plays an important mechanistic role in PD 
pathogenesis. 
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The 1.4 Mb LRRK2 gene consists of 51 exons encoding a protein of 2527 
amino acids. Structurally the 286 kDa LRRK2 harbours multiple functional domains; 
ankyrin repeats (ANK), leucine-rich repeat domain (LRR), Ras in complex proteins 
domain (ROC), C-terminal of ROC region (COR), mitogen activated protein kinase 
kinase kinase (MAPKKK) domain and a WD40 domain (Fig 1.4, adapted from [200]). 
Based on sequence predictions the kinase domain consists of 2 structurally 
homologous lobes connected through an active hinge region. The ROC domain 
contains a guanosine triphosphate (GTP) binding site while the LRRK2 COR segment 
is thought to be a regulator of the ROC GTPase activity [201]. In vitro kinase and 
GTPase activity measurements confirmed LRRK2 as a catalytically active molecule 
[202, 203]. There is evidence to suggest the two enzymatic domains are intrinsically 
linked as GTP binding to the ROC domain is important for LRRK2 kinase activity 
[203]. However, GTP activity of kinase deficient LRRK2 are comparable to those of 
the wild type protein and GTP concentrations do not seem to affect kinase activity 
[203-206] suggesting the kinase is likely the modulator rather than output of 
enzymatic activity. The flanking ankyrin repeats, LRR and WD40 are domains 
regulating protein-protein interactions. WD40 contribution to the regulation of 
LRRK2 enzymatic activity is supported by the lack of detectable kinase activity in C 
terminally truncated LRRK2 mutants [202, 208].  
The quaternary structure of LRRK2 is believed to be that of a kinase inactive 
oligomer. GTP binding leads to the dissociation of the complex and heterodimer 
formation with a concominant activation of the kinase. The ROC-COR region of 
LRRK2 has been mapped to the dimer interface and GTPase activity reported to 
mediate steady state dimer levels [209, 210]. 
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1.3.2 LRRK2 kinase 
As well as its inherent autophosphorylation capacity [203, 204, 211], LRRK2 
can in vitro phosphorylate myelin basic protein (MBP) [203, 204] and an artificial 
peptide LRRKtide, based on predicted phosphorylation sites of the LRRK2 substrates 
ezrin, radixin and moesin [202].  
Recently, a number of ATP competitive LRRK2 kinase inhibitors have been 
developed, varying in their structure (Appendix Fig A1), selectivity properties and 
potencies both in in vitro and ex vivo studies. LRRK2 IN1 [212] is a LRRK2 kinase 
inhibitor with IC50=13 and 6 nM for recombinant human wild type and G2019S 
LRRK2 respectively. Kinase selectivity profiling identified 12 additional targets for 
LRRK2 IN1 including IC50=160 nM for mitogen activated protein kinase 7 (MAPK7 or 
ERK5) and IC50>1 µM for CHK2 checkpoint homolog (CHEK2), myosin light chain 
kinase (MYLK) and calmodulin binding kinase kinase 2 (CAMKK2). CZC25146 [213] 
has an IC50=1-5 nM and 2-7 nM for the recombinant human wild type and G2019S 
LRRK2 enzymes respectively. Kinase selectivity profiling identified 5 additional target 
kinases with an IC50=10 nM-2 µM which include Polo-like kinase 4 (PLK4) and cyclin G 
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associated kinase (GAK) with no common LRRK2 IN1 targets identified in this IC50 
range. TAE-684 [214] has a biochemical potency of IC50=7.8 nM and 6.1 nM for 
recombinant human wild type and G2019S LRRK2. TAE-684 has been described as a 
potent binder of many kinases with an IC50<100 nM for CHK2 and CAMKK2 and 
considerably less selective than LRRK2 IN1 and CZC25146. Identification of 14-3-3 as 
a LRRK2 interacting substrate and characterization of the phospho serine residues 
required for 14-3-3 binding has revealed an inherent relationship between kinase 
inhibition, 14-3-3 association and serine phosphorylation [215, 216]. These 
characteristics have been used to determine the effective inhibitor doses for LRRK2 
in cells and animal models [213, 214, 216]. 
1.3.3 LRRK2 PD mutations  
PD associated mutations are located in the enzymatic domains of LRRK2. 
The glycine residue at position 2019 forms part of a kinase activation motif 
conserved among LRRK2 kinase homologues [217]. Substitution of glycine with a 
bulkier alanine residue is thought to perturb the activation loop and produce an 
overactive kinase with greater affinity for ADP. In support of the structural 
predictions in vitro studies of LRRK2 enzymatic activities have consistently reported 
an increase in kinase activity of the protein associated with the G2019S mutation 
[201-203, 218]. Overall GTPase mutations seem to modestly raise the kinase activity 
of LRRK2, however, variable effects on LRRK2 kinase function have been reported 
[201-203, 218]. 
Mutations within the ROC-COR domain seem to induce both structural and 
activity associated changes. R1441G/C and Y1699C GTPase mutations have 
consistently been shown to lower the GTPase activity of the molecule [219, 220]. In 
addition R1441G/C but not Y1699C GTPase mutations perturb the LRRK2 dimer 
structural integrity [209, 210]. Kinase domain mutants appear not to impact on the 
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structure of the dimeric species [208, 221] but G2019S LRRK2 increases GTP 
hydrolysis [222]. 
1.3.4 LRRK2 PD mutations and neurotoxicity 
In vitro studies implicate LRRK2 enzymatic changes in nigral dopaminergic 
cell death of LRRK2 PD patients. Neurotoxic effects of LRRK2 have been modelled in 
cell culture systems. Neuroblastoma cells, primary rat and mouse cortical cultures 
expressing mutant LRRK2 often present with nuclear shrinkage, reduced viability and 
enhanced sensitivity to toxic insult [203, 223, 224]. Mechanistically, over-expressed 
LRRK2 has been shown to interact with the apoptotic machinery. LRRK2 association 
with Apaf1, the main component of the apoptosome - a reported initiator of the cell 
death cascade [225] positions the protein downstream of a cytochrome c mediated 
death pathway. LRRK2 association with the death adaptor Fas associated protein 
(FADD) further emphasises the role of caspases in the toxic events associated with 
the mutant protein.  
An additional link to PD pathology in cell culture systems is shown by the 
ability of mutant LRRK2 to aggregate in HEK293 and SHSY5Y cells over-expressing 
the protein [215, 223, 224]. LRRK2 aggregates are positive for ubiquitin and could 
potentially represent a form of toxic species [226]. Some but not all the pathogenic 
mutants are reported to enhance aggregate formation [215, 223, 224]. However, 
LRRK2 aggregates are not always observed in over-expressing SHSY5Y and HEK293 
cell systems [227, 228] and identification of equivalent species in animal models and 
human G2019S subjects warrants further investigation. 
1.3.5 LRRK2 models and PD 
Some of the pathogenic hallmarks observed with mutant LRRK2 in cell 
culture systems have been extended to animal models of LRRK2 toxicity. Drosophila 
melanogaster and Caenorhabditis elegans contain a single homologue of the LRRK2 
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gene (dLRRK and lrk-1), with approximately 20% sequence identity to the human 
LRRK2 protein. The relevant LRRK2 homologues contain a conserved leucine rich 
core kinase (LRCK) sequence and the predicted conservation of LRRK2 tertiary 
structure bodes in favour of conserved cellular roles. Rodent LRRK2 homologues 
share 82 % sequence identity with the human LRRK2.  
Over-expression of the G2019S C.elegans lrk-1 homologue results in early 
larval arrest suggesting mutant LRRK2 is potentially toxic [229]. Although over-
expression of human LRRK2 is less aggressive, the mutant protein increases the 
sensitivity of C. elegans dopaminergic neurons to mitochondrial toxins, suggesting 
the DA neurons are less viable [230]. Motor abnormalities, alterations in brain 
dopamine levels and dopaminergic cell defects are pronounced in Drosophila LRRK2 
PD models [231, 232]. Defective dopamine transmission is consistently observed in 
mutant human LRRK2 transgenic (G2019S and R1441G/C) rodents correlating with 
an age dependent decrease in locomotor activity, responsive to L-Dopa treatment 
[233-235]. Mitochondrial abnormalities were noted in LRRK2 transgenic mouse 
models, associated with the over-expression of wild type and G2019S protein [233, 
236]. Degeneration of axonal projections in rodent SNpc dopaminergic neurons is 
similar to the axonal demise observed in cell culture and C.elegans models. These 
axonal defects are thought to account for the striatal dopamine depletion and 
potentially reflect the human pathological scenario [233]. The severity of the mutant 
phenotype is dose dependent as mice expressing higher levels of the mutant LRRK2 
protein present with more pronounced PD pathology [233]. Dopaminergic cell loss is 
rarely observed and α-synuclein deposits have never been reported in any LRRK2 
models. 
Locomotor dysfunction, dopamine deficiency, cell toxicity and mitochondrial 
abnormalities observed in LRRK2 transgenic animal models are comparable to those 
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observed for other genetic PD models, suggesting overlapping pathways in PD 
pathogenesis.  
1.3.6 LRRK2 detection antibodies 
Although low levels of ectopic wild type LRRK2 expression do not seem to 
affect cell viability, high expression has been linked to toxicity in cell culture systems, 
albeit milder relative to G2019S LRRK2 [227].  
When this project was initiated, LRRK2 protein characterization in the brain, 
peripheral tissues and cell culture models relied on a library of in house and 
commercial antibodies raised against the LRRK2 sequence. Both polyclonal and 
monoclonal antibodies have been generated, targeting C and N terminal regions as 
well as the core domains of the protein. Early reports utilized over-expressing 
systems for antibody characterization struggling to detect low levels of endogenous 
LRRK2 [237]. Subsequent validation of commercial antibodies with LRRK2 knockout 
tissue identified non specific species of comparable molecular mass to full length 
LRRK2 protein [237]. Additional lower molecular weight immunoreactivity is 
common in LRRK2 detection by SDS PAGE, however, a limited number of these 
immunoreactive bands have been characterized [238, 239].   
To address the problem of endogenous LRRK2 detection, enzyme 
purification for LRRK2 activity measurements and facilitate studies of LRRK2 
function, Alessi et al have reported an immunoprecipitation protocol using a 
combination of two commercial LRRK2 antibodies to detect endogenous LRRK2 [202, 
215, 216]. This method has not been applied to human brain samples or for 
quantitative comparison of LRRK2 protein expression. 
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1.3.7 LRRK2 mRNA and protein distribution 
In terms of mRNA expression, LRRK2 has consistently been shown to occur 
at high levels in kidneys, lungs and lymph nodes [240-243] with lower mRNA 
abundance in the brain [244]. In rodent and primate regional brain distribution 
studies, the striatum expressed significant levels of LRRK2 mRNA while nigral LRRK2 
mRNA appeared to be of considerably lower abundance [245-248]. In an attempt to 
correlate LRRK2 protein distribution to early reports of LRRK2 mRNA, relative LRRK2 
expression has been described for rodent and primate tissues [244, 248, 249]. LRRK2 
antibodies have been utilized for immunological detection. In general 
immunohistochemical data on LRRK2 protein distribution appears to correlate with 
the mRNA literature with high LRRK2 abundance in striatum, cortex and cerebellum 
[244, 248, 249]. More recent reports, utilizing validated antibodies of better quality 
have confirmed high striatal LRRK2 expression providing confidence for localization 
and functional data published in earlier studies [250]. In general, LRRK2 brain 
distribution involves regions of the dopaminergic pathway. Regional and cell specific 
expression may have functional implications for the LRRK2 protein in neuronal sub-
populations. 
1.3.8 LRRK2 cellular distribution 
In addition to tissue distribution studies LRRK2 antibodies have been utilized 
to determine LRRK2 cellular localization. Cellular fractionation analyses have 
identified LRRK2 in mitochondrial, lysosomal, ER and vesicular compartments further 
supported by immunohistochemical and EM studies [201, 218, 251]. LRRK2 
dimerization has been confirmed for protein immunoprecipitated from cells with 
membrane associated dimers described to exhibit enhanced kinase activity, adding 
to the initial in vitro studies [218, 239, 252]. Assuming accuracy in quantitative 
immunological assessment there is no evidence to suggest PD associated mutations 
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altered LRRK2 protein levels or cellular distribution in any of the cell models 
analyzed [218, 239, 252].   
1.3.9 LRRK2 function 
LRRK2 detection and characterization of its intracellular distribution in 
combination with the phenotypic changes associated with wild type, mutant and 
LRRK2 knockdown models have contributed to the functional studies and 
investigation of intracellular pathways potentially involving the LRRK2 protein.  
1.3.9.1 LRRK2 and vesicles 
LRRK2 abundance in synaptosomes and vesicle enriched fractions combined 
with changes in dopamine transmission reported for mutant and LRRK2 deficient 
mouse models suggested a role for LRRK2 in synaptic function. Knockdown of LRRK2 
correlated with morphological abnormalities at the pre synapse [253] and altered 
vesicle recycling dynamics [254]. The G2019S hyperactive kinase LRRK2 impaired 
synaptic vesicle endocytosis potentially through its association with the vesicular 
machinery [255]. The sub-cellular distribution of α-synuclein closely mimics that of 
LRRK2 [24]. In addition, α-synuclein has been shown to interact with the soluble N-
ethylmaleimide sensitive factor (NSF) attachment protein receptor (SNARE) 
complex, mediating neurotransmitter uptake and release [256] potentially 
suggesting a functional link between α-synuclein and LRRK2.  
Another subset of vesicles thought to functionally require LRRK2 are 
involved in endocytic-lysosomal trafficking. A membrane association with 
multivesicular bodies (MVBs) and autophagic vacuoles (AVs), prime vesicle 
components of this pathway, has been demonstrated by electron microscopy [257]. 
Knockdown of LRRK2 increased flux through the pathway while the R1441C mutant 
LRRK2 was described to cause an autophagic imbalance resulting in accumulation of 
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AVs and MVBs. Autophagic clearance of mutant and excess α-synuclein may 
therefore involve LRRK2.  
1.3.9.2 LRRK2 and microtubules 
Axonal degeneration, neurite defects and tau pathology commonly 
associated with mutant LRRK2 models and PD patients implicated microtubule 
dynamics in PD pathogenesis [258-260]. The subsequent identification of the 
interaction between LRRK2 and β-tubulin, the main component of microtubules, and 
kinase dependent regulation of tubulin polymerization events [261, 262] supported 
a direct mechanistic role for LRRK2 in the observed phenotype. More recently, 
another microtubule related protein Tau, the main component of neurofibrillary 
tangles in PD and AD, was reported as an integral part of the LRRK2 β-tubulin 
complex [263] potentially providing an additional link between LRRK2 mutations and 
Tau pathology.  
Microtubule regulation has also linked LRRK2 to the canonical Wnt signalling 
pathway where a genetic interaction with α-synuclein is thought to take place. Tau 
phosphorylation is believed to be enhanced by the interaction of LRRK2 with the 
dishevelled protein (Dvl) [264], a downstream target of GSK3β which also induces α-
synuclein dependent tau phosphorylation [265].  
1.3.9.3 LRRK2 transcription and translation  
Multiple protein interaction domains present in the LRRK2 sequence as well 
as its cytosolic abundance implicate the protein’s involvement in signalling cascades 
transcriptional and translational regulation. Microarray analyses of wild type, 
mutant LRRK2 over-expression and knockdown LRRK2 models implicated 
transcriptional contribution to the regulation of pathways involved in axonal 
guidance, actin cytoskeleton dynamics, calcium signalling, cell cycle and 
differentiation as LRRK2 mediated events [266]. Furthermore, mRNA expression of 
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genes involved in neuronal maintenance appeared to be mediated by LRRK2 levels in 
mouse embryonic stem cells [267]. The link between dysregulation of gene 
expression and PD pathology is demonstrated by increased α-synuclein mRNA levels 
in PD patient SNpc [268]. A number of reports suggest LRRK2 regulates α-synuclein 
steady state mRNA levels, potentially altering intracellular protein concentrations 
which may lead to aggregation [269, 270].  
In support of the microarray data, mechanistic analyses implicated LRRK2 in 
transcriptional activation, albeit in peripheral tissues whereby LRRK2 was found to 
mediate the nuclear factor of activated T-cells (NFAT) cytosolic to nuclear 
translocation and gene regulation in response to inflammation [271]. LRRK2 
interaction with the dishevelled protein (Dvl) is associated with β-catenin mediated 
transcriptional regulation in the canonical Wnt signalling pathway [272].  
Translational repression and or degradation of mRNA inhibiting, miRNA 
particles through LRRK2 interaction with human Argonaute 2 protein (Ago2) and the 
eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP) was shown to 
impact on PD associated genes in a LRRK2 kinase dependent mechanism [273]. In 
addition aberrant phosphorylation of 4E-BP by mutant LRRK2 correlated with 
dopaminergic cell death and morphological defects in the post synapse [231]. LRRK2 
was also shown to mediate steady state 4E-BP protein levels suggesting a possible 
negative feedback loop [274]. A genetic interaction has been described between 
LRRK2, PINK1, parkin and 4E-BP. Knockdown of PINK1 or parkin affected cell viability 
of dopaminergic neurons in Drosophila, a phenotype exacerbated by the loss of the 
4E-BP protein [275]. Knockdown of LRRK2 rescued this dopaminergic phenotype 
suggesting a potential interplay between PD assicated proteins and the 4E-BP 
pathway. 
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In addition, LRRK2 has been shown to mediate cellular stress responses 
through participation in canonical NFκB and MAPK cascades [203, 276, 277], 
pathways previously implicated in PD pathogenesis [278, 279], further emphasising 
altered transcriptional response in LRRK2 linked PD. 
1.3.9.4 LRRK2 and mitochondria  
Mitochondrial involvement in LRRK2 pathogenesis is supported by a number 
of pathological, morphological and functional observations. In addition, cellular 
localization studies have confirmed a mitochondrial interaction [251, 280, 281] 
estimating approximately 10 % of the LRRK2 cellular pool at the outer mitochondrial 
membrane. LRRK2 appears to regulate survival of dopaminergic neurons by 
conferring resistance to oxidative stress [282] while LRRK2 toxicity induced by 
protein over-expression is exacerbated in rotenone and paraquat treated cells [283] 
potentially due to increased sensitivity to Complex I inhibition [284]. Mitochondrial 
respiratory chain defects have been described in mutant LRRK2 expressing cells 
correlating with structural alterations to the mitochondrial network [280, 281, 285]. 
Dopaminergic cell death has been linked to LRRK2 interaction with the 
mitochondrial apoptotic machinery [227, 286]. 
Although mechanistic links have been proposed for some of the LRRK2 
associated cellular pathways with respect to other PD related genes, the strongest 
genetic association has involved the mitochondria. Defects in mitochondrial cristae 
observed in PINK1 deficient C.elegans were rescued by dLRRK2 knockdown 
suggesting an antagonistic mechanism of gene regulation [229]. In addition, 
rotenone sensitivity of LRRK2 mutant flies is suppressed by parkin, PINK1 or DJ1 co-
expression [284, 287]. Furthermore, excessive mitochondrial fragmentation, 
reported in LRRK2, parkin, PINK1 or DJ1 deficient cells can be rescued by the 
artificial introduction of mitochondrial fusion machinery Mfn2 or a dominant 
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negative form of DLP1 which promotes fusion [280, 281, 284, 287], potentially 
linking the converging mechanisms. 
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1.4 Hypothesis  
We hypothesised a role for LRRK2 in the regulation of mitochondrial 
function, proposing the G2019S mutation would impact on the electron transport 
chain. We predicted, if confirmed, a detailed evaluation of upstream regulatory 
pathways could reveal overlapping and novel signalling events potentially reflecting 
previously unexplored mechanisms in idiopathic PD. 
1.5 Aims 
1. To characterize primary and transformed cell culture models expressing 
endogenous and ectopic wild type or G2019S LRRK2 protein. Characterization 
will require screening of commercially available antibodies for their ability to 
detect native, denatured and immunoprecipitated LRRK2 by Western blot and 
immunohistochemistry. 
2. To determine whether the previously validated immunoprecipitation protocol 
can be used for quantitative evaluation of LRRK2 protein levels in order to assess 
relative expression levels in the cell models and brain tissue.  
3. To use the primary and transformed cells as a LRRK2 model system to look at the 
impact of the G2019S mutation on mitochondrial function. A LRRK2 siRNA 
knockdown model will be used to address whether the ETC is regulated by 
endogenous wild type LRRK2. 
4. To determine whether the functional state of the mitochondria in control, wild 
type and G2019S LRRK2 over-expressing cells or LRRK2 siRNA knockdown system 
correlates with morphological changes in the mitochondrial network.  
5. To characterize the effects of LRRK2 kinase inhibitors in the over-expressing 
neuroblastoma model and determine the optimal parameters for subsequent 
evaluation of LRRK2 kinase contribution to mitochondrial function. 
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6. To explore the functional role of LRRK2 in upstream mechanisms regulating 
mitochondrial function. 
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Chapter 2: Materials and Methods 
All chemicals were obtained from Sigma or Merck & Co. unless otherwise stated.  
2.1 Plasmid constructs 
pET-DEST51 plasmids (Invitrogen) containing the cDNA encoding full length 
human wild type or G2019S LRRK2 with a C terminal V5 tag, AmpR gene (ampicillin 
resistance for bacterial selection) and bsr gene (blasticidin resistance for mammalian 
selection) were kindly provided by Mark Cookson (Bethesda, USA), [221]. 
Mammalian gene expression in pET-DEST51 was driven by the elongation factor 1 
(EF-1α) promoter. pEGFPN1 plasmid (Clontech) with an N terminally tagged GFP 
UCP2 insert, KmR gene (kanamycin resistance for bacterial selection) was provided 
by Koji Nishio (Nagoya, Japan) [288]. Mammalian gene expression in pEGFPN1 was 
driven by the cytomegalovirus (CMV) promoter. pGIPZ (Thermo Scientific) vector 
(scrambled shRNA: ATCTCGCTTGGGCGAGAGTAAG) or pGIPZ containing shRNA 
targeting the 3‘ UTR of the DJ1 gene (CCTACAAATTGTGTCTATA), sequence encoding 
GFP, AmpR and Pac (puromycin resistance for mammalian selection) genes were 
obtained from the University College London (UCL) shRNA library (Open Biosystems) 
and provided by Gyorgy Szabadkai (UCL). Mammalian gene expression in pGIPZ was 
driven by the CMV promoter. 
2.2 Brain samples 
               Human brain samples from two control subjects of 24 hour post mortem 
delay were obtained from the Queen Square Brain Bank.  Cases were collected using 
a protocol approved by the London Multicentre Research Ethics Committee and 
stored under a license issued by the Human Tissue Authority. Human brain samples 
of 5 individuals (3 control, 1 IPD case, 1 Alzheimer’s disease case) of short post 
mortem delay times were obtained from Jose Obeso (Pamplona, Spain) and studied 
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with the approval of the Ethics Committee. Details of brain samples are described in 
(Table 2.1). 
                Brain stem, olfactory lobe, mid brain, cerebellum, striatum and cortical 
regions were dissected from fresh brains of control male 6 week old mice (C57BL/6 
strain). Equivalent tissue regions of one marmoset brain were obtained from Peter 
Jenner (King’s College, London). The marmoset brain was from a 2 year old female 
animal that received daily subcutaneous MPTP (2.0 mg/kg) injections for 5 
consecutive days. LRRK2 knockout mouse brains obtained from C57BL/6 strain 
animals with a partial deletion of exon 39 and complete deletion of exon 40 of the 
LRRK2 gene [289] were kindly provided by D. Alessi (Dundee).  
 
2.3 Cell lines 
                  Punch skin biopsies from PD patients carrying G2019S LRRK2 mutations 
and age matched controls (Table 2.2) were collected by Dr. Daniel G Healy (Royal 
Free Hospital, UCL). Human skin fibroblasts were established by Dr. Susannah Horan 
and Dr. Jan Willem Taanman (Clinical Neuroscience, UCL).  
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Venous blood (8 mls) was collected from the same subjects with a hypermic needle 
as part of a vacutainer in ethylenediaminetetraacetic acid (EDTA) vacuum tubes 
(Beckton Dickinson and Co). Peripheral blood mononuclear cells were isolated and 
commercially transformed into lymphoblastoid cell lines by Epstein-BarrVirus (EBV) 
(ECACC, Salisbury, UK). 
SHSY5Y cell lines stably expressing pGIPZ vectors containing shRNA targeting the 
3’UTR of the DJ1 gene or scrambled shRNA were generated and kindly provided by 
Dr. Zhi Yao (Physiology Department, UCL).  
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2.4 Cell culture 
All cell culture medium was supplemented with 10 % (v/v) foetal calf serum 
(FCS, BioSera), penicillin (100 U/mL), streptomycin (100 mg/mL) and sodium 
pyruvate (100 mg/mL) unless stated otherwise. Adherent cells were grown on 10 cm 
plates while suspension cultures were maintained in surface-ventilated 75 cm flasks. 
Cells were cultured in a temperature-controlled, humidified incubator with 5 % CO2 
at 37 oC (Hera Cell 240, Thermo Scientific, Essex UK).  
Adherent cell lines were passaged or harvested by trypsinization in versene 
(Invitrogen) containing 0.1 % trypsin enzyme. Briefly, culture medium was aspirated, 
cells washed once in phosphate buffer saline (PBS) and 1 ml of trypsin solution 
applied to each 10 cm plate with cells monitored until all of the culture detached 
from the surface in the trypsin suspension. Trypsin was neutralised with 10 ml 
culture medium and cells re-plated at 1:4 dilutions. Unless otherwise stated cell lines 
were cultured up to passage 25. 
Suspension cells or trypsinized adherent lines were harvested by 
centrifugation (1000 g, 10 min, RT). Cell counts were performed using a phase 
contrast Olympus CK2 Microscope (London, UK) on Trypan blue stained cells 
mounted on Fastread slides (Immune Systems Ltd., Devon, UK).  
Cell stocks were frozen slowly to -80 oC in culture medium containing 10 % 
dimethyl sulfoxide (DMSO) and stored in liquid nitrogen. 
Fibroblasts were cultivated under standard conditions in Dulbecco’s 
Modified Eagle Medium (DMEM, Invitrogen) [290]. Skin biopsies were stored in 
sterile flasks containing fibroblast culture medium and processed on the same day. 
Following removal of subcutaneous fat tissue, skin sections were dissected into 
~1mm2 explants and placed skin side up on 5 cm petri dishes containing 2 ml pre 
warmed growth medium. Surface tension of the medium maintained biopsies 
 70 
 
adhered to the plate. Explants were cultured under standard growth conditions with 
the addition of 0.5 ml growth medium every 2 days. Upon appearance of epithelial 
monolayers and migrating fibroblasts the medium was replaced by 3 mls of fresh 
solution. Once confluent, fibroblasts were separated from the epithelial cells by 
trypsinization, re-plated in 10 cm dishes and expanded for stocks. Experiments were 
restricted to passages 4-12 to avoid cell senescence. In studies performed under 
substrate limiting conditions glucose free DMEM (Invitrogen) was supplemented 
with 4.5 g/L galactose and cells equilibrated in galactose medium for 24 hours prior 
to analysis.  
Lymphoblast cells were commercially provided as frozen stocks of 1 million 
cells per vial. Cells were defrosted at 37 oC, washed once (1000 g, 10 min, RT) in 10 
ml of Roswell Park Memorial Institute (RPMI) 1640 culture medium (Invitrogen) 
containing 20 mM HEPES buffer (Invitrogen) and pelleted cells resuspended in 10 
mls of fresh growth medium before transferring cell suspensions to 75 cm flasks 
[291]. 
SHSY5Y neuroblastoma cells were cultivated in 50/50 DMEM/F12 medium 
(Invitrogen) containing 0.1 % uridine and 1 % MEM non essential amino acids 
(Invitrogen) [292].  
2.5 Transformation of DH5α cells and DNA extraction 
pET-DEST51 and pGIPZ plasmid DNA (approximately 2 µg) was supplied 
spotted on Whatman filter paper. Marked regions containing the dried plasmid were 
excised under sterile conditions, placed in a sterile eppendorf tube and plasmids 
recovered by reconstitution in 50 µl TE buffer (10 mM Tris base, 1 mM EDTA, pH 
8.0). Reconstituted plasmids (100 ng) were transformed into competent DH5α 
Escherichia coli cells (50 µL, Invitrogen) by incubation on ice (30 min) and heat shock 
(2 min, 42 oC) to close the cellular pores. Transformed cells were equilibrated in 1 ml 
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of Lysogeny broth (Sigma) (1 % tryptone, 0.5 % yeast extract, 1 % NaCl, 0.1 % 
glucose) on a temperature controlled shaker (37 o C, 2 hrs, 180 rpm). Isolated 
colonies were expanded overnight (37 o C) by plating on 10 cm agar (Sigma) plates 
containing appropriate antibiotic (ampicillin or kanamycin at 150 mg/ml where 
stated).  
Mini plasmid preparations were carried out for DNA sequencing. Single 
colonies were inoculated in 5 ml of Lysogeny broth containing antibiotic and 
expanded overnight in aerated flasks (37 o C, 180 rpm). Glycerol stocks (15 % 
glycerol, 85 % culture) were prepared for each colony, immediately flash frozen in 
liquid nitrogen and stored at -80 o C for subsequent culture expansions. Plasmids 
were isolated from the remaining 4 ml of pelleted culture (4 o C, 10 min, 1000g) with 
the Plasmid Miniprep kit (Quiagen, Chatsworth, CA, USA) according to 
manufacturer’s instructions and sequenced to confirm the integrated plasmid 
product. 
Large scale plasmid production (Maxi prep) was required to generate 
concentrated plasmid stocks for mammalian cell transfections. Pre cultures in the 
exponential growth phase (10 hrs, 37 o C, 180 rpm) were transferred to aerated 
conical flasks containing 50 ml broth with appropriate antibiotic  and expanded for a 
further 8-10 hours. Plasmids were isolated from pelleted cultures (4 o C, 10 min, 
1000g) with the Wizard miniprep kit (Promega, Hampshire, UK) or Maxiprep kit 
(Quiagen, Chatsworth, CA, USA) according to manufacturer’s instructions. The 
Wizard miniprep kit was specifically used for purification of LRRK2 containing pET-
DEST51 plasmids as it generated the best yield for this plasmid (1 mg of plasmid per 
10 ml of culture). Quiagen maxiprep kit was used to purify the pEGFPN1 plasmid 
containing the UCP-GFP construct. 
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2.6 Concentration and purity of nucleic acids 
Concentration and purity of DNA and RNA samples was determined using a 
NanoDrop 1000 spectrophotometer (Thermo Scientific). Briefly, 1.5 µL of the sample 
was spotted onto the pedestal of the machine with sample absorbance determined 
at 260 nm (nucleic acid) and 280 nm (protein). The concentration of nucleic acids 
was calculated electronically by the NanoDrop 1000 software based on the equation 
A=εcl; where A is the absorbance of the sample, ε is the extinction coefficient, c is 
the concentration and l is the path length of sample. The 260/280 absorbance ratio 
was subsequently used to determine the purity of the DNA/RNA sample whereby 
values >1.8 for DNA and >2.0 for RNA were acceptable. Lower ratios suggested the 
presence of protein, phenol and other contaminants. 
2.7 Restriction enzyme digest of pET-DEST51 
To increase the probability of integration of the full length LRRK2 gene in 
mammalian cells LRRK2 containing plasmids were enzymatically digested targeting a 
region outside the LRRK2 coding sequence. The Fsp1 restriction enzyme (restriction 
site 5’tgc^gca3’, 3’acg^cgt5’, 5000 U/ml, New England Biolabs, Hitchin, UK) was 
chosen targeting position 6886 of the 7464 base pair pET-DEST51 plasmid. pET-
DEST51 plasmids (25 µg) purified as described in section 2.5  were digested (37 oC, 2 
hours) with Fsp1 in a final volume of 200 µl containing 20µl NEB buffer 2 (New 
England Biolabs). Digestion was terminated by enzymatic inactivation (65 oC, 20 
min). Digested constructs were recovered by ethanol precipitation (10 % NaAc, 250 
% v/v ethanol, -20 oC, o/n) and pelleted by centrifugation (4 oC, 30 min, 17,000 g). 
Pellets were washed in 80 % ethanol, air dried and resuspended in 20 µl deionised, 
sterile TE buffer. 
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2.8 Agarose gel electrophoresis 
Electrophoresis of PCR products, intact and digested plasmids was carried 
out on agarose gels. Briefly, 1 µg of sample was combined with 6X loading buffer 
(Fermentas) and electrophoresed (60 V) on 0.8 – 2 % Agarose gels prepared in Tris-
acetate-EDTA buffer ((TAE), 40 mM Tris, 20 mM acetic acid, 1 mM EDTA, pH 8) 
containing 0.005 % SYBR safe DNA gel stain (Life technologies) for visualization of 
separated band products. Bands were visualised by ultraviolet illumination with 
relative sizes estimated based on migration of adjacent reference markers (BioLabs). 
UV illuminated bands were captured on an Olympus digital camera. 
2.9 Transfection of mammalian cells 
                 SHSY5Y cells stably expressing wild type and G2019S LRRK2-V5 containing 
pET-DEST51 plasmids were generated and kindly donated by Dr. JM Cooper and Dr. 
K Chau (Clinical Neurosciences, UCL). Transfections of SHSY5Y cells with the 
linearized pEF-DEST51 plasmids containing the LRRK2 gene were carried out as 
previously described [293] using Superfect reagents (Quiagen, Hilden, Germany) 
according to manufacturer’s instructions. Plasmids (25 µg) were complexed with 
transfection reagent by incubation (15 min, RT) in serum free cell culture medium. 
Serum was omitted to prevent potential interference with complex formation. 
SHSY5Y Cells grown at 40 % confluency on 10 cm plates were treated with the 
mixture for 4 hours allowing for endocytosis of the plasmid, cultured overnight 
under standard conditions and subjected to blasticisdin (400 µg/ml) or puromycin 
selection (400 µg/ml) over a 6 week period. Culture medium was replaced every 2 
days to remove dead cells with the formation of antibiotic resistant colonies 
monitored over this time course. Isolated colonies grown to a radius of 0.5 mm were 
separated by polystyrene microchambers (Sigma), trypsinized and transferred to 2 
cm plates. Clones were grown to confluency and expanded for frozen stocks.  
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                 For transient protein expression purified plasmids were introduced into 
cells by electroporation. Cells (2.5 x 105) were harvested, washed once in PBS and 
resuspended in a mixture of 9 µl of reagent R and 1 µl of plasmid DNA (1 µg/ µl). The 
mixture was electroporated (Neon, Invitrogen, 1000 V, 30 seconds, 2 pulses), 
transferred to 1 ml growth medium without antibiotic and plated (1:5) on 6 well 
plates in a final volume of 2 ml. Cells cultured for a further two days under standard 
growth conditions.  
Gene silencing in SHSY5Y cells was achieved by introduction of small 
interfering RNA (siRNA) by the method of transient transfection. Details of siRNA 
sequences are described in (Appendix Table A1). Optimal siRNA delivery conditions 
for SHSY5Y cells were determined using fluorescently labelled siRNA constructs 
(Ambion). Transfection reagents; HiPerfect (Qiagen, Hilden, Germany), TransIT-TKO 
(Mirus ML015), TransIT-siQUEST (Mirus ML033), TransIT-2020 (Mirus MIR5400) were 
tested to determine which reagent achieved the most efficient siRNA delivery in the 
SHSY5Y cell line. Two volumes of transfection reagent (1 and 4 µl) were tested to 
determine whether the concentration would affect the efficiency of siRNA delivery. 
Transfection reagent was incubated with 10 nM fluorescently labelled siRNA in a 
final volume of 100 µl serum free culture medium (15 min, RT). SHSY5Y cells were 
plated at a density of 9 x 10-4 per well (24 well plate) in 500 µL of complete culture 
medium. Transfection mix was immediately added to the plated cells which were 
subsequently cultured overnight under standard culturing conditions. Transfected 
cells were identified by immunofluorescence 24 hours post transfection by red 
fluorescent punctate staining indicating the uptake of siRNA (Fig 2.1).  
Red punctuate staining was observed for SHSY5Y cells transfected with 4 µL 
of HiPerfect, ML015 and MIR5400 transfection reagents (Fig 2.1). 4 µL of HiPerfect 
reagent were chosen as the optimal siRNA delivery conditions as all the transfected 
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SHSY5Y cells contained red punctuate structures, unlike ML015 and MIR5400 where 
30 % and 60 % of the cells were positive for red fluorescence. 
 
2.10 Reverse transcriptase 
Total RNA was extracted from fibroblasts or SHSY5Y cells (1-5x104) with the 
RNeasy Mini kit (Qiagen) according to manufacturer’s instructions and quantified 
spectraphotometrically as described in Section 2.6. Purified RNA template (0.5 µg) 
was denatured and annealed (65 oC, 5 min) to random nanoamine primers (1 µL) in 
final volume of 10 µl (Primer design). Samples were cooled on ice (5 min) prior to 
addition of deoxyribonuclease 1 (1 µL), deoxynucleaotide triphosphate mix (dNTPs, 
0.5 mM), reducing agent dithiothreitol (DTT, 10 mM) (Primer Design) and sterile 
water to a final volume of 20 µl. The reverse transcriptase extension step (25 oC, 5 
min, 55 oC, 20 min), initiated at the primer binding sites, reverse transcribed the RNA 
template to produce complementary DNA (cDNA). Following reverse transcription, 
the enzyme was heat inactivated (75 oC , 15 min).  
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2.11 Real Time PCR 
For quantification of gene expression, 1 µL of the first strand cDNA sample 
was used as template in quantitative real-time PCR amplification with the TaqMan 
system or SybrGreen assay (Applied Biosystems, Paisley, UK). In TaqMan reactions 
an initial polymerase activation step (95 oC, 10 min) was followed by 40 cycles of PCR 
as described in the supplier’s protocol (15 sec at 95 oC, 1 min at 60 oC). Annealing 
temperatures for SybrGreen primers are described in (Appendix, Table A2), 
determined by subtracting 5 oC from the melting temperature (Tm) of the primer 
strand as calculated by the manufacturer (Eurogenetech), based on the length and 
nucleotide composition of the primer. Standard denaturation (95 °C, 15 sec) and 
extention (72 oC, 30sec) conditions were maintained across all SybrGreen 
experiments. 
SybrGreen primers were validated by cDNA template titration with a valid primer 
concentration range for PCR requiring one amplification cycle increase with doubling 
of template concentration (Fig 2.2A). RT PCR product melting curves were generated 
in a temperature range of 60-90 oC at 0.3 oC increments for each SybrGreen reaction 
to ensure specificity of amplifications for the gene target. Melting points of 
amplicons were considered appropriate in the range from 80 oC to 85 oC with 
additional peaks in the lower temperature range (60-80 oC) assigned to primer 
dimers (Fig 2.2B, C). Furthermore, TaqMan and SybrGreen PCR product sizes were 
checked by agarose gel electrophoresis with relative sizes estimated based on 
migration of adjacent reference markers (BioLabs) (Appendix, FigA2).  
The comparative cycle threshold (CT) method was used to quantify mRNA 
expression, correcting gene amplification to GAPDH CTs determined by the 
equation: Relative mRNA expression = (2-[∆∆Ct], ∆∆Ct = Ctgene-CtGAPDH) where the Ct 
value is the  cycle number at which the fluorescence signal crosses the threshold 
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(0.01), (Fig 2.2D). Threshold values were chosen based on the first detectable 
increase in fluorescence from RT-PCR products and maintained across all 
experiments.  
 
 
 
 78 
 
2.12 LRRK2 mutation screen in fibroblasts and SHSY5Y cells 
cDNA from control or G2019S fibroblasts, wild type and G2019S LRRK2-V5 
over-expressing SHSY5Y cells was screened for the presence of the G2019S mutation 
at position 6055 of the LRRK2 gene. Primers were designed targetting the LRRK2 
sequence flanking a 700 bp fragment on exon 41 of the LRRK2 gene containing the 
6055 nucleotide as part of the codon encoding the G2019A/S residue (Table A2). 
Primers (0.5 µM) were combined with 2 µL of total cDNA, and Phusion Flash High 
Fidelity PCR mastermix (Thermo Fisher Scientific, Loughborough, UK) in a final 
volume of 50 µl. The targeted region of LRRK2 was amplified by 30 cycles of a three 
step PCR amplification protocol as suggested by the manufacturer (denaturation 98 
oC 10 min, annealing 20 sec, elongation 72 oC 30 sec). Annealing temperatures were 
determined by subtracting 5 oC from the melting temperature (Tm) of the primer 
strand as calculated by the manufacturer (Eurogenetech), based on the length and 
nucleotide composition of the primer. A final 10 minute extention step (72 oC) 
completed the PCR reaction. The approximate size of PCR products was determined 
by agarose gel electrophoresis (Section 2.8). Products were sequenced at the 
Scientific Support Unit (Wolfson Institute for Biomedical Research, University 
College London). Sequence comparison was ncarried out by BLAST alignment 
(PubMed) on the human LRRK2 fasta entry registered in the Uniprot Database 
(NP_940980) with sequence profiles generated by Sequencher 5.0. 
2.13 Whole cell and tissue extractions 
                 SHSY5Y, fibroblast, lymphoblast cell pellets (1x106) or brain tissue (1 mg 
dry weight) were prepared for Western blot analysis by solubilization in 50 µl 0.1 % 
sodium dodecyl sulphate (SDS), 10 mM Tris HCL containing a cocktail of protease 
inhibitors (Thermo Scientific, targeting serine, cysteine, aspartic acid-proteases and 
amino peptidases). Brain tissue was homogenized in buffer with a Potter type 
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homogeniser, cleared by centrifugation (4oC, 17,000 g, 30 min) and sonicated (2 x 15 
s pulses on ice (Decon Fs 100b)). Chromosomal DNA in whole cell extracts was 
digested by treating samples with DNAse1 (Promega, 1/10th the total reaction 
volume) in enzyme buffer (1/10th the total reaction volume, 45 min, 37 oC). 
Following DNAse treatment cell extracts were centrifuged (4oC, 17,000 g, 10 min) to 
remove insoluble and aggregated components. 
2.14 Immunoprecipitation 
                  Immunoprecipitation procedures (IP) essentially followed those published 
by [215]. Cell pellets (6x106 cells per 500 µl buffer) were extracted (10 min, on ice) in 
lysis buffer  (LB: 50 mM Tris HCl, 0.27 M sucrose, 1 mM Na3VO4, 1 mM EDTA, 1 mM 
EGTA, 10 mM β-glycerophosphate, 5 mM sodium pyrophosphate, 50 mM NaF 
supplemented with 1 % Triton X100 (IP) or 1 % nonidet P-40 (NP-40) (for co-IP), 1 
mM benzamidine, 0.1 mM phenylmethanesulfonylfluoride (PMSF) and protease 
inhibitor cocktail), retaining detergent soluble fractions following centrifugation (4 
oC, 17,000g, 10 min).  
                 For brain IP, samples were processed as described in the Abcam IP 
datasheet in LB buffer (2.5 mg frozen tissue per 1 ml buffer) by 30 strokes with a 
Potter type homogenizer, pulsed twice by sonication and cleared by centrifugation 
(4oC, 17000 g, 30 min). In co-IP experiments sonication steps were substituted by 10 
passages through a 27 gauge needle (Terumo) to maintain integrity of protein 
complexes. 
               Immunoprecipatation required 1 mg of protein, incubated with 20 µL of 
Protein G agarose beads (Invitrogen) pre coupled to antibody (4 °C, 30 min). 1 mg of 
lysate with 20 µ agarose beads without the addition of antibody were included in 
parallel control experiments to discount potential binding of immunoprecipitated 
proteins to beads. Samples were incubated with rotation (4 °C, 2 hours), beads 
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collected by centrifugation (17,000 g, 1 min) and non specific interactions removed 
by washes in salt (500 mM NaCl for IP, 150 mM for co-IP) containing LB followed by 
two washes in LB buffer (17,000 g, 1 min). Pulled down proteins were eluted from 
the beads by solubilisation in 50 µl 2 X LDS sample buffer (Invitrogen) supplemented 
with 2X reducing agent (Invitrogen) with 25 µl of the eluted sample used for SDS 
PAGE.  
                 An un-cropped Western blot of LRRK2 immunoprecipitates from control 
fibroblasts is shown in (Appendix Fig A3) where a single 280 kDa 3514-1 
immunoreactive species was observed. 
2.15 Protein quantification 
                Protein quantification was carried out using the bicinchoninic acid (BCA) 
protocol (Pierce, Cramlington, UK) [294]. 2 and 4 µl of SDS (Section 2.13) or Triton 
X100 (Section 2.14) cell and tissue extracts were mixed with PBS to a final volume of 
25 µl in a 96 well plate (Starsted). Blank samples were those containing sample 
extraction buffer and PBS while bovine serum albumin (BSA, 0-2000 µg/ml) was used 
as protein standard. Kit components A and B were mixed in a 1:50 ratio and 200 µL 
of the mixture added to each well. Samples were incubated at 37 oC for 30 minutes 
and assessed spectraphotometrically by quantifying the light absorbance at 562 nm 
(Synergy HT BioTEK spectrophotometer). Protein concentrations were determined 
from the linear absorbance plot generated by the known concentrations of bovine 
serum albumin (BSA) protein standards for each measurement.   
2.16 SDS PAGE 
                Western blot analysis of SDS soluble lysates (Section 2.13) or Triton X100 
extracts (Section 2.14) required 25 µg of protein denatured in NuPAGE LDS sample 
buffer (Invitrogen) supplemented with NuPAGE sample reducing agent (Invitrogen). 
Proteins were heated (65 °C, 5 min) and electrophoresed on precast NuPAGE Novex 
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12 % or 4-12 % polyacrylamide Bis-Tris gels (Invitrogen) in the presence of MES (50 
mM MES, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.3 for higher molecular 
weight proteins, >150 kDa) or MOPS (50 mM MOPS, 50 mM Tris Base, 0.1% SDS, 1 
mM EDTA, pH 7.3, for lower molecular weight species, <150 kDa) SDS running buffer 
(Invitrogen) (RT, 45 min, 200 V) using the BioRad system (Hertfordshire, UK). For 
proteins of molecular weight >150 kDa, electrophoresis was extended to 60 minutes 
to improve the separation of higher molecular weight species [244]. 
2.17 Western blot analysis 
                SDS PAGE separated proteins were transferred to polyvinylidene fluoride 
(PVDF) membranes (GE Healthcare) (RT, 90 min, 30 V, BioRad system). Transfers 
were extended to 120 minutes for higher molecular weight proteins (>150 kDa). 
Membranes were subsequently blocked (RT, 1 hr) with 5 % w/v semi skimmed milk 
containing PBS with tween (PBS-T 0.3 % v/v) and incubated with primary antibodies 
under specified conditions (Appendix Table A3). Following washes in PBS-T (3 X 10 
min), horseradish peroxidase labelled secondary antibodies (Dako) were applied at 
1:3000 dilution in 5 % milk (RT, 1 hr). Membranes were washed again with PBS-T and 
protein bands visualized by chemiluminescence (Thermo Pierce) on X-ray film (GE 
Healthcare) estimating band molecular weights relative to standard protein markers 
of 10-250 kDa range (Precision Plus Protein Standards, BioRad). Protein bands were 
quantified by densitometry using Image J software. 
2.18 Native gel electrophoresis 
Blue native PAGE (BN PAGE) electrophoresis was carried out to investigate 
the native structure of LRRK2 complexes, according to manufacturer’s instructions 
based on the protocol developed by [295]. To recover soluble proteins, flash frozen 
brain tissue (1 mg) or freshly prepared cell pellets (8x106 cells) were homogenised 
(Potter homogeniser) in 50 µl volume of 4X Native PAGE sample buffer (50 mM 
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BisTris, 6N HCl, 50 mM NaCl, 10 % w/v glycerol, 0.001 % Ponceau S, pH 7.2, 
Invitrogen) with the addition of a cocktail of protease inhibitors (Thermo scientific). 
Samples were further processed with a 27 gauge needle (20 strokes) and cleared by 
centrifugation (4oC, 30 min, 20,000 g). Protein samples (20 µg) were loaded on to 4-
12 % Native-PAGE Novex Bis-Tris gels (Invitrogen) in the presence of 0.25 % v/v 
coomassie blue loading additive (Invitrogen). Electrophoresis was carried out in 
anode buffer (AB, outer tank chamber: 50 mM BisTris, 50 mM Tricine pH 6.8) and 
cathode buffer (inner tank chamber, AB containing 0.02 % v/v coomassie brilliant 
blue) at 150 V. Once approximately 1/3 of the coomassie blue border migrated 
down the gel, the cathode buffer was replaced by AB containing 0.002 % v/v 
coomassie buffer and electrophoresed for a further 1 hour (150 V). Separated 
proteins were transfer to PVDF membranes (30 V, 120 min). Membranes were 
equilibrated in absolute methanol to remove excess coomassie dye. NativeMark 
Unstained Protein Standards (20-1236 kDa, Invitrogen) were visualized by incubating 
in Ponceau S staining solution as reference markers to approximate the molecular 
weight of resolved protein complexes. 
2.19 Immunofluorescence of cultured cells 
Cells plated up to 40 % confluency on 22 mm coverslips were fixed in 4 % 
paraformaldehyde (PFA, room temperature, 15 min) and permeabilized in absolute 
methanol (MeOH, -20 oC, 20 min) [296]. For visualization of nuclear proteins, 
paraformaldehyde fixation was followed by permeabilization with 0.1 % Triton 
(room temperature, 30 min) [297]. Nuclear staining required detergent 
concentrations to be maintained throughout the immunostaining procedure. 
Immunocytochemistry for LRRK2 labelling omitted PFA and required MeOH (-20 oC, 
20 min), acetone (-20 oC, 5 min) permeabilization/fixation conditions [298]. During 
protocol optimization to determine optimal conditions for LRRK2 staining; PFA 
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fixation followed by sodium citrate (95 oC, 20 min), 1 % Triton X 100 (RT, 30 min) or 
MeOH permeabilization (as above) were also tested on control versus wild type 
LRRK2-V5 over-expressing SHSY5Y cells. Permibilized cells were subsequently 
processed in parallel using the same conditions. 
PBS washes (3X times) were preformed after each stage of the staining 
procedure. Following permeabilization, non specific binding was blocked by 10 % 
normal goat serum (NGS, Life Technologies) (RT, 30 min) and primary antibodies 
applied at appropriate dilutions (Appendix, Table A3) in 10 % NGS (RT, 2 hrs), 
followed by incubation with fluorescently labelled secondary antibodies (1:200, 
Molecular Probes) in 2 % NGS. Coverslips were mounted on glass slides with Citifluor 
containing Hoechst trihydrochloride trihydrate (1 mg/ml, Invitrogen) for nuclear 
counterstain.  
Fluorescent images were acquired using the same exposure settings with an 
Axiophot fluorescent microscope, KS400 software (Zeiss, Welwyn Garden City, UK) 
equipped with 40X and 100X PlanNeoFluar lenses and the appropriate fluorescent 
filters.  
2.20 Immunohistochemistry on human and mouse brains  
Flash frozen mouse brain hemispheres embedded in optimum cutting 
temperature medium (OCT, Sakura) were cut into 12 µm sagittal slices by cryostat 
(OTF5000, Bright, Huntingdon, UK) sectioning and mounted on glass slides. Sections 
were dried (37 oC, 15 min) and frozen (-80 oC) until further processing. On the day of 
the staining, sections were thawed (RT, 15 min) and fixed in 4 % PFA (RT, 15 min) 
[299]. 
PBS washes (3X, 5min) were preformed after each stage of the procedure. 
Endogenous peroxidases were blocked (MeOH, 1 % H2O2, 10 min), followed by 
blocking of non specific binding (10 % goat serum, 30 min) and incubation with 
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primary antibodies (Table A3, 4 oC, o/n). The following day, sections were incubated 
with biotin labelled anti-rabbit secondary antibodies (Gibco, 1:200, RT, 30 min) and 
positive immunoreactivity visualized by 3’,3’diaminobenzidine (DAB) oxidation 
induced by hydrogen peroxide (1% in PBS solution). DAB brown colour development 
was monitored at 1 minute intervals to obtain the optimal signal to noise staining for 
each set of experiments. DAB oxidation was terminated by washing slides in PBS 
solution. Nuclei were counterstained with haematoxyline (5 min) and differentiated 
in acid alcohol (0.3 %) to remove background colouration. Differentiation was 
arrested by rinsing slides in warm tap water where the alkaline environment 
converted the histone bound haematin to a blue colour. Sections were dehydrated 
in ethanol baths of increasing ethanol concentration (70 – 100 %) followed by xyline 
to prepare slides for mounting with organic based neutral mounting medium (DPX, 
Leica).  
Images of relevant brain regions were captured on the Leica opitical imaging 
system (DM4000 B, Wetzlar, Germany) at 20X, 100X and 200X magnifications. 
2.21 LRRK2 kinase activity assays 
In vitro LRRK2 kinase activity assays were performed on LRRK2 
immunoprecipitated from 1 mg of cell lysate or 0.5 µg of recombinant GST-LRRK2 
(with the help of Francisco Inesta-Vaquera (Dundee)). Recombinant GST-LRRK2, GST-
Moesin and GST-UCP2 proteins were prepared and purified by Francisco Inesta-
Vaquera (Dundee) as previously described [202]. Briefly, 5 µg of pEBG-2T encoding 
residue 1326-end of LRRK2, full length Moesin or full length UCP2 was transiently 
transfected into HEK293 cells with 60 µl polyethylenimine in 3 mls of media, as 
suggested by the manufacturer (Sigma). Cells were cultured for 36 hours following 
transfection and extracted in LB (50 mM Tris HCl, 0.27 M sucrose, 1 mM Na3VO4, 1 
mM EDTA, 1 mM EGTA, 10 mM β-glycerophosphate, 5 mM sodium pyrophosphate, 
 85 
 
50 mM NaF) supplemented with 0.5 % NP40 and 150 mM NaCl. GST tagged proteins 
were purified from cell lysates by chromatography on glutathione-sepharose and 
bound proteins eluted in buffer containing 20 mM glutathione and 0.27 M sucrose.  
Kinase assays [215] were carried out in a volume of 50 µL containing kinase 
reaction buffer (RB, 50 mM Tris, 0.1 mM EGTA, pH 7.5), 10mM MgCl2, 0.1 M DTT, 20 
µM of LRRKtide substrate (RLGRDKYKTLRQIRQ) and 0.1 mM [32P] adenosine 
triphosphate (ATP) (300 cpm/pmol). LRRK2 bound to IP beads was in a volume of 15 
µL with the final reaction volume obtained by the addition of deionised H2O. 
Reactions were initiated with the addition of the LRRK2 kinase and incubated for 20 
minutes at 30 oC. Reactions were terminated by addition of 12.5 µL EDTA (50 mM), 
centrifuged (17,000 g, 1 min) and 40 µL of the supernatant spotted on 
phosphocellulose p81 paper (Whatman). Samples were air dried and washed 
sequentially in 50 mM ortho-phosphoric acid (20 min, 3 times). Following acid 
treatment, samples were rinsed with 100 % acetone, dried and the amount of 
incorporated radioactivity assessed by Cerenkov counting in the presence of 
scintillation fluid.  
The LRRK2 kinase specific activity was calculated as: SA= cpm from 
reaction/[(SA of [32P] ATP in cpm/pmol)*(reaction time (min))*(enzyme amount in 
µg)]*[(reaction volume)*(spot volume)]. 
LRRK2 bound to beads in the pelleted fraction was eluted by addition of 4X 
sample buffer (Invitrogen) and analysed by Western blotting to correct for LRRK2 
input.  
2.22 Isolation of PMBCs and cell sorting 
Peripheral blood mononuclear cells (PMBCs) were isolated from 50 ml of 
whole blood by density gradient centrifugation (Axis Shield, Dundee, UK), as 
described by the manufacturer. Briefly, blood (diluted 1:1 in isolation buffer (IB: PBS, 
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0.5 % bovine serum albumin (BSA), 2 mM EDTA, pH7.2), layered onto a buffy coat 
gradient was fractionated by centrifugation (8,000 g, RT, 20 min). The white PMBC 
enriched layer located below the serum fraction was extracted with a 3 ml pasteur 
pipette into a 50 ml falcon tube. PMBCs were subsequently washed in cold IB (4 oC, 
800 g, 5 min), counted as described in section 2.4 and incubated with magnetically 
labelled anti CD4, CD8 or CD19 antibodies (10 µl/105 cells) (Miltenyi, Surrey, UK, 4 
oC, 1hr). Labelled cells were purified by positive magnetic selection (MiniMACS 
separator, Miltenyi) on LS columns (Miltenyi). 
Purified cells were re-suspended at a concentration of 1x106cells/ml in HBSS 
(156 mM NaCl, 3 mM KCl, 2 mM MgSO4, 1.25 mM KH2PO4, 2 mM CaCl2, 10 mM 
glucose, 10 mM HEPES, pH 7.35) and 100 µl of the cell suspension added to 4ml 
polystyrene round bottomed tubes (Sigma). Mouse anti human conjugated 
monoclonal antibodies used to analyse purified cells were supplied by Becton 
Dickinson Biosciences (Oxford, UK) and used at a volume of 10 µl/105 cells. 10 µl of 
CD4 (FITC), CD8 (FITC), CD19 (PC) and CD21 (CytC) were added to the tubes, samples 
vortexed and incubated at room temperature in the dark for 15 minutes. Cells were 
then washed free of excess antibody by adding 2mls of HBSS and centrifuged (200 g, 
5 min). Supernatants were decanted and cells re-suspended in 500 µl of HBSS prior 
to flow cytometry acquisition. 
FACS analysis was carried out by Janet North (Royal Free Hospital, UCL). All 
readings were acquired on a BD FACSAria II analyser as list mode data files using 
FACSDiva software. A forward scatter (FSC) versus side scatter (SSC) dot plot was 
created to gate on the live lymphocyte like region of cells (P1) and to exclude cell 
debris. A second dot plot was created to show expression of cells from P1 region for 
CD19 against FSC. Region P2 was drawn to include all live cells from P1. A third dot 
plot was generated to show CD19 versus CD21 which included cells from P1 and P2 
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regions. A fourth dot plot was created to look at the expression of CD4 and CD8 on 
P1 and P2 regions to identify any contaminating T cells. Purity of CD8 and CD4 T cells 
was analysed in a similar manner. Cell populations of >90 % purity were used for 
Western blot analysis. 
2.23 Cellular fractionation  
Lymphoblasts or SHSY5Y cells were harvested as described in Section 2.4. 
Cell pellets (20x106) were resuspended in homogenization buffer (2 ml, HB: 320 mM 
sucrose, 10 mM Tris HCl, 1 mM EDTA pH 7) containing protease inhibitors (Thermo 
Scientific). Disruption of plasma membranes was achieved by nitrogen cavitation 
(Parr Instrument Company, Moline Illinois) at 1200 psi (4 oC, 20 min). Sub-cellular 
fractions were obtained by sequential centrifugation at; 1000 g (P1); 12,000 g (P2); 
27,000 g (P3) (4 oC, 10 min, Sorvall Super T21, DuPont); 47,000 g (P4) (4 oC, 15 min, 
Kontron, P4, T124, Centrikon, Zurich, Switzerland) and 200,000 g (P5) (4 oC, 90 min, 
P5, Beckman Coulter, High Wycombe, UK) respectively [300]. Pellets were washed 
once in HB buffer while cytosolic fractions were concentrated in 30 kDa cut off 
concentrator columns (Millipore) to a final volume of 50 µL. Fractions were 
solubilised in 50 µl of SDS sample buffer and 10 % of each sample analysed by 
Western blotting. 
2.24 Affinity purification of mitochondria 
Lymphoblasts or SHSY5Y cells were harvested as described in Section 2.4. 
Cells (4x106) were lysed by repeated passage through a 27 gauge needle. Optimal 
homogenization conditions were determined by visual inspection of intact cell 
densities in trypan blue stained cell sample following increasing strokes with a 27 
gauge needle in 1 ml buffer supplied with the mitochondrial isolation kit (Miltenyi, 
Surrey, UK). Conditions (25 strokes for lymphoblasts, 30 strokes for SHSY5Y cells) 
achieving >90 % disruption of cells were chosen for subsequent experiments. 
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Extracted cell suspensions were centrifuged to remove unbroken cells and nuclei (10 
min, 4 oC, 1000 g). 10 % of the post nuclear supernatant (PNS) was retained to 
evaluate mitochondrial recovery. Magnetically tagged Tom22 antibodies labelled 
mitochondria in cell extracts (4 oC, 1 hr with rotation) and immunoreactive products 
were isolated by positive magnetic selection (MiniMACS separator, Miltenyi) on 
isolation columns (LS columns with a 30 µM cut-off, Miltenyi) [301]. Magnetically 
bound products were washed three times in buffer supplied with the kit and eluted 
in a final volume of 1 ml by removing samples from the magnet and applying the 
plunger supplied with the column. Affinity purified mitochondria were pelleted by 
centrifugation (12,000 g, 2 min).  
The PNS sample and affinity purified mitochondria were solubilised in 
equivalent volumes of SDS sample buffer and analysed by Western blotting as 1/10 
PNS and 9/10 mitochondria. 
2.25 Mitochondrial sub-fractionation  
 Mitochondrial enriched fractions (MEF) isolated by differential 
centrifugation (12,000 g, as described in section 2.23) or mitochondria isolated by 
affinity purification from (4x106 for each extraction condition) SHSY5Y cells were 
incubated (30 min, 4 oC) in HB buffer, HB supplemented with increasing 
concentration of digitonin (0.5 – 3 mg/ml), hypotonic buffer (10 mM Tris HCl, 100 
mM NaCl, pH 7.6) or 100 mM Na2CO3 (pH 11.5 followed by 5 min sonication) [302]. 
Samples were separated into soluble and insoluble components by centrifugation (4 
°C, 20,000 g, 30 min) and pellets washed in appropriate buffers. Final pellets and 
soluble fractions were solubilised in 50 µl of SDS sample buffer and 10 % of each 
sample analysed by Western blotting. 
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2.26 Proteinase K digestion of mitochondria 
Affinity purified mitochondria (12x106 SHSY5Y cells) resuspended in 
proteinase K buffer (0.6 M sorbitol, 20 mM HEPES K-OH, pH 7.4) were digested with 
0.5 or 1 µg/ml freshly prepared proteinase K enzyme (stock 50 µg/ml in buffer PB) 
for increasing incubation periods (0-30 min) [302]. Digestion was terminated by 
inhibiting proteinase K with phenyl methyl sulphonyl fluoride (PMSF, 1 µM, 4 °C, 10 
min). Samples were subsequently separated into soluble and insoluble components 
by centrifugation (4 °C, 17,000 g, 10min), solubilised in 50 µl of SDS sample buffer 
and 10 % of each sample analysed by Western blotting. 
2.27 Single cell analysis by confocal microscopy 
2.27.1.1 Mitochondrial membrane potential: TMRM 
Tetramethylrhodamine Methyl Ester (TMRM) is a cationic lipophilic 
fluorescent dye incorporated into the mitochondrial matrix specifically by the 
electrochemical gradient generated by the mitochondrial membrane potential (Ψm) 
and can be used to quantify the Ψm in live cells. Fibroblasts or SHSY5Y cells were 
seeded on 20 mm coverslips at 30 % confluency and cultured over night under 
standard culturing conditions. The following day, mitochondrial membrane potential 
was assessed by staining cells with 25 nM TMRM (Molecular probes, 45 min, RT) in 
respiration buffer (HBSS: 156 mM NaCl, 3 mM KCl, 2 mM MgSO4, 1.25 mM KH2PO4, 2 
mM CaCl2, 10 mM glucose, 10 mM HEPES, pH 7.35) [303]. TMRM intensity was 
measured in the presence of oligomycin (2 mg/ml), trifluorocarbonyl cyanide 
phenylhydrazone (FCCP, 0.5 M), LRRK2 IN-1 inhibitor (1 µM 90 min treatment prior 
to rate measurements) and genipin (1.375-10 nM) where stated. 
               Fluorescent images were acquired on an inverted laser scanning confocal 
microscope (LSM510 Zeiss, Oberkochen, Germany) by exciting samples at 543 nm 
with maximum laser power directing speciments with the HFT 485/540 short pass 
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filter. Emitted red fluorescence was captured by 40x magnification through an oil 
objective with numerical aperture of 1.2 where a 560 nm long pass filter transmitted 
all light above 560 nm. Pinhole diameter was set at 244 to eliminate out of focus 
fluorescence reaching the detector. The detector gain was adjusted to 464 allowing 
for amplification of the fluorescent image and the amplifier offset set to 0.035 as the 
cut off thresh hold below which pixels were displayed as black. 12 Bit images were 
collected as the average of four scans (scan speed 7); 255 x 255 pixels for normal 
resolution increasing the pixel depth to 1024 x 1024 for high resolution images. In 
time course measurements images were acquired by a single image scan as 8 bit; 
255 x 255 pixels at 5 or 8 minute intervals to reduce laser exposure to cells.  
                Images were projected through the 1.52 µm Z stacks for a maximum 
intensity two dimentional TMRM image. TMRM fluorescence was quantified using 
Metamorph software calculating the average signal intensity per cell with a set 
threshold value to eliminate background noise determined independently for the 
daily set of TMRM measurements. Approximately 30 individual SHSY5Y cells or 15 
fibroblasts were analysed for each imaged field, four fields per coverslip in two 
(SHSY5Y) or four (fibroblasts) independent experiments (n=200 cells per cell line). 
Data was expressed as the mean ± SEM, relative TMRM fluorescence (RFU) per cell. 
2.27.1.2 Method validation for TMRM 
TMRM staining of control fibroblasts resulted in accumulation of the red dye 
within the mitochondrial compartment ((↓)Fig 2.3A). The TMRM fluorescence was 
found to be stable for at least one hour after the initial incubation period and all 
subsequent measurements were confined to this time frame (Fig 2.3A). 
Trifluorocarbonyl cyanide phenylhydrazone (FCCP) is a chemical uncoupler of 
oxidative phosphorylation known to dissipate the mitochondrial membrane 
potential. FCCP addition (1 µM) resulted in a 2 fold reduction of the TMRM signal 
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intensity accompanied by redistribution of the dye to the cytosolic compartment 
(*↓) consistent with dissipation of the proton gradient (Fig 2.3A, B). TMRM 
response to FCCP treatment validated the specificity of the dye for mitochondrial 
structures in pre treated cells.  
Oligomycin inhibits the mitochondrial ATPase, complex V of the 
mitochondrial respiratory chain resulting in the accumulation of protons in the 
mitochondrial matrix and increased mitochondrial membrane potential. Monitoring 
TMRM intensity over time in the presence of oligomycin (4 mg/ml) detected a 
gradual 75 % increase in TMRM fluorescence when compared to the stable signal of 
untreated cells (Fig 2.3C, D). Increased TMRM intensity reflected changes to the 
mitochondrial proton gradient consistent with the accumulation of protons in the 
mitochondrial matrix due to inhibited ATPase activity. TMRM response to FCCP and 
oligomycin suggested the methodology could be manipulated in a predictable way. 
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2.27.2 Mitochondrial content  
                Mitochondrial content was assessed by TMRM staining of fibroblasts 
seeded at 40 % confluency on 20 mm cover slips. Live cell TMRM images were 
collected before (↓) and after (*↓) addition of 1 µM FCCP releasing the TMRM dye 
into the cytosol to provide an image of the cell contour (Fig 2.4). Maximal intensity Z 
projections of the TMRM signal were binarized in Image J and the proportion of the 
binarized signal quantified relative to the cell contour (**↓). Quantification of the 
binarized TMRM signal in Image J generated four values; minimum = 0, black image, 
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maximum = 255 white image, cell area and the mean TMRM intensity representing 
the proportion of the highlighted area as white. The % TMRM density per area of cell 
was calculated as [(mean TMRM intensity/255)*100]. 
 
2.27.3 GFP 
                SHSY5Y cells transiently transfected with GFP-UCP2 constructs (1 µg) were 
seeded on 20 mm coverslips at 40 % confluency and assessed by confocal 
microscopy 48 hours post transfection for the presence of green fluorescence. 
               Fluorescent images were acquired on an inverted laser scanning confocal 
microscope (LSM510 Zeiss, Oberkochen, Germany) by exciting samples at 488 nm 
with 10 % laser power directing speciments with the HFT 405/488/543 short pass 
filter. Emitted red fluorescence was captured by 40x magnification through an oil 
objective with numerical aperture of 1.2, a 515 nm long pass filter transmitted all 
light above 515 nm. Pinhole diameter was set at 244 eliminating out of focus 
fluorescence reaching the detector. The detector gain was adjusted to 688 allowing 
for amplification of the fluorescent image and the amplifier offset set to 0.015 as the 
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cut off threshold below which pixels were displayed as black. Image resolution 
parameters; pixel depth, scan speed and time course acquisition specifications are 
described in Section 2.27.1.1. 
2.28.1.1 Cellular respiration: oxygen electrode 
                Cellular oxygen utilization rates were analyzed polarographically using a 
micro-Clark-type oxygen electrode (YSI, Hampshire, UK) [304]. The electrode was 
calibrated with air saturated respiration buffer (HBSS) thermostatically maintained 
at 37 °C. Whole fibroblasts or SHSY5Y cells (4x106) were resuspended in 250 µL of 
respiration medium (HBSS) and extracellular oxygen levels monitored in a sealed 
chamber over a period of 10 min. Uncoupled rates and mitochondrial proton leak 
were measured in the presence of FCCP (0.5-2 µM) or oligomycin (1-4 mg/ml) 
respectively. In experiments involving LRRK2 IN1, cells were treated with the 
inhibitor under standard culturing conditions (1 µM, 90 min) with LRRK2 IN1 
maintained in solution throughout the harvesting steps and respiration 
measurements. Rates were calculated as the % decrease in the full scale deflection 
(FSD) per minute with 0 % FSD determined by addition of 1 μM cyanide. The rates of 
change of FSD were converted to changes in oxygen concentration assuming 406 
nmol O per ml at the given temperature and corrected for protein content. 
2.28.1.2 Method validation for the oxygen electrode 
Extracellular oxygen concentrations measured by the oxygen electrode for 
control fibroblasts showed a linear decrease in the signal over the course of the 10 
minute measurement consistent with oxygen depletion as a result of cellular 
respiration (Fig 2.5A). Oxygen levels were stable in the presence of the respiratory 
chain complex IV inhibitor cyanide, reflecting inhibition of cellular oxygen 
consumption and validating the specificity of our linear rate signals.  
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FCCP was used to investigate maximal respiratory capacity by the Clark type 
oxygen electrode. Polarographic measurements of oxygen consumption in control 
fibroblasts showed that the same concentration of FCCP (1 µM) used to dissipate the 
mitochondrial membrane potential (Fig 2.3B) resulted in a two fold increase in the 
rate of cellular oxygen consumption consistent with an uncoupling effect on the ETC 
(Fig 2.5B). Titrating in more FCCP to 2 µM resulted in a reduced respiratory rate 
indicative of mitochondrial toxicity as has previously been described for this 
compound [305]. 
Oligomycin was used to investigate mitochondrial proton leak by the Clark 
type oxygen electrode. Polarographic measurements of oxygen consumption in 
control fibroblasts showed that addition of oligomycin at 4 mg/ml stabilized 
extracellular oxygen levels (Fig 2.5C) consistent with inhibition of cellular respiration. 
Lower oligomycin concentrations (1-3 mg/ml) showed a partial (70 %) decrease in 
the linear rate of oxygen depletion rate signal potentially due to incomplete 
inhibition of the mitochondrial ATPase. 4 mg/ml oligomycin were chosen for 
subsequent experiments as the concentration required to inhibit the mitochondrial 
ATPase in fibroblasts. Inhibition of mitochondrial respiration by cyanide and 
oligomycin as well as mitochondrial uncoupling by FCCP suggests the methodology 
could be manipulated in a predictable way. 
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2.28.2.1 Cellular respiration: phosphorescent analysis 
                Phosphorescent analysis of cellular oxygen utilization is an assay based on 
the ability of oxygen to quench the excited state (lifetime) of the porphyrin based 
extracellular MitoXpress probe. As cellular respiration occurs oxygen is depleted in 
the surrounding environment correlating with an increase in the probe 
phosphorescent signal.  
                Phosphorescent analysis of oxygen utilization required 50,000 fibroblasts 
seeded per well on standard 96-well plates (Sarstedt) pre-coated with 0.007 % 
collagen IV (Sigma) [306]. Measurements were conducted in 100 µl of air-
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equilibrated DMEM supplemented with 1 mM pyruvate, 10 mM glucose (or 10 mM 
galactose where stated), 20 mM HEPES (pH 7.4) and 100 nM of phosphorescent 
MitoXpress-Xtra probe (Luxel Biosciences). Compounds used in the manipulation of 
respiratory chain function (antimycin A (1 µM), rotenone (1 µM), FCCP and 
oligomycin) were added at this point. Medium was overlaid with 50 µl of highly 
viscous oil to prevent oxygen diffusion.  
                The plate was monitored at 37 °C on a Victor 2 time resolved fluorescent 
(TR-F) reader (PerkinElmer, Cambridge, UK) with a Samarium filter set (340 nm 
excitation, 642 nm emission). Duplicate TR-F intensity (F1, F2) readings were 
recorded in a gated (100 µs) measurement window at two delay (t1=30, t2 =70 µs) 
intervals. Measured TR-F intensity signals (F1, F2) for each well were converted into 
phosphorescence life-time values as follows: τ = (t1–t2)/ln(F1/F2). To determine the 
rate of change of probe phosphorescence in the presence of respiring cells lifetime 
values were determined at 2 min intervals over 90 min. An initial temperature 
equilibration phase of the probe lasting approximately 15 minutes was excluded 
from the rate measurement.  
                Oxygen consumption rates were calculated as the rate of phosphorescent 
life intensity change in relative phosphorescent units (RPU) by taking the slope of 
the background subtracted linear signal. Rates were corrected for protein content. 
2.28.2.2 Method validation of phosphorescent analysis 
Phosphorescent analysis of control fibroblasts determined a linear increase 
in the probe phosphorescent lifetime consistent with oxygen depletion in the 
extracellular medium (Fig 2.6A). The rate of change of phosphorescent lifetime was 
reduced to 30 % of the basal rate in untreated fibroblasts with the addition of 
rotenone (1 µM) consistent with inhibition of mitochondrial respiration (Fig 2.6B).  
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Control fibroblasts were treated with increasing concentrations (0-5 µM) of 
the chemical uncoupler. FCCP at 1 µM, a concentration shown to dissipate the 
mitochondrial membrane potential resulted in a 50 % increase in phosphorescent 
lifetime rate values with respiration rates reaching a maximum of 170 % at 1.5 µM 
relative to untreated cells (Fig 2.6C). Rates were comparable to basal values at 
higher FCCP concentrations. FCCP induced reduction in oxygen consumption at 
higher concentrations are indicative of mitochondrial toxicity [305]. The 
phosphorescent response to rotenone and FCCP suggested the methodology could 
be manipulated in a predictable way. 
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2.29.1 Extracellular acidification 
               The pH-Xtra probe monitors cellular acid extrusion. The pH-Xtra 
phosphorescence signal is modulated by pH changes such that increased 
acidification causes increased phosphorescence. Extracellular acidification is an 
indirect measure of the conversion of pyruvate to lactic acid in cells and provides 
information on rates of glycolytic activity. 
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                 Rates of extracellular acidification were monitored as previously described 
[305]. Fibroblasts (50, 000 cells per well) were seeded on standard 96- well plates 
(Starstedt) pre-coated with 0.007 % collagen IV. Cells were maintained in buffer free 
DMEM supplemented with 1 mM pyruvate, 10 mM glucose (or 10 mM galactose 
where stated), 20 mM HEPES (pH 7.4) in a CO2 free incubator at 37 °C for 3 hours 
prior to analysis. Medium was replaced with 100 µL of fresh solution containing 1 
µM of pH-Xtra probe. Compounds used in the manipulation of respiratory chain 
function (antimycin A (1 µM) and FCCP) were added at this point. 
               Time resolved fluorescence (TR-F) was recorded on a Victor 2 plate reader 
thermostatically maintained at 37 °C utilizing a europium filter set (340 ± 35 nm 
excitation, 615 ± 8.5 nm emission). Duplicate TR-F intensity (F1, F2) readings were 
recorded in a gated (30 µs) measurement window at two delay (t1=100, t2 =300 µs) 
intervals allowing for calculations of phosphorescence lifetime values τ = (t1–
t2)/ln(F1/F2). For calculations of extracellular acidification τ was converted to pH = 
(1893.4 - τ )/227.54 and [H+] = (ln(- pH)) (Fig 2.7A, B, C). To determine the rate of 
change of probe phosphorescence, pH and [H+] lifetime values were acquired at 2 
min intervals over 90 min. An initial temperature equilibration phase of the probe 
lasting approximately 15 minutes was excluded from the rate measurement.  
                Extracellular acidification rates were calculated as the rate of change in [H+] 
per minute by taking the slope of the background subtracted linear signal and 
corrected for protein content. 
2.29.2 Method validation for extracellular acidification measurements 
Fluorescent analysis of the pH sensitive probe in the presence of control 
fibroblasts determined a linear increase in the lifetime of probe phosphorescence 
consistent acidification of the extracellular medium (Fig 2.7A). 
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FCCP effects on extracellular acidification rates showed a dose dependent 
increase in the phosphorescent signal (Fig 2.7D) suggesting faster extracellular 
acidification as a result of increased rates of anaerobic glycolysis. The titration 
reached maximum rates, 50 % above basal acidification at 1 µM, comparable to 
rates observed at higher FCCP concentrations consistent with glycolysis functioning 
at maximum capacity despite mitochondrial toxicity.  
Inhibition of the mitochondrial respiratory chain by antimycin A increased 
the basal rate of extracellular acidification by 50 % (Fig 2.7E), mimicking the 
response to FCCP treatment and consistent with upregulated glycolytic flux in 
response to complex III inhibition. The probe phosphorescent lifetime response to 
FCCP and antimycin A suggested the methodology could be manipulated in a 
predictable way. 
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2.30 Cellular ATP content 
Fibroblasts were seeded at a density of 10, 000 cells per well on opaque-
walled 96 well plates (Nunc) and total cellular ATP was quantified in luminescence 
units using CellTiter-Glo assay (Promega) according to manufacturer’s instructions. 
Briefly, following removal of culture medium and a PBS wash, 100 µL of CellTiter-Glo 
reagent containing renilla luciferase was added to each well. Cells were incubated 
with the reagent (10 min, RT) allowing for cell lysis to occur. Plates were incubated 
on a built in orbital shaker (Victor 2 plate reader) for 2 minutes following which end 
point luminescence readings were acquired (excitation 375 nm, emission 495 nm). 
Luminescence values were corrected for protein content.  
2.31 Cellular ROS production: Array Scanner 
               Oxidised forms of dihydroethidium dye (DHE) have high affinity for DNA. 
Upon oxidation, the fluorescent characteristics of reduced DHE (blue) change and 
the red signal accumulates in the nucleus. Fluorescent properties of DHE can be 
exploited to measure cellular ROS production.  
                Fibroblasts seeded at a density of 5000 cells/well on 96 well plates (Nunc) 
were stained with 4’,6-diamidino-2-phenylindole (DAPI) in culture medium (1 µM, 37 
°C, 20 min). Medium was replaced with HBSS containing 100 nM dihydroethidium 
(Molecular probes). Generation of reactive oxygen species was monitored by 
exciting samples with LED light source (543 nm (DHEox) and 361 nm (DAPI)) at 37 °C, 
5% CO2 at 2 minute intervals for 1 hr (Array Scan VTI HCS Reader, Thermo Scientific, 
Pittsburg, USA) [307]. Emitted Red fluorescence was captured within the Dapi 
stained nuclear contour by a 20 X LD Plan-Neofluar objective through an automated 
filter wheel monitoring the increase in red fluorescence over the course of the 
measurement (Fig 2.8). Images were analyzed with the Cellomics Target Activation 
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Bio Application to assess the average DHE intensity per cell (n=100 per cell line) for 
each time point allowing for rates of DHE oxidation to be quantified in real time. 
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Chapter 3: Results 
Characterization of LRRK2 in cell models and brain tissue 
Western blot analysis of LRRK2 expression has previously been used to detect 
over-expressed LRRK2 in cultured cells as well as endogenous LRRK2 in cells of the 
immune system and tissues like kidneys, lungs and lymph nodes. However, previous 
reports using in house and commercial antibodies have struggled to detect low levels 
of endogenous LRRK2, suggesting better antibodies or more sensitive detection 
methods are required. Immunohistochemistry has been used to detect LRRK2 in 
mouse and human brain tissue while immunoprecipitation has been reported to 
detect endogenous brain LRRK2 protein and is often utilized for LRRK2 isolation from 
cells for use in enzymatic activity assays, however its use for quantitative comparison 
of LRRK2 expression has not been fully assessed. This chapter explored Western 
blotting, BN PAGE, immunohistochemistry and a combined immunoprecipitation and 
Western blot approach as methods to characterize LRRK2 protein expression in 
SHSY5Y cells over-expressing wild type and G2019S LRRK2-V5, control and G2019S 
PD patient fibroblasts, lymphoblasts and brain tissue, addressing the problem of 
endogenous LRRK2 detection. Furthermore, the protein detection methods were 
extended to characterization of LRRK2 cellular distribution and enzymatic activity 
measurements to determine the properties of the wild type LRRK2 protein as well as 
effects of the G2019S mutation on LRRK2 expression, localization and enzymatic 
activity.  
3.1. Western Blot analysis of LRRK2 protein expression in cell models and brain 
tissue 
To determine the sensitivity of LRRK2 detection by Western blot in our 
endogenous and over-expressing LRRK2 cell model systems, four commercially 
available antibodies (NT2, 100-500, C terminal, 3154-1) raised to different regions of 
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the LRRK2 protein (Fig 3.1A) were screened for their ability to detect LRRK2. The 
polyclonal NT2 antibody was raised against a synthetic peptide encoding amino 
acids 100-200 of the human LRRK2 sequence. The 100-500 monoclonal antibody was 
raised against a synthetic peptide encoding amino acids 100-500 of the human 
LRRK2 sequence. The C terminal monoclonal antibody was raised against a synthetic 
peptide encoding amino acids 2079-2100 of human LRRK2 conjugated to a keyhole 
limpet hemocyanin (KLH) sequence. The 3514-1 monoclonal antibody was raised 
against a synthetic peptide encoding amino acids 970-2527 of the human LRRK2 
sequence. All antibodies were raised in rabbits with target LRRK2 sequences 100 % 
conserved in mouse and rat LRRK2 homologues. Antibodies were evaluated for their 
ability to detect endogenous and over-expressed LRRK2 in human whole cell lysates 
of untransfected SHSY5Y cells, fibroblasts, lymphoblasts, human brain cortex and 
wild type LRRK2-V5 over-expressing SHSY5Y cells. Human cell lines c1 (fibroblasts) 
and c2 (lymphoblasts) described in Table 2.2 were used for the analysis.  
All four antibodies tested were able to detect a band at 280 kDa 
corresponding to the full length protein in the LRRK2-V5 over-expressing SHSY5Y 
cells as shown by the immunoreactive band in the (WT) lanes with the 
corresponding signal absent in the untransfected cell line (Fig 3.1B). NT2 and 3514-1 
antibodies produced an immunoreactive band of appropriate molecular weight for 
full length LRRK2 in the lymphoblast cell line. None of the antibodies tested were 
able to clearly detect 280 kDa immunoreactivity in fibroblast lysates (Fig 3.1B). Weak 
280 kDa immunoreactivity was also observed in control SHSY5Y cells (Fig 3.1B) and 
brain tissue for the 3514-1 but not 100-500 antibody (Fig 3.1C). 
Additional immunoreactive species of lower molecular weight were 
detected by NT2, 100-500 and 3514-1 in the over-expressing cell line (Fig 3.1B). 
Some bands, 20-75 kDa, (i) were of equal intensity to those in untransfected control 
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cells while others, 100-150 kDa (ii) were present in the over-expressing cells only 
suggesting species (ii) corresponded to the over-expressed LRRK2-V5 protein. Lower 
molecular weight bands (30-100 kDa) were also detected in lymphoblast, fibroblast, 
control SHSY5Y cells and human brain lysates (NT2, 100-500, 3514-1 (iii)) co-
migrating with those in the LRRK2-V5 over-expressing SHSY5Y cells potentially 
representing endogenous forms of LRRK2. Lower molecular weight bands (30-150 
kDa) absent in SHSY5Y cells were also detected in lymphoblast, fibroblast and 
human brain lysates by the NT2 and 100-500 antibodies (iv), consistent with cell and 
tissue specific antibody immunoreactivity (Fig 3.1B,C). As we did not have the 
appropriate LRRK2 knockdown or knockout controls for fibroblast and lymphoblast 
cell lines we were unable to rule out non-specific binding of antibodies in these cell 
lines.   
The lower molecular weight band patterns were unique to each antibody 
potentially representing the position of antibody epitopes and the corresponding 
LRRK2 fragment. In addition, variability was observed between blots as shown by 
differences between the band pattern for wild type LRRK2 over-expressing SHSY5Y 
cells, comparing 100-500 and 3514-1 immunoreactivities in (Fig. 3B and C), 
complicating the identification of the true LRRK2 species. Our data suggests Western 
blot detection of the LRRK2 protein can identify over-expressed full length LRRK2, 
however, most antibodies identify additional immunoreactive bands of lower 
molecular weight questioning their specificity. Lower molecular weight 
immunoreactive species were also observed in cells and tissues expressing 
endogenous LRRK2 while immunoreactivity for the full length endogenous protein 
was weak. 
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3.2 Characterization of LRRK2-V5 over-expressing SHSY5Y cells 
3.2.1 Western blot analysis of LRRK2 protein in SHSY5Y cells 
SHSY5Y cells stably expressing LRRK2-V5 were generated by J.M Cooper and 
D. Chau, and positive clones expressing the wild type or G2019S LRRK2-V5 were 
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obtained. Western blot analysis of untransfected, wild type or G2019S LRRK2-V5 
over-expressing SHSY5Y whole cell lysates revealed a single 280 kDa band 
immunoreactive for V5 in SHSY5Y cells transfected with wild type and G2019S 
LRRK2-V5 absent in control SHSY5Y cell extracts (Fig 3.2A). The band intensity in wild 
type extracts was 2 fold higher relative to the G2019S clone when corrected for 
protein loading by GAPDH immunoreactivity. To ensure consistent expression of the 
LRRK2 constructs, protein levels were assessed with increasing passage number. 
Positive V5 immunoreactivity was detected by Western blot for both wild type (Fig 
3.2B) and G2019S (Fig 3.2C) clones for passages 7-22. LRRK2 expression was reduced 
by 40 % in G2019S LRRK2-V5 over-expressing cells at passages 21 and 22 when 
corrected for protein loading by GAPDH immunoreactivity suggesting the stability of 
over-expressed G2019S LRRK2 protein was affected at these passages. All functional 
analyses were carried out for passages 8-20 to compare the effects of over-
expressed wild type and G2019S LRRK2.  
3.2.2 LRRK2 mutation screen in SHSY5Y cells 
To determine whether the LRRK2 pathogenic G2019S mutation was 
expressed in wild type and G2019S LRRK2-V5 over-expressing cell lines, mRNA was 
extracted from each clone, reverse transcribed and the corresponding coding DNA 
analysed for the presence of the G2019S mutation in exon 41 of the LRRK2 gene. 
Successful amplification of the 700 base pair fragment from exon 41 of LRRK2 cDNA 
in SHSY5Y cells was confirmed by the presence of a single DNA band co-migrating 
with a fragment amplified from the LRRK2 plasmid absent in the water blank 
reaction (Appendix Fig A4). DNA sequencing of wild type PCR products confirmed 
100 % base pair complementarity to the human LRRK2 gene registered on the 
UniProt database (Fig 3.2D). cDNA from SHSY5Y cells stably over-expressing mutant 
LRRK2 protein was identified to have the adenine nucleotide at base pair position 
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6055 with endogenous wild type LRRK2 (guanine at position 6055) not resolved by 
sequencing potentially due to the differential level of expression (Fig 3.2E). The 
guanine to adenine substitution results in a codon encoding the serine (S) amino 
acid, confirming expression mutant LRRK2 protein in SHSY5Y cells. 
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3.2.3 Western blot analysis of LRRK2 sub-cellular distribution in SHSY5Y cells 
Having demonstrated wild type and G2019S LRRK2-V5 over-expression in 
SHSY5Y cells, LRRK2 cellular distribution was evaluated in these cells lines. SHSY5Y 
cells over-expressing LRRK2 were ruptured by nitrogen cavitation and fractionated 
by differential centrifugation. Western blot analysis of wild type LRRK2-V5 
expressing cell fractions identified V5 immunoreactivity in all the isolated SHSY5Y 
compartments with highest abundance (47 %) in the 250,000 g and cytosolic 
fractions (Fig 3.3A). Quantification of LRRK2 immunoreactive bands by densitometry 
approximated 5 % (n=1) of cellular LRRK2 in each of the 10-47,000 g fractions.     
Compartmental characterization identified lysosomal abundance in the 47,000 g 
fraction as determined by the double immunoreactive GCase band of approximately 
60 kDa representing the glycosylated and non glycosylated form of the lysosomal 
enzyme. Mitochondrial enrichment was found in the 47,000 g (60 %), 27,000 g (30 
%) and 1,000 g (10 %) fractions, as determined by immunoreactivity to the Core 
Complex III mitochondrial marker. Immunoreactivity for the endoplasmic reticulum 
marker, calreticulin, was detected in 27,000 g (55 %), 12,000 g (40 %) and 47,000 g 
(5 %) fractions. Synaptophysin immunoreactivity, representing synaptic vesicle 
abundance were identified in 250,000 g (35 %) and cytosolic (55 %) compartments 
with the remaining 10 % synaptophysin immunoreactivity distributed equally 
between fractions 1-45,000 g. These data shows that wild type, over-expressed 
LRRK2-V5 can be found abundant in the cytosolic and vesicle enriched cellular 
compartments, with lesser abundance in fractions containing ER, lysosomal and 
mitochondrial markers. 
To determine whether G2019S expression is associated with altered LRRK2 
cellular distribution in G2019S LRRK2-V5 over-expressing SHSY5Y cells, differential 
centrifugation and Western blot analysis was performed on the mutant cell line. 
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G2019S LRRK2 compartmental distribution in SHSY5Y cells reflected that of the wild 
type protein with highest LRRK2 abundance identified in 250,000 g (60 %) and 
cytosolic (30 %) fractions with 6 % (n=1) of the total V5 immunoreactivity distributed 
equally between the fractions 10-47,000 g (Fig 3.3B). Unlike wild type over-
expressed LRRK2, 3 % of G2019S LRRK2 was identified in the 1,000 g fraction, 
corresponding to unbroken cells and nuclear components, potentially representing 
incomplete cellular disruption. Compartmental characterization of G2019S LRRK2 
expressing fractions identified lysosomal abundance (95 %) in the 12,000 g fraction 
as determined by the double immunoreactive GCase band of approximately 60 kDa. 
Mitochondrial enrichment was found in the 47,000 g (30 %), 27,000 g (60 %) and 
1,000 g (10 %) fractions, as determined by immunoreactivity to the Core Complex III 
mitochondrial marker. Calreticulin immunoreactivity, representing the endoplasmic 
reticulum was abundant in 27,000 g (55 %) and 12,000 g (35 %) fractions, while 
synaptophysin immunoreactivity was identified in 250,000 g (60 %) and cytosolic (35 
%) fractions as well as 5 % of the total synaptophysin immunoreactivity distributed 
equally between fractions 1-47,000 g. 
Lysosomal and mitochondrial markers in fractionated G2019S LRRK2-V5 
over-expressing SHSY5Y cells were detected in fractions isolated at lower 
centrifugation speeds (12,000 g) relative to the wild type LRRK2-V5 over-expressing 
SHSY5Y cells (47,000 g) potentially reflecting the smaller size of mitochondrial and 
lysosomal organelles. ER and synaptic markers were identified in fractions isolated 
by comparable centrifugation speeds (12,000 and 27,000 g) and (250,000 g 
respectively) for both wild type and G2019S LRRK2-V5 over-expressing cells. Our 
data shows that over-expressed LRRK2 V5 can be found abundant in the cytosolic 
and vesicle enriched cellular compartments, with smaller amounts present in 
fractions containing ER, lysosomal and mitochondrial markers. In addition G2019S 
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LRRK2-V5 cellular localization mirrors the cellular distribution of the wild type 
LRRK2-V5 protein in SHSY5Y cells. However, the difference in centrifugation speeds 
required to isolate the majority of the mitochondrial and lysosomal pools may 
reflect a difference in organelle boyant density between the wild type and G2019S 
LRRK2-V5 over-expressing SHSY5Y cells.  
 
 
 
3.2.4 Immunocytochemistry of LRRK2 sub-cellular distribution in SHSY5Y cells 
In addition to Western blot analysis, wild type LRRK2-V5 over-expression 
and cellular distribution in SHSY5Y cells was characterized by immunocytochemistry. 
In an attempt to visualise LRRK2 over-expression by imunocytochemistry four 
permeabilization and fixation conditions were tested; methanol and acetone, 
paraformaldehyde and Triton X100, paraformaldehyde and methanol, 
paraformaldehyde and sodium citrate. Immunocytochemistry utilizing methanol and 
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acetone conditions confirmed LRRK2-V5 over-expression in wild type expressing 
SHSY5Y cells as determined by V5 immunoreactivity absent in untransfected cells 
(Fig 3.4A). Immunostaining conditions utilizing paraformaldehyde in combination 
with Triton X100 and methanol permeabilization or boiling in sodium citrate 
produced V5 immunoreactive signals in control SHSY5Y cells of comparable 
intensities to that observed in wild type LRRK2 over-expressing SHSY5Y cells. V5 
positive immunoreactivity in paraformaldehyde fixed control SHSY5Y cells was likely 
due to non specific binding of the antibody under these conditions.  
Methanol acetone processing of SHSY5Y cells identified V5 positive 
immunoreactivity in wild type LRRK2 over-expressing SHSY5Y cells as spread 
diffusely throughout the cell body with some immunoreactive punctate structures 
detected (Fig 3.4B). Co-localization with compartmental markers was not assessed 
due to this diffuse nature of the LRRK2 signal. G2019S LRRK2-V5 over-expression in 
SHSY5Y cells could not reliably be identified by immunocytochemistry this may 
reflect the 2 fold lower expression of the G2019S LRRK2-V5 protein relative to wild 
type LRRK2-V5 over-expressing cells, questioning the sensitivity of this detection 
method. 
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3.3 Characterization of endogenous LRRK2 in lymphoblasts 
3.3.1 Western blot analysis of LRRK2 protein in lymphoblasts 
Western blot analysis of LRRK2 protein detected endogenous expression in 
lymphoblasts with the NT2 antibody (Fig 3.1B) consistent with high LRRK2 
abundance as previously reported for this cell type [244]. Lymphoblast cells are 
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derived from peripheral blood mononuclear cells (PMBCs) isolated from whole 
blood. To determine whether LRRK2 expression in control lymphoblasts reflects 
LRRK2 protein abundance in PMBCs, LRRK2 expression was compared by Western 
blot analysis. It was not possible to obtain PMBCs from any of the lymphoblast 
donors and hence PMBCs from 5 healthy control subjects of different ages (23-62 
years) were screened for LRRK2 expression. A lymphoblast cell line (control subject, 
56 years) was used for comparison. Positive NT2 immunoreactivity in the 280 kDa 
region confirmed LRRK2 expression in PMBCs with LRRK2 levels comparable 
between transformed and primary cells relative to GAPDH immunoreactivity (Fig 
3.5A). LRRK2 PMBC expression was similar between the five control donors 
suggesting LRRK2 lymphoblast expression reflects levels in untransformed cells.  
PMBCs purified by density gradient isolation consist of a combination of T 
and B lymphocytes of differential abundance [308] while lymphoblasts are derived 
primarily from Epstein-Barr virus transformed B cells. To determine which 
lymphocyte subpopulations express LRRK2 protein PMBC cells (control subject, 49 
years) were used for affinity purification and characterization of T (CD4, CD8) and B 
(CD19) lymphocyte cell subtypes. PMBCs were fractionated by positive selection 
using magnetically tagged antibodies specific for CD4, CD8 and CD19 lymphocytes 
and characterised for LRRK2 protein expression by Western blotting. Western Blot 
analysis of purified T and B cell extracts produced a strong NT2 immunoreactive 
band in the CD19 cells, 10 fold lower intensity immunoreactive signal in CD8 relative 
to GAPDH when corrected for protein loading but no clear LRRK2 immunoreactivity 
in CD4 cells (Fig 3.5B) consistent with LRRK2 protein abundance in B cells and 
substantially lower expression in T cells.  
Having shown that LRRK2 protein expression in transformed lymphoblasts 
reflects the protein levels of CD19 positive B cells from which the lymphoblasts were 
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derived, we set out to determine whether LRRK2 protein abundance is altered with 
G2019S expression. LRRK2 levels were compared between control and G2019S 
expressing lymphoblasts. Western blot analysis of control and G2019S lymphoblast 
cell lines was carried out by Susannah Horan (Clinical Neurosciences, UCL). As the 
NT2 antibody was not available at the time, the previously validated rabbit 
polyclonal NB300-268 was used (refer to diagram in 3.1A for epitope details). 
Western blot analysis of NB300-268 immunoreactivity indicated variability in LRRK2 
levels between the cell lines within the control and G2019S lymphoblast groups (Fig 
3.5C). When immunoreactivities were quantified, variability of 10 fold intensity 
difference was noted between highest and lowest LRRK2 expressing lymphoblast 
lines. The variability of LRRK2 expression in lymphoblasts complicated the 
assessment of G2019S expression effects on LRRK2 abundance.  
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3.3.2 Western blot analysis of LRRK2 sub-cellular distribution in lymphoblasts 
Western blot analysis of LRRK2 protein expression with the NT2 antibody 
determined that LRRK2 levels were approximately 3 fold lower in a high LRRK2 
expressing lymphoblast cell line (c2) relative to wild type LRRK2-V5 over-expression 
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in SHSY5Y cells (Fig 3.1B). To compare the cellular distribution of endogenous LRRK2 
in lymphoblasts to the data obtained for wild type and G2019S LRRK2-V5 SHSY5Y 
cells, differential centrifugation and Western blot analysis were carried out on the c2 
lymphoblast cell line (Fig 3.6). 280 kDa NT2 immunoreactivity was abundant in the 
cytosolic (60 %) and 250,000 g (35 %) compartments  with 5% of the total NT2 
immunoreactivity distributed equally between 1-47,000 g compartments (Fig 3.6), 
comparable to the V5 immunoreactive pattern observed for wild type and G2019S 
LRRK2-V5 expressing SHSY5Y cells (Fig 3.3A, B). Higher molecular weight NT2 
immunoreactive species (approximately 290 and 300 kDa) were detected in 12,000 g 
and 250,000 g fractions, absent in the 1,000, 27,000, 47,000 g and cytosolic 
fractions. 
Characterization of cellular compartmental distribution identified lysosomal 
abundance in the 12,000 g (60 %), 27,000 g (30 %) and 1,000 g (10 %) fractions as 
determined by GCase immunoreactivity. A single immunoreactive band was 
detected by the GCase antibody in these fractions suggesting lymphoblast derived 
GCase exists in a single 60 kDa form, potentially corresponding to the unglycosylated 
enzyme. Mitochondrial abundance was identified in 1,000 g (45 %) and 12,000 g (50 
%) fractions with additional bands in 27,000 g and 47,000 g (5 %) compartments, as 
determined by Core CIII immunoreactivity. Calreticulin (ER) markers were present in 
the 47,000 g (40 %) fractions where a double band was detected potentially 
representing a post translationally modified form of calreticulin [309]. A single band 
(*) immunoreactive for the calreticulin antibody was identified in the 27,000 g 
fraction accounting for 60 % of the total calreticulin immunoreactivity, potentially 
representing the unglycosylated form of the protein.  
Similar to the results obtained in the LRRK2-V5 over-expressing SHSY5Y 
system, endogenous LRRK2 in lymphoblasts can be found abundant in the cytosolic 
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compartment, as well as minor levels in fractions containing ER, lysosomal and 
mitochondrial markers. These results suggest that LRRK2 cellular distribution was 
not affected by LRRK2 over-expression.  
 
 
 
3.4 LRRK2 immunoprecipitation 
3.4.1 Characterization of LRRK2 immunoprecipitation for quantitative comparison 
We addressed the problem of endogenous LRRK2 detection in fibroblasts, 
SHSY5Y cells and brain tissue. The immunoprecipitation protocol, based on 
methodology described by Alessi et al, was extended to the detection of 
endogenous LRRK2 protein [215]. Additional characterization of methodology was 
carried out to validate the use of this method for quantitative comparison.  
LRRK2 immunoprecipitated from control and LRRK2 knockout mouse brain 
cortex or SHSY5Y cells over expressing wild type LRRK2-V5 was assessed by Western 
blot analysis. Successful immunoprecipitation of full length LRRK2 from mouse 
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cortex was confirmed by the presence of a 280 kDa band undetected in the 
corresponding LRRK2 knockout brain immunoprecipitates and the no antibody 
control lane as determined by Western blot analysis with 3514-1 antibody (Fig 3.7A). 
LRRK2 immunoreactive bands co-migrated with full length wild type LRRK2-V5 in 
whole cell extracts and immunoprecipitates from SHSY5Y over-expressing cells. A 
250 kDa species (*) was also present in immunoprecipitates of wild type LRRK2-V5 
over-expressing SHSY5Y cells but absent in mouse brain and no antibody control 
immunoprecipitates suggesting the presence of an additional LRRK2 
immunoreactive species in this cell type (Fig 3.7A). 
The solubility of LRRK2 in buffer used for immunoprecipitation was assessed 
in SHSY5Y cells over-expressing LRRK2 by Western blot analysis of detergent soluble 
and insoluble fractions. Non ionic detergent (1 % Triton X100 and NP-40) containing 
buffers retained little of the cellular LRRK2 in the insoluble pellet with >95 % of 
LRRK2 found in the soluble fraction as determined by V5 immunoreactivity (Fig 
3.7B). Substitution of non ionic with ionic (2 % CHAPS, 1 % Cholate) or zwitterionic (1 
% DDM) detergents recovered comparable levels (>95 %) of LRRK2 in the soluble 
faction. An additional band immunoreactive for the V5 antibody was detected in all 
soluble fractions (*). The relative size of the band (250 kDa) was comparable to the 
species identified in the LRRK2-V5 over-expressing SHSY5Y cells by 
immunoprecipitation (Fig 3.7A). Our data suggests >95 % of the cellular LRRK2 pool 
can be recovered in IP buffer supplemented with ionic, non ionic and zwitter ionic 
detergents in LRRK2 over expressing SHSY5Y cells.  
The linearity of the IP signal was assessed by immunoprecipitation of 
endogenous LRRK2 from increasing concentrations (100-600 µg) of fibroblast lysate 
extracted in 1 % Triton X100 containing IP buffer. 3514-1 immunoreactivity was 
detected in all fibroblast immunoprecipitates (Fig 3.7C) consistent with the presence 
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of LRRK2 protein in fibroblasts. The lower molecular weight species detected by IP 
and Western blot in wild type LRRK2-V5 over-expressing SHSY5Y cells (Fig 3.7A) was 
absent in the fibroblast IP. The 3514-1 band intensity was determined to be in linear 
proportion to the concentration of fibroblast input lysate as shown by plotting the 
band intensity relative to µg of lysate (Fig 3.7D).  
Our data demonstrated the specificity of the LRRK2 immunoprecipitation 
procedure as determined by analysis of wild type and LRRK2 knockout brain tissue, 
efficient LRRK2 solubilization (>95 %) using the IP buffer conditions in LRRK2 over 
expressing SHSY5Y cells and signal linearity based on the IP LRRK2 recovery from 
fibroblast input lysates confirming the suitability of IP for quantitative comparison of 
LRRK2 protein expression.  
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3.4.2 LRRK2 kinase activity in lymphoblasts and SHSY5Y cells 
Immunoprecipitation of LRRK2 from lymphoblasts and LRRK2 over-
expressing HEK293 cells has previously been shown to produce a LRRK2 protein with 
sufficient purity for enzymatic activity measurements in vitro [202, 215]. LRRK2 was 
immunoprecipitated from 1 mg of 1 % Triton X100 lysates of control lymphoblasts, 
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wild type and G2019S LRRK2-V5 over-expressing SHSY5Y cells and assessed for 
kinase activity. Six lines of control lymphoblasts were used to determine the 
potential correlation between LRRK2 expression and kinase activity. Successful 
immunoprecipitation of LRRK2 was determined by the single 280 kDa 3514-1 
immunoreactive band identified for all samples. The intensity of 3514-1 
immunoreactivity was found to be variable for the lymphoblastoid cells (Fig 3.8A), 
consistent with the variable LRRK2 protein expression identified by Western blot 
analysis of whole cell lysates (Fig 3.5C). The 3514-1 band intensity was stronger for 
immunoprecipitates of wild type and G2019S LRRK2-V5 SHSY5Y cells consistent with 
greater LRRK2 protein expression in this cell type. 
Following immunoprecipitation, LRRK2 isolated from control lymphoblasts 
and over-expressing SHSY5Y cells was assessed for kinase activity by rate 
measuments of radiolabelled 32P incorporation into the LRRKtide substrate. Kinase 
activity measurements were carried out in Dundee with the help of Fransisco Inesta-
Vaquera. GST-LRRK2 isolated from HEK293 cells was used as a positive control for 
the reaction [202]. LRRKtide phosphorylation by the purified GST-LRRK2 was 
identified by detection of incorporated radioactivity as counts per minute abolished 
in the presence of a LRRK2 kinase inhibitor LRRK2-IN1, suggesting GST-LRRK2 was 
active and confirming LRRKtide as a GST-LRRK2 substrate (Fig 3.8B).  
Calculating specific activities from cpm values of the LRRK2 enzyme 
immunoprecipitated from lymphoblasts determined substantial variability between 
the control lymphoblast cell lines, with values ranging from 0.6-1 µmol/min/mg 
protein (Fig 3.8C). Due to variability in LRRK2 specific activity for control 
lymphoblasts, LRRK2 kinase activity was not assessed in G2019S expressing 
lymphoblast cells.  
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The specific activity of wild type and G2019S LRRK2-V5 immunoprecipitated 
from SHSY5Y over-expressing cells was 4-8 fold lower relative to the lymphoblast 
cells (Fig 3.8C) suggesting the over-expressed LRRK2 kinase is potentially less active 
in the SHSY5Y cells. The specific activity of immunoprecipitated G2019S LRRK2-V5 
was approximately 2 fold greater relative to the wild type LRRK2 consistent with 
higher kinase activity associated with G2019S LRRK2-V5 (Fig 3.8C). 
Our data show that the active LRRK2 enzyme can be effectively 
immunoprecipitated from LRRK2-V5 over-expressing SHSY5Y cells and lymphoblasts. 
In addition, we have demonstrated that the kinase activity of LRRK2 is greater for 
LRRK2 immunoprecipitated from lymphoblasts relative to LRRK2-V5 over-expressed 
in SHSY5Y cells while the G2019S LRRK2 mutation correlates with the characteristic 
increase in the kinase activity of the mutant protein in our SHSY5Y LRRK2-V5 over-
expressing system. 
 
 126 
 
 
 
3.5 Characterization of fibroblast cell lines  
3.5.1 Immunoprecipitation of LRRK2 protein from fibroblasts 
Six control and eight G2019S patient fibroblast cell lines were generated 
with details about the age of donor and age at collection described in Table 2.2. 
Having demonstrated endogenous LRRK2 protein expression in fibroblasts (Fig 3.7C) 
and evaluated the IP procedure for use in quantitative comparison of LRRK2 protein 
expression, we set out to determine whether the G2019S mutation correlated with 
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altered LRRK2 protein abundance in patient derived fibroblasts. Endogenous LRRK2 
was immunoprecipitated from equivalent amounts of input Triton X100 lysates (1 
mg) of 3 control and 3 G2019S patient fibroblast cell lines. The relative band 
intensity of the LRRK2 immunoreactive signal was comparable for wild type and 
G2019S fibroblast cell lines when corrected for IP input by quantifying the GAPDH 
immunoreactivity (Fig 3.9A). Unlike control and G2019S lymphoblasts (Fig 3.5C), 
LRRK2 protein expression in control and G2019S patient fibroblasts was less 
variable, despite differences in the age at sample collection of the donors. 
3.5.2 LRRK2 mutation screen in control and G2019S fibroblasts 
To confirm expression of the pathogenic G2019S mutation, mRNA was 
extracted from each fibroblast cell line (6 control, 8 G2019S), reverse transcribed 
and the corresponding coding DNA analysed for the presence of the G2019S 
mutation on exon 41 of the LRRK2 gene. Successful amplification of the 700 base 
pair fragment from exon 41 of LRRK2 cDNA in fibroblasts confirmed by the presence 
of a single DNA band co-migrating with a fragment amplified from the LRRK2 
plasmid absent in the water blank reaction (Appendix Fig A3). DNA sequencing of 
wild type PCR products confirmed 100 % base pair complementarity to the human 
LRRK2 gene registered on the UniProt database for all control cell lines (Fig 3.9B). All 
clinically diagnosed PD G2019S cases were found to contain the heterozygous 
mutant allele as determined by 50 % adenine abundance at base pair position 6055 
of the LRRK2 gene (Fig 3.9C). 
3.5.3 LRRK2 mRNA expression in control and G2019S fibroblasts 
To determine whether LRRK2 expression was altered in cells expressing the 
G2019S mutation, quantitative real time PCR analysis was carried out on 6 control 
and 8 G2019S fibroblast cell lines. Amplification of LRRK2 cDNA produced a PCR 
product in cycles 22-24 (equivalent GAPDH in cycles 14-16) of the RT PCR reaction 
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indicative of low levels of endogenous LRRK2 expression (Fig 3.9D). Quantification of 
LRRK2 cycle threshold relative to the cDNA loading control marker GAPDH for 
control versus G2019S fibroblast lines revealed a similar level of LRRK2 mRNA 
abundance (Fig 3.9E), consistent with equivalent LRRK2 mRNA expression in wild 
type and G2019S LRRK2 fibroblasts. Our data is consistent with comparable LRRK2 
mRNA and protein abundance in control and G2019S patient fibroblasts. 
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3.6 Analysis of LRRK2 knockdown in SHSY5Y cells 
In addition to the quantitative comparison of LRRK2 protein expression 
between control and G2019S patient fibroblasts, LRRK2 protein detection by the 
combined immunoprecipitation and Western blot approach was extended to the 
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characterization of the LRRK2 siRNA knockdown model in SHSY5Y cells. LRRK2 siRNA 
was introduced into control SHSY5Y cells by the method of transient transfection. 
For prolonged LRRK2 gene silencing, cells were re-transfected with siRNA at day 3. 
SHSY5Y cells were analysed after 3 and 6 days of silencing for LRRK2 mRNA 
expression by quantitative real time PCR and LRRK2 protein abundance by 
immunoprecipitation and Western blot analysis.  
Following siRNA treatment, mRNA was extracted from SHSY5Y cells, reverse 
transcribed to cDNA and LRRK2 expression quantified by real time PCR. Data was 
expressed as % LRRK2 expression relative to untreated cells. Quantification of LRRK2 
amplification relative to GAPDH CT values identified a 70 % reduction in LRRK2 
mRNA expression in SHSY5Y cells treated with siRNA for 3 and 6 days when 
compared to untreated cells (Fig 3.10A) consistent with a reduction in LRRK2 gene 
expression. 
LRRK2 was immunoprecipitated from 1mg of 1 % Triton X100 lysates of 
control SHSY5Y cells and cells treated with LRRK2 siRNA. Western blot analysis of 
immunoprecipitates revealed a 65 % reduction in 3514-1 280 kDa immunoreactivity 
3 days post transfection relative to untreated cells when corrected for GAPDH 
immunoreactivity representing IP input (Fig 3.10B, C). The observed 65 % reduction 
in 3514-1 band intensity was consistent with reduced LRRK2 protein expression in 
LRRK2 siRNA treated SHSY5Y cells. Extending the LRRK2 siRNA treatment to 6 days 
reduced the 3514-1 immunoreactive LRRK2 band to 85 % of the untreated SHSY5Y 
cells suggesting SHSY5Y LRRK2 protein levels were less abundant following 
prolonged incubations with LRRK2 siRNA. An additional 3514-1 immunoreactive 
band at 250 kDa (*) was identified for endogenous LRRK2 immunoprecipitated from 
SHSY5Y cells with the approximate molecular weight comparable to the species 
observed in the IP of the wild type LRRK2-V5 over-expressing SHSY5Y cells (Fig 3.7A). 
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The intensity of this band was reduced following LRRK2 siRNA treatment suggesting 
the band represents LRRK2 protein. 
Analysis of the LRRK2 siRNA SHSY5Y knockdown model not only revealed an 
efficient reduction of endogenous LRRK2 protein level but also further validated the 
specificity of the IP procedure as the intensity of the 280 kDa LRRK2 immunoreactive 
bands was sensitive to LRRK2 siRNA. 
 
 
 
 132 
 
3.7 Immunoprecipitation of endogenous LRRK2 protein from brain 
Using the combined immunoprecipitation and Western blot protocol we 
analysed LRRK2 expression in two control human brains of 24 hour post mortem 
delay. LRRK2 was immunoprecipitated from equivalent amounts of Triton X100 
lysates (1 mg) of human cerebellum, caudate nucleus, medial putamen and A10 
region of the cortex. Western blot analysis revealed a weak 3514-1 280 kDa 
immunoreactive band in cerebellum 2 immunoprecipitate (←), co-migrating with 
the 280 kDa immunoreactive species detected in the fibroblast IP. This band was 
only seen following prolonged blot exposure, potentially representing low abundant 
full length LRRK2 protein. LRRK2 immunoreactivity was not readily detected in 
human brain caudate nucleus, medial putamen or cortical immunoprecipitates using 
this approach (Fig 3.11A).  
LRRK2 was immunoprecipitated from equivalent amounts of Triton X100 
lysates (1 mg) of control human cortex and amygdala brain regions with post 
mortem delay times of 3h30-8h30 as well as an idiopathic PD brain of 1h30 and 
Alzheimer’s disease brain of 1h45 post mortem delay times respectively. We were 
unable to obtain control brains of 1h30 and 1h45 post mortem delays. Western blot 
analysis of LRRK2 immunoprecipitates identified weak 3514-1 280 kDa 
immunoreactivity for the 1h30 cortical extract of an idiopathic PD case (←). No clear 
bands were detected in the other cortical samples or amygdala immunoprecipitates 
suggesting low LRRK2 human brain abundance or a problem with the 
immunoprecipitation procedure (Fig 3.11B). 
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As LRRK2 could be immunoprecipitated from fresh mouse brain cortical 
extracts (Fig 3.7A), we assessed LRRK2 brain distribution in different regions of the 
mouse brain. Immunoprecipitation and Western blot analysis of LRRK2 from brain 
stem, olfactory lobe, mid brain, striatum, cortex and cerebellum regions of the 
mouse brains revealed a 3514-1 immunoreactive 280 kDa band in all brain regions 
analysed (Fig. 3.12A). This 280 kDa band co-migrated with the 3514-1 
immunoreactivity of LRRK2 fibroblast immunoprecipitates and was absent in the IP 
where the LRRK2 antibody was omitted. LRRK2 immunoprecipitation from mouse 
brain produced strongest immunoreactivity in the striatum, two fold greater than 
that of the cerebellum and cortex, 5 fold higher when compared to the band 
intensity in the brain stem and 10 fold greater than that of the 280 kDa band in the 
midbrain and olfactory lobe (Fig 3.12A). Comparable 3514-1immunoreactive 
patterns were detected in the equivalent regions of the rat brain (Fig 3.12B) with 
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striatal band intensity 10 fold greater when compared to that detected in the 
midbrain. 3514-1 immunoreactivity was 2 fold greater in the cortex when compared 
to the striatum with a higher molecular weight band (←) consistently detected in 
immunoprecipitates from this region but absent in the equivalent mouse brain 
areas. 280 kDa immunoreactivities could not be detected in the rat olfactory lobe or 
brain stem at these exposure times potentially due to lower LRRK2 protein 
abundance. Extending these analyses to non human primates, LRRK2 was 
immunoprecipitated from equivalent regions of MPTP treated marmoset brains. We 
were unable to obtain brains from untreated control animals. Western blot analysis 
of LRRK2 immunoprecipitates produced a single 280 kDa 3514-1 immunoreactive 
band in the striatum and a band of 3 fold greater intensity in the cortex (Fig 3.12C). 
Weaker (10 fold) 3514-1 immunoreactivity was detected in the marmoset brain 
stem, olfactory lobe and midbrain, reflecting the LRRK2 protein distribution pattern 
identified in the equivalent brain regions of the rodent brains. Although the pattern 
of LRRK2 protein distribution is comparable between the mouse, rat and marmoset 
brains, we cannot rule out the potential effects of MPTP on LRRK2 expression. 
Our data shows that endogenous LRRK2 can be readily immunoprecipitated 
from rodent and non human primate brain tissue in contrast to the human brain 
tissue raising the question whether the contents of the human brain extracts could 
potentially be interfering with the IP procedure. To test this fibroblast IP lysates 
were spiked with equal concentrations of mouse or human brain cortex IP lysates 
and subject to LRRK2 immunoprecipitation. LRRK2 readily immunoprecipitated from 
fibroblast and mouse cortical extracts as determined by 3514-1 280 kDa 
immunoreactivity (Fig 3.12D). The relative band intensity in fibroblast 
immunoprecipitates spiked with a mouse brain extract was equivalent to the sum of 
the band intensities detected in the individual fibroblast and mouse brain samples. 
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No clear immunoreactivity was detected for the LRRK2 immunoprecipitates from a 
human cortical extract while a 3 fold reduction in signal intensity was observed for 
the fibroblast immunoprecipitate spiked with the human lysate relative to the band 
intensity detected in the pure fibroblast immunoprecipitate (Fig 3.12D) suggesting 
the composition of the human brain lysate may be affecting immunoprecipitation.  
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3.8 Comparison of LRRK2 expression in cell models and brain tissue 
Due to potential interference in the human LRRK2 IP, mouse brains were 
used for comparative analysis of LRRK2 protein expression with fibroblasts, 
lymphoblasts, control and LRRK2-V5 over-expressing SHSY5Y cells. LRRK2 
immunoprecipitated from equal concentrations (1 mg) of input lysates confirmed 
highest endogenous LRRK2 abundance in lymphoblasts. Levels were 10 fold lower in 
fibroblasts and 50 fold lower in control SHSY5Y cells (Fig 3.13) based on 
quantification of 3514-1 280 kDa immunoreactivity. In mouse brains, 3514-1 
immunoreactivity was greatest in the striatum and cortex, consistent with previous 
findings (Fig 3.12A) comparable to the relative band intensities detected in SHSY5Y 
cells and 7 fold lower than those in fibroblast immunoprecipitates. Wild type LRRK2-
V5 over-expression in SHSY5Y cells was quantified as 3.6 fold higher than in control 
lymphoblast and approximately 25 fold greater than in fibroblast 
immunoprecipitates as determined by 3514-1 280 kDa immunoreactivity (Fig 3.13). 
Additional lower molecular bands of 250 kDa were identified in over-expressing cells  
and lymphoblasts (←) while longer exposures revealed equivalent immunoreactive 
bands in fibroblast IPs (←) resembling the bands previously identified by Western 
blotting in LRRK2-V5 over-expressing SHSY5Y cells (Fig 3.7B). These species were also 
identified in control SHSY5Y cells and reduced upon LRRK2 siRNA treatment (Fig 
3.10B, C) suggesting the 250 kDa species is found in both the LRRK2 over-expressing 
cell lines and systems expressing endogenous LRRK2. 
Our results show that control SHSY5Y cells and fibroblasts express LRRK2 
protein at levels similar to those detected in the brain while the LRRK2 over-
expressing SHSY5Y model has comparable LRRK2 expression relative to endogenous 
LRRK2 abundance in lymphoblasts.  
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3.9 Analysis of LRRK2 protein expression by blue native PAGE electrophoresis  
As an alternative analysis of LRRK2 in the human brain samples blue native 
PAGE combined with Western blotting was carried out with the 3514-1 LRRK2 
antibody. To determine whether preserving the native structure of LRRK2 would 
improve the 3514-1 antibody specificity, blue native PAGE electrophoresis was 
carried out on soluble cell extracts of SHSY5Y cells over-expressing wild type LRRK2-
V5. In parallel, blots were probed with the V5 antibody to compare the specificities 
of the two antibodies. Cells were solubilised in extraction buffer in the absence and 
presence of detergent (1 % DDM or Triton X100) to determine whether inclusion of 
detergent would improve LRRK2 recovery. A single V5 280 kDa immunoreactive 
band (i) was detected by Western blot in soluble extracts of LRRK2-V5 over-
expressing SHSY5Y cells. A 3514-1 280 kDa immunoreactive band of comparable size 
and signal intensity was also identified (Fig 3.14A) suggesting the two antibodies 
recognised the same species. Longer exposures revealed 900 kDa immunoreactive 
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species for both the V5 and 3514-1 antibodies (ii), potentially corresponding to a less 
abundant higher molecular weight wild type LRRK2-V5. 
Solubilisation of wild type LRRK2-V5 over-expressing SHSY5Y cells in buffer 
containing 1 % DDM, revealed a poorly resolved V5 immunoreactive smear by 
Western blot with 280 kDa (i) and 900 kDa (ii) bands visible at short exposures. 
Solubilisation of wild type LRRK2-V5 over-expressing SHSY5Y cells in buffer 
containing 1 % Triton X100 also produced some V5 immunoreactive smearing and a 
280 kDa band at low exposure (i) with a weak 900 kDa band resolving at longer 
exposures (ii). Inclusion of DDM and Triton detergent appeared to promote recovery 
of monomeric (280 kDa) LRRK2 as the relative band intensity of the 280 kDa species 
was greater for both Triton and DDM containing samples relative to detergent free 
extracts. In addition, DDM produced a V5 immunoreactive 900 kDa species at short 
blot exposures (bands absent in detergent free extracts at these exposure times) 
with the detergent possibly promoting the recovery of the higher molecular weight 
LRRK2 species. However due to the sample smearing encountered at longer blot 
exposures we concluded that the conditions obtaining optimal signal to noise ratios 
in LRRK2-V5 over-expressing SHSY5Y cells were those which omitted the use of 
detergent. 
BN PAGE and Western blot analysis of detergent free, soluble extracts of 
human and wild type but not LRRK2 knockout mouse cerebellum revealed a weak 
280 kDa 3514-1 immunoreactive band (←) co-migrating with wild type LRRK2-V5 in 
SHSY5Y over-expressing cells (Fig 3.14B). Higher molecular weight (900 kDa) 3514-1 
immunoreactive species were not detected on this blot, suggesting variability 
related to sample processing or the Western blot procedure, as has previously been 
described for the 3514-1 antibody (Fig 3.1B,C).  
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BN PAGE electrophoresis of cerebellum, cortex, caudate nucleus and medial 
putamen regions of the human brain revealed a 3514-1 immunoreactive band of 
approximately 280 kDa (i) in all regions analysed, co-migrating with the 280 kDa 
band in wild type mouse cerebellum extracts (Fig 3.15, long exposure blots). At long 
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exposures, a 280 kDa 3514-1 immunoreactive band was also detected in the LRRK2 
knockout mouse cerebellum, albeit at lower intensity relative to the wild type 
mouse cerebellum extract suggesting the antibody detected a non specific species at 
the molecular weight of monomeric LRRK2 under the conditions tested. Lower 
molecular weight (55-250 kDa) 3514-1 immunoreactive bands of weaker intensities 
(ii) were observed in all human brain regions as well as the wild type and LRRK2 
knockout mouse cerebellum. Higher molecular weight, 900 kDa 3514-1 
immunoreactive bands were also identified in all human and mouse brain samples 
including the mouse LRRK2 knockout cerebellum (iii), potentially corresponding to 
non-specific binding of the antibody. Multiple poorly resolved bands in both the 
mouse and human brain extracts prevented quantitative comparison of endogenous 
LRRK2 expression (Fig 3.15). In addition, the specificity of antibodies made it difficult 
to identify the true native LRRK2 species in the samples analysed. 
 
 141 
 
 
 
3.10 Immunohistochemical analysis of LRRK2 protein in brain 
Endogenous LRRK2 protein has also previously been detected by 
immunohistochemical analysis of wild type mouse and control human brains. To 
determine whether the 3514-1 antibody can detect LRRK2 in the human brain by 
immunohistochemistry the antibody was initially tested on wild type and LRRK2 
knockout mouse cerebellum brain sections. We focused on the cerebellum region of 
the mouse brain as it was easy to identify and based on our previous finding of high 
cerebellar LRRK2 protein abundance determined by the combined IP and Western 
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blot analysis (Fig 3.12A). Immunohistochemistry was subsequently used to address 
the problem of LRRK2 detection in the human brain rather than to study LRRK2 brain 
distribution hence other brain regions were not evaluated. 
The mouse cerebellum showed the characteristic pattern of neuronal 
haematoxyline staining of intricate patterns of folds and fissures. Paraformaldehyde 
fixation and subsequent 3514-1 antibody staining of flash frozen wild type mouse 
brain tissue revealed positive DAB immunoreactivity in the Purkinje neurons of the 
cerebellum (Fig 3.16A, B). Equivalent regions in the LRRK2 knockout mouse brain did 
not show DAB positivity when processed in parallel to wild type mouse brain 
sections suggesting DAB staining represented LRRK2. Diluting the concentration of 
the 3514-1 antibody (1:50-500) revealed the most intense DAB immunoreactivity for 
the 1:50 antibody dilution with lower intensity DAB staining a lower antibody 
concentrations (Fig 3.16 C). The pattern of 3514-1 DAB staining in the cerebellar 
sections, with purkinje neuron positivity was maintained across all antibody 
concentrations (1:50-500).  
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3514-1 staining (1:100 dilution) of flash frozen human cerebellar sections 
produced DAB positive staining in the purkinje neurons, comparable to the staining 
observed for wild type mouse cerebellum suggesting that LRRK2 protein is present in 
this cell population (Fig 3.17). Our results confirm that LRRK2 protein is expressed in 
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the human cerebellum at least, despite our inability to detect LRRK2 by Western blot 
or by the immunoprecipitation and Western blot approach.  
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Chapter 4: Results 
LRRK2 and mitochondrial function 
Mitochondrial abnormalitites that have previously been linked to PD in 
genetic and environmental PD models include reduced respiratory chain enzyme 
activity [97-100], limited substrate supply to oxidative phosphorylation due to 
defects in the glucose transport system [172] and ATPase reversal in the presence of 
gross mitochondrial respiratory chain defects [172]. These reported defects have 
correlated with reduced activity of the mitochondrial respiratory chain and elevated 
ROS generation [107, 172]. Furthermore, mitochondrial localization of PD associated 
proteins; PINK1, parkin, DJ1 and α-synuclein have been linked to mitochondrial 
functional changes associated with their respective mutant proteins.  
Having characterised LRRK2 expression in fibroblast, lymphoblast and 
SHSY5Y cell models in Chapter 3, this chapter evaluated mitochondrial function in 
wild type and G2019S LRRK2 expressing fibroblasts and SHSY5Y cells by measuring 
cellular oxygen consumption, mitochondrial membrane potential, glycolytic 
metabolism, basal ATP content and ROS generation. In addition, the underlying 
mechanisms of compromised mitochondrial energetics were explored; the 
relationship between mitochondrial changes, LRRK2 mitochondrial localization and 
kinase activity was evaluated in wild type and G2019S LRRK2-V5 over-expressing 
SHSY5Y cells in the presence and absence of LRRK2 kinase inhibition. The potential 
correlation between LRRK2 levels and mitochondrial function were assessed in LRRK2 
over-expressing cells and the LRRK2 siRNA knockdown SHSY5Y model. 
4.1 Mitochondrial function in fibroblast cell lines 
4.1.1 The analysis of mitochondrial respiration in control and G2019S fibroblasts 
Cellular oxygen consumption was evaluated in intact control and G2019S 
fibroblasts by measuring extracellular oxygen concentration using two methods; 
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phosphorescent oxygen probes and polarographically with the Clark type oxygen 
electrode. 
Phosphorescent measurements were carried out on fibroblasts cultured 
under standard conditions (37 ˚C, 5 % CO2) in glucose rich medium with respiration 
rates measured over the period of one hour. Phosphorescent analysis of oxygen 
consumption in control fibroblasts revealed comparable respiratory rates (0.16-0.18 
RFU/min/µg protein) for the six cell lines (Fig 4.1A) while substantial variability in 
cellular respiration rates  was observed in the 8 G2019S LRRK2 fibroblast lines (0.18-
0.6 RFU/min/µg protein). Comparing the fibroblast cell lines as control versus 
G2019S groups revealed a 128 % (p<0.0005) increase in cellular respiration rates for 
the G2019S cohort (Fig 4.1B).  
Polarographic measurements of oxygen consumption in the presence of 
glucose identified a 76 % (p<0.05) increase in respiration for the G2019S fibroblast 
group (n=8) relative to control (n=6) cell lines (Fig 4.1C). The increase in respiration 
identified in G2019S LRRK2 fibroblasts by the phosphorescent analysis and 
polarographic measurements is consistent with an up-regulation of mitochondrial 
function in these cell lines relative to control cells.  
Polarographic methods were also used to assess maximal respiratory rates 
in control and G2019S fibroblasts in response to addition of the chemical uncoupler, 
FCCP. FCCP induced a two fold increase in the basal oxygen consumption for control 
cells (Fig 4.1C). In G2019S cell lines FCCP addition increased the rate of oxygen 
consumption to that seen in FCCP treated control fibroblasts indicating no change in 
the maximal mitochondrial capacity. However, ratios of maximal to basal respiration 
were reduced compared to control cells suggesting mitochondria may be more 
uncoupled in LRRK2 G2019S cells.  
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4.1.2 The analysis of mitochondrial content in control and G2019S LRRK2 
fibroblasts 
Cellular mitochondrial content can impact on cellular respiratory capacity 
therefore interpretation of oxygen consumption measurements required 
assessment of mitochondrial abundance. Mitochondrial content was quantified by 
Western blot analysis of various mitochondrial proteins in whole cell lysates of 
control and G2019S LRRK2 fibroblasts and the proportion of cells stained with 
TMRM. Relative to control fibroblasts the levels of inner mitochondrial membrane 
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localized Complex III (Core CIII) and II (SDHA) subunits as well as the mitochondrial 
transcription factor (TFAM) were similar in G2019S cells as determined by Core 
Complex III, SDHA and TFAM immunoreactivities (Fig 4.2A). Actin immunoreactivity 
demonstrated equivalent protein loading. These results are consistent with 
comparable electron transport chain subunit densities and abundance of 
mitochondrial DNA transcriptional regulators.  
Confocal analysis and quantification of the cellular proportion of control and 
G2019S LRRK2 fibroblasts stained with TMRM revealed comparable TMRM volumes 
per cell (20%) consistent with similar levels of mitochondria in control and G2019S 
cell lines (Fig 4.2B). Both analyses suggest LRRK2 G2019S expression in fibroblasts 
did not affect mitochondrial levels in fibroblasts. 
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4.1.3 The analysis of mitochondrial membrane potential in control and G2019S 
LRRK2 fibroblasts 
Mitochondrial membrane potential was assessed in 6 control and 8 G2019S 
fibroblasts cultured in glucose rich respiration buffer by TMRM staining and confocal 
microscopy. The intensity of TMRM staining appeared reduced in G2019S fibroblasts 
relative to control cells (Fig 4.3A). Quantification of TMRM intensity revealed 
comparable average values (1150-1200 RFU) for all the cell lines in the control group 
(Fig 4.3B). TMRM fluorescence was decreased for all G2019S fibroblast lines by 20 % 
(p<0.0001) relative to control cells (Fig 4.3C), consistent with a reduction in the 
mitochondrial membrane potential.  
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4.1.4 The analysis of cellular ATP content in control and G2019S LRRK2 fibroblasts 
Basal ATP content was assessed in 6 control and 4 G2019S cell lines by 
measuring luciferase luminescence in cellular extracts. Considerable variability was 
observed in luciferase luminescence for control (3.7x106 -4.8x106 RFU/µg protein) 
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and G2019S mutant fibroblasts (3.6 x106 – 4.4 x106 RFU/µg protein) (Fig 4.4A). 
Statistical comparison of control and G2019S fibroblasts identified a 10 % (p<0.05) 
decrease in average luminescence for the G2019S cells (Fig 4.4B), consistent with a 
reduced basal ATP content. The reduction in ATP content for the four G2019S cell 
lines did not correlate with changes in oxygen consumption rates (Fig 4.1A). 
 
 
 
4.1.5 The analysis of extracellular acidification rates in control and G2019S LRRK2 
fibroblasts 
Extracellular acidification rates were assessed in 6 control and 8 G2019S 
LRRK2 fibroblasts. Mesurements were carried out on whole cells in glucose rich, 
buffer free culturing conditions (37 ˚C) using pH sensitive phosphorescent probes 
over the period of one hour. Analysis of pH probe fluorescence revealed 
considerable variation in phosphorescent lifetime rate measurements for the 
control (1.2 x10-10-2.4 x10-10 [H+]/min/µg protein) and G2019S (0.3 x10-10 -4 x10-10 
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[H+]/min/µg protein) fibroblast groups (Fig 4.5A) suggesting variable rates of 
anaerobic glycolysis. Statistical comparison of control versus G2019S cell groups 
showed comparable extracellular acidification rates despite the variability observed 
among the individual cell lines (Fig 4.5B). Data shown indicates there was no obvious 
perturbation in glycolytic rates or correlation with changes in oxygen consumption in 
the G2019S fibroblasts. 
 
 
 
4.1.6 The analysis of cellular ROS in control and G2019S LRRK2 fibroblasts 
To determine whether ROS levels were altered in G2019S expressing 
fibroblasts relative to control cells, ROS generation was evaluated by measuring 
dihydroethidium oxidation. Dihydroethidium oxidation was monitored in 3 control 
and 3 G2019S fibroblast cell lines as the rate of increase in red fluorescence. The 
average rate of nuclear accumulation of red DHE fluorescence was 36 % (p<0.005) 
 153 
 
slower in G2019S cell lines relative to control fibroblasts (Fig 4.6) consistent with 
reduced rates of reactive oxygen species generation in the LRRK2 mutant cell lines.  
 
 
 
4.1.7 The analysis of mitochondrial proton leak in control and G2019S LRRK2 
fibroblasts 
To further investigate the possibility of mitochondrial uncoupling, 
mitochondrial proton leak was evaluated by measuring oxygen consumption rates 
polarographically in the presence of oligomycin for control and G2019S fibroblasts. 
Polarographic measurements of oxygen consumption rates in 4 control fibroblasts in 
the presence of glucose detected a respiratory rate comparable to the previous 
measurement (Fig 4.1A). The addition of oligomycin resulted in ablation of 
mitochondrial respiration in control cells (Fig 4.7), an effect that has previously been 
associated with complex V inhibition. In contrast, respiration rates detected in 
oligomycin treated G2019S fibroblasts were 14 % of untreated rates (p<0.05) 
consistent with a mitochondrial proton leak.  
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4.1.8 The analysis of mitochondrial morphology in control and G2019S LRRK2 
fibroblasts 
Mitochondrial morphology has previously been reported to correlate with 
functional changes of the mitochondrial respiratory chain, [119, 121]. Mitochondrial 
morphology was assessed in 6 control and 8 G2019S LRRK2 cells by confocal 
microscopy focusing on the pattern of TMRM staining. Fibroblasts were imaged in 
respiration buffer following incubation with TMRM. In control fibroblast cells TMRM 
stained mitochondrial structures consisted of a web of interconnected 
mitochondrial processes, dense around the nuclear contour and stretching 
throughout the cell body (Fig 4.8). Both long (0.5 µm, ↓) and short (0.025 µm, ↓*) 
mitochondrial fragments could be identified representing elongated and fragmented 
regions of the mitochondrial network.  
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The G2019S fibroblast cell lines presented with a TMRM staining pattern 
resembling that of control cells consistent with a similar architecture of 
mitochondrial networks (Fig 4.8). The pattern of TMRM staining was similar for the 
individual cells in each control and G2019S fibroblast cell line, consistent with a 
uniform mitochondrial distribution and structure. 
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4.2 Mitochondrial dysfunction models 
To exclude other potential causes that could account for the observed 
G2019S changes, control fibroblast cell lines were used to model; respiratory chain 
enzymatic activity defects, limited substrate supply and mitochondrial ATPase 
reversal to determine how the bioenergetic changes associated with these models 
compare to changes identified in G2019S expressing fibroblasts. 
4.2.1 The use of control fibroblasts treated with rotenone or antimycin A as a 
model of respiratory chain dysfunction 
Respiratory chain enzymatic activity defects, such as those reported in 
idiopathic PD patients, α-synuclein over-expressing SHSY5Y cells and PINK1 mutant 
fibroblasts from PD patients were modelled by treating control fibroblasts with 
inhibitors of Complex I (rotenone 1 µM) and complex III (antimycin A, 1 µM). Oxygen 
consumption rates of control fibroblasts, treated or untreated with ETC inhibitors 
were assessed polarographically in the presence of glucose. A 70 % reduction in 
phosphorescent lifetime rate values was detected for control fibroblasts treated 
with 1 µM rotenone relative to untreated cells, reflecting reduced respiratory chain 
activity (Fig 4.9). Oxygen consumption was not completely inhibited, as shown by 
the 30 % basal respiration still taking place in fibroblasts treated with rotenone, 
potentially reflecting compensatory effects of increased substrate supply through 
complex II of the respiratory chain. The rate of change of phosphorescent lifetime 
was reduced to 30 % of the basal rate for untreated fibroblasts with the addition of 
antimycin A, comparable to the response of fibroblasts to rotenone (Fig 4.9).  
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4.2.2 The use of control fibroblasts treated with rotenone and oligomycin to 
evaluate the influence of ETC inhibition on the mitochondrial ATPase 
Mitochondrial ATPase reversal has previously been associated with PINK1 
and parkin linked PD as well as electron transport chain response to enzymatic 
inhibition. When complex I is inhibited the mitochondrial membrane potential is 
maintained by the reversal of the ATPase [310]. Control fibroblasts were treated 
with rotenone (1 µM) and the mitochondrial proton gradient monitored in 
respiration buffer by confocal microscopy of TMRM stained cells. Quantification of 
TMRM intensity of rotenone treated control fibroblast revealed fluorescent intensity 
values comparable to those of untreated cells 3 minutes after administration of the 
drug (Fig 4.10A). Addition of oligomycin (4 mg/ml) resulted in a time dependent 
increase in TMRM fluorescence in untreated control fibroblasts consistent with an 
increase in the mitochondrial membrane potential as a result of ATPase inhibition 
and accumulation of protons in the mitochondrial matrix. In contrast, oligomycin 
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addition to rotenone treated fibroblasts resulted in an immediate 30 % decrease in 
TMRM fluorescent intensity consistent with the dissipation of the mitochondrial 
proton gradient. 
TMRM fluorescent intensity in G2019S fibroblast cell lines was stable for 6 
minutes following addition of oligomycin (4 mg/ml), comparable to oligomycin 
effects on control cells. Hence there is no evidence to suggest the mitochondrial 
membrane potential is being maintained in these cells by reversal of the ATPase (Fig 
4.10B).  
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4.2.3 The use of control fibroblasts cultured in galactose rich conditions as a model 
of limited cellular substrate supply 
Oxygen consumption rates were assessed in control fibroblasts by 
phosphorescent analysis under glucose or galactose culture conditions (37 ˚C, 5 % 
CO2) over the course of one hour. As the rate limiting enzyme in galactose 
metabolism has slow first order rate kinetics, glycolytic flux is restricted. 
Phosphorescent probe lifetime rate measurements of control fibroblasts cultured in 
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galactose medium were 1.5 fold (p<0.0005) greater relative to rates recorded for 
control fibroblasts cultured in glucose consistent with an increase in cellular oxygen 
consumption when galactose was supplied as a substrate source (Fig 4.11A).  
Extracellular acidification rates were assessed for control fibroblasts in 
glucose or galactose rich, buffer free culture conditions (37 ˚C, 5 % CO2) using pH 
sensitive phosphorescent probes over the period of one hour. Control fibroblasts 
cultured in glucose showed a linear rate of increase in extracellular proton 
concentrations, consistent with a steady rate of anaerobic glycolysis and lactate 
generation (Fig 4.11B). Monitoring extracellular acidification rates in control 
fibroblasts cultured in galactose, revealed 10 fold slower (p <0.0005) extracellular 
acidification rates relative to fibroblasts cultured on glucose consistent with a 
decreased rate of glucose metabolism. 
The mitochondrial membrane potential was assessed in control fibroblasts 
cultured in glucose or galactose rich respiration buffer by confocal microscopy of 
TMRM stained cells. Quantification of TMRM fluorescent intensity identified a 10 % 
(p<0.0001) increase in TMRM fluorescence of fibroblasts cultured in galactose 
medium when compared to cells cultured under glucose conditions (Fig 4.11C) 
consistent with an increase in the mitochondrial membrane potential.  
Basal ATP levels were evaluated in control fibroblasts cultured in glucose or 
galactose rich conditions by quantification of luciferase luminescence in lysed cells. 
Luminescence was comparable in cells cultured on glucose or galactose (Fig 4.11D), 
suggesting basal ATP levels were unaffected by restriction in glycolytic substrate 
supply.  
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4.3 The analysis of respiratory chain function in the SHSY5Y LRRK2-V5 over-
expressing model 
To confirm the defect in fibroblasts was replicated in SHSY5Y cells over-
expressing G2019S LRRK2 mitochondrial function was evaluated in the SHSY5Y cell 
model. Control, wild type and G2019S LRRK2-V5 over expressing SHSY5Y cells were 
assessed for oxygen consumption rates by polarographic measurements, 
mitochondrial membrane potential by TMRM staining and confocal microscopy and 
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reactive oxygen species by spectrophotometric quantification of cellular aconitase 
activity.  
Polarographic measurements of oxygen consumption by the Clark type 
oxygen electrode revealed basal respiration in control SHSY5Y cells (4 nmol 
O/min/µg protein) comparable to rates determined for wild type LRRK2-V5 over-
expressing SHSY5Y cells (Fig 4.12A). In contrast SHSY5Y cells over-expressing G2019S 
LRRK2-V5 had an 80 % (p<0.05) increase in the rate of oxygen consumption relative 
to control and wild type LRRK2-V5 over-expressing SHSY5Y cells (Fig 4.12A). 
Quantification of TMRM intensity determined comparable intensity measurements 
for control and wild-type LRRK2-V5 over-expressing SHSY5Y cells while a 20 % 
(p<0.0001) reduction in TMRM intensity was identified for G2019S LRRK2-V5 over-
expressing SHSY5Y cells (Fig 4.12B), consistent with a decrease in the mitochondrial 
membrane potential. Comparable aconitase activities were determined for control, 
wild type and G2019S LRRK2-V5 over-expressing SHSY5Y cell lines consistent with 
the absence of oxidative stress (Fig 4.12C).  
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4.4 LRRK2 kinase activity 
4.4.1 The analysis of LRRK2 kinase inhibition in the SHSY5Y LRRK2-V5 over-
expressing model  
LRRK2 kinase activity was previously shown to be greater for G2019S LRRK2-
V5 immunoprecipitated from SHSY5Y over-expressing SHSY5Y cells relative to the 
wild type protein (Fig 3.8C). To determine the influence of LRRK2 kinase inhibition 
on Serine 935 phosphorylation and mitochondrial function in SHSY5Y cells, LRRK2 
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over-expressing SHSY5Y cells were subject to treatment with LRRK2 specific kinase 
inhibitors. LRRK2 was immunoprecipitated from the cells and assessed by Western 
blot analysis using phospho Serine 935 specific LRRK2 antibodies. Mitochondrial 
function was assessed polarographically and by TMRM staining following LRRK2 
kinase inhibition. 
4.4.1.1 LRRK2-IN1 
LRRK2 was immunoprecipitated from wild type LRRK2-V5 over-expressing 
SHSY5Y cells treated with increasing concentrations of LRRK2 IN1 (0-2 µM). Western 
blot analysis of immunoprecipitates revealed a dose dependent reduction of 
phospho Serine 935 immunoreactivity relative to the 3514-1 immunoreactive band 
corresponding to the full length immunoprecipitated LRRK2-V5 (Fig 4.13A). 
Quantification of the phospho Serine 935 band intensity relative to 3514-1 
determined a 90 % reduction in the signal intensity for wild-type LRRK2-V5 SHSY5Y 
cells treated with 1µM LRRK2-IN1 when compared to untreated cells, consistent 
with a marked inhibition of LRRK2 kinase activity [215]. The effective LRRK2-IN1 
concentration (1 µM) was within the range used to dephosphorylate Serine 935 in 
HEK293 and lymphoblast cell culture models [215]. Time course analysis (0-90 min) 
of wild type LRRK2-V5 over-expressing SHSY5Y cells with 1 µM LRRK2-IN1 treatment 
revealed a time dependent reduction in phospho Serine 935 immunoreactivity with 
a 90 % decrease in phospho signal relative to 3514-1 band intensity detected 
following 90 minutes of treatment when compared to untreated cells (Fig 4.13B), in 
line with previous reports.  
4.4.1.2 CZC25146 
LRRK2 was immunoprecipitated from wild type LRRK2-V5 over-expressing 
SHSY5Y cells treated with increasing concentrations of CZC25146 (0-1 µM). Western 
blot analysis of immunoprecipitates revealed a dose dependent reduction of 
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phospho Serine 935 immunoreactivity relative to the 3514-1 immunoreactive band 
corresponding to the full length immunoprecipitated LRRK2-V5 (Fig 4.13C). 
Quantification of the phospho Serine 935 band intensity relative to 3514-1 
determined a 90 % reduction in the signal intensity for wild-type LRRK2-V5 SHSY5Y 
cells treated with 0.3 µM CZC25146 when compared to untreated cells, consistent 
with a marked inhibition of LRRK2 kinase activity. The effective CZC25146 
concentration (0.3 µM) was within the range used to dephosphorylate Serine 935 in 
HEK293 and lymphoblast cell culture models [216]. In addition, the 0.3 µM 
CZC25146 dose resulted in comparable levels of phospho Serine 935 
dephosphorylation as the 1 µM dose of LRRK2-IN1 suggesting CZC25146 was more 
potent than LRRK2-IN1 in our SHSY5Y cell culture model. 
4.4.1.3 TAE-648 
LRRK2 was immunoprecipitated from wild type LRRK2-V5 over-expressing 
SHSY5Y cells treated with increasing concentrations of TAE-684 (0-1 µM). Western 
blot analysis of immunoprecipitated LRRK2 revealed a dose dependent reduction of 
phospho Serine 935 immunoreactivity relative to the 3514-1 immunoreactive band 
corresponding to the full length immunoprecipitated LRRK2-V5 (Fig 4.13D). 
Quantification of the phospho Serine 935 band intensity relative to 3514-1 
determined a 90 % reduction in the signal intensity for wild-type LRRK2-V5 SHSY5Y 
cells treated with 0.3 µM TAE-684 when compared to untreated cells, consistent 
with a marked inhibition of LRRK2 kinase activity. The effective TAE-684 
concentration (0.3 µM) was within the range used to dephosphorylate Serine 935 in 
HEK293 and lymphoblast cell culture models [214]. In addition, the 0.3 µM TAE-684 
dose resulted in comparable levels of phospho Serine 935 dephosphorylation, 
relative to total LRRK2 as the 1 µM dose of LRRK2-IN1 suggesting TAE-684 was a 
more potent LRRK2 kinase inhibitor in our cell culture model.  
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4.4.2 The use of LRRK2 kinase inhibitors to evaluate effects of LRRK2 kinase 
inhibition on mitochondrial function in the SHSY5Y LRRK2-V5 over-expressing 
model  
4.4.2.1 Evaluation of the effects of LRRK2 kinase inhibition on mitochondrial 
respiration 
Polarographic measurements of cellular oxygen consumption in the 
presence of glucose carried out on control, wild type and G2019S LRRK2-V5 cells or 
cells treated with LRRK2-IN1 (1 µM, 90 min) revealed comparable respiration rates 
for control and wild type LRRK2-V5 over-expressing SHSY5Y cells in the presence and 
absence of LRRK2-IN1 (Fig 4.14A) suggesting LRRK2 kinase inhibition did not 
influence mitochondrial respiration. In contrast, a 25 % (p<0.05) reduction in oxygen 
consumption rate was reported for G2019 LRRK2-V5 over-expressing SHSY5Y cells 
following LRRK2 kinase inhibition with LRRK2-IN1. The inhibited rates were 
comparable to untreated control and wild type LRRK2-V5 over-expressing SHSY5Y 
cells (Fig 4.14A). LRRK2 Serine 935 phosphorylation status was evaluated following 
the respiratory measurements. Phospho Serine 935 immunoreactivity relative to 
3514-1 band intensity, corresponding to total LRRK2-V5 levels, was reduced by >80 
% for LRRK2-IN1 treated wild type and G2019S LRRK2-V5 over-expressing SHSY5Y 
cells relative to untreated cells (Fig 4.14B), consistent with a marked inhibition of 
LRRK2 kinase activity.  
4.4.2.2 Evaluation of the effects of LRRK2 kinase inhibition on the mitochondrial 
membrane potential 
Control, wild type and G2019S LRRK2-V5 cells were treated with LRRK2-IN1 
(1 µM, 90 min), CZC25146 (0.3 µM) or TAE-684 (0.3 µM) following which the 
mitochondrial membrane potential was assessed in untreated or inhibitor treated 
cells by confocal microscopy of TMRM stained cells in glucose rich respiration buffer. 
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LRRK2-IN1 treatment of wild type and G2019S LRRK2-V5 over-expressing SHSY5Y 
cells resulted in 10 % and 40 % increases (p<0.0001) in TMRM fluorescence relative 
to untreated cells (Fig 4.14C) suggesting LRRK2 kinase inhibition increased the 
mitochondrial membrane potential.  
CZC25146 (0.3 µM) treatment of control and wild type LRRK2-V5 over-
expressing SHSY5Y cells resulted in a 10 % (p<0.0001) decrease in the TMRM 
fluorescence relative to untreated cells consistent with a reduction in the 
mitochondrial membrane potential. CZC25146 effects on the TMRM intensity for 
wild type LRRK2-V5 over-expressing SHSY5Y cells contrasted the 10 % TMRM 
intensity increase observed with LRRK2-IN1 treatment (Fig 4.14D), potentially due to 
the different off target effects described for the two compounds. In contrast, 
CZC25146 treatment of G2019S LRRK2-V5 over-expressing cells resulted in a 10 % 
(p<0.0001) increase in the intensity of TMRM staining consistent with an increase in 
the mitochondrial membrane potential. Although opposite effects were observed 
for control and wild type LRRK2-V5 over-expressing SHSY5Y cells in response to 
LRRK2-IN1 and CZC25146 treatment, the increase in TMRM intensity for the G2019S 
LRRK2-V5 expressing cells following kinase inhibition suggest LRRK2 kinase inhibition 
potentially restores the mitochondrial abnormality associated with G2019S LRRK2-
V5 protein.  
TAE-684 (0.3 µM) treatment of control, wild type and G2019S LRRK2-V5 
over-expressing SHSY5Y cells resulted in a 60 % (p<0.0001) decrease in TMRM 
fluorescence relative to untreated cells suggesting TAE-684 could potentially inhibit 
mitochondrial function, possibly due to the broader selectivity profile of the drug 
(Fig 4.14D). 
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4.5 LRRK2 mitochondrial localization 
4.5.1 Mitochondrial affinity purification 
Cellular fractionation experiments carried out in chapter 1 identified 10 % of 
the total LRRK2 cellular pool in the mitochondrial enriched fractions (MEF) for wild 
type and G2019S LRRK2-V5 over-expressing SHSY5Y cells as well as endogenous 
LRRK2 in lymphoblasts.  
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To determine whether LRRK2 localizes to the mitochondria and quantify the 
mitochondrial LRRK2 pool, mitochondrial affinity purification was carried out on wild 
type, G2019S LRRK2-V5 over-expressing cells and lymphoblasts. Affinity purified 
mitochondria were isolated from the post nuclear supernatant (PNS) of cells and 
assessed by Western blot analysis. A fraction (1/10th) of the PNS sample was 
retained for analysis of LRRK2 and mitochondrial input with all Western blot 
quantifications corrected for sample loading: PNS (1/10) and purified mitochondria 
(9/10) unless stated otherwise.  
Affinity purified mitochondria were identified by Western blot analysis of 
the 39 kDa immunoreactive band for Core Complex III marker of the inner 
mitochondrial matrix, quantified as 11 fold greater signal intensity relative to the 
Core Complex III in the PNS input fraction (Fig 4.15A). Correcting the Core Complex 
III immunoreactive signal for sample loading calculated >90 % recovery of 
mitochondria from the PNS input. Western blot immunoreactivity for cytochrome C 
(12 kDa), a marker of the inter membrane space, was 2 fold lower relative to the 
signal detected in the PNS input suggesting a portion of cytochrome C was lost 
during the affinity purification procedure. Western blot analysis detected calreticulin 
and GCase immunoreactivities in the PNS fraction of SHSY5Y cells but were absent in 
extracts of affinity purified mitochondria suggesting they were generally free from 
lysosomal and ER contaminants. V5 immunoreactivity was detected in the PNS and 
mitochondrial affinity purified fractions. Quantification of the mitochondrial V5 band 
intensity relative to PNS and corrected for sample loading determined 1-2 % (n=3) of 
the post-nuclear V5 immunoreactivity in the affinity purified fraction consistent with 
a mitochondrial localization of LRRK2-V5.  
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4.5.1.1 Mitochondrial affinity purification versus differential centrifugation 
Direct comparison of LRRK2 recovery from mitochondria isolated by 
differential centrifugation or affinity purification identified a 39 kDa immunoreactive 
band of 10 fold greater signal intensity relative to the PNS input lysates of wild type 
LRRK2-V5 over-expressing SHSY5Y cells, suggesting comparable mitochondrial 
recoveries by the two purification methods (Fig 4.15B). While mitochondrial 
enriched fractions isolated by differential centrifugation were immunoreactive for 
GCase, affinity purified preparations did not reveal clear GCase immunoreactivity in 
the same exposure time consistent with low lysosomal abundance. V5 
immunoreactivity in mitochondria isolated by differential centrifugation was of 2 
fold lower intensity relative to V5 in PNS input consistent with 7 % (n=1) of the PNS 
LRRK2 pool present in this mitochondrial isolation when corrected for sample 
loading (1/15th of the PNS was retained for Western blot analysis in this experiment). 
A V5 immunoreactive signal of 6 fold lower intensity was detected in affinity purified 
preparations consistent with 1% of the PNS LRRK2 pool in this mitochondrial 
fraction, consistent with previous observations (Fig 4.15A). Our data suggests the 
LRRK2 signal in the mitochondrial enriched fraction of crude preparations is 
potentially overestimated.  
4.5.1.2 Mitochondrial affinity purification from G2019S LRRK2-V5 over-expressing 
SHSY5Y cells 
The 280 kDa immunoreactive V5 band was detected in mitochondrial affinity 
purifications from wild type and G2019S LRRK2-V5 over-expressing SHSY5Y cells. 
Quantification of wild type or G2019S V5 immunoreactivity in the affinity purified 
mitochondrial fraction relative to PNS and corrected for sample loading determined 
1.5 and 1.6 % (n=2) of the V5 signal in the purified mitochondrial compartment 
consistent with comparable levels of LRRK2 mitochondria isolated from wild type 
 172 
 
and G2019S LRRK2-V5 over-expressing SHSY5Y cells (Fig 4.15C). Mitochondrial 
affinity preparations from SHSY5Y cells over-expressing wild type or G2019S LRRK2-
V5 were free of lysosomal contaminants as determined by the absence of a clear 
GCase immunoreactive signal as detected in the PNS input. 
4.5.1.3 Mitochondrial affinity purification, LRRK2 kinase inhibition 
To determine whether LRRK2 phosphorylation status affects its 
mitochondrial localization, SHSY5Y wild type over-expressing LRRK2-V5 cells were 
treated with LRRK2 IN1 (1 µM, 90 min) and affinity purified mitochondrial fractions 
assessed for relative LRRK2-V5 abundance by Western blot. Inhibition of LRRK2 
kinase activity and Serine 935 de-phosphorylation did not affect the efficiency of 
mitochondrial recovery as determined by comparable Core Complex III 
immunoreactivities for LRRK2-IN1 treated and untreated wild type LRRK2-V5 over-
expressing SHSY5Y cells relative to the PNS when corrected for sample loading (Fig 
4.15D). The 280 kDa immunoreactive V5 band was detected in mitochondrial affinity 
purifications from LRRK2-IN1 treated and untreated wild type LRRK2-V5 cells. 
Quantification of the V5 band intensity relative to PNS input and sample loading 
determined 1.6 and 1.7 % (n=2) of V5 immunoreactivity in untreated and LRRK2-IN1 
treated SHSY5Y cells consistent with comparable LRRK2 mitochondrial abundance in 
the presence and absence of LRRK2 kinase inhibition and Serine 935 
dephosphorylation. 
4.5.1.4 Mitochondrial affinity purification from lymphoblasts 
Affinity purified mitochondria were isolated from lymphoblasts to 
determine the proportion of endogenous protein in the mitochondrial compartment 
of this cell type. Successful purification of mitochondria was confirmed by the 
presence of a 39 kDa immunoreactive Core Complex III band in the affinity purified 
mitochondrial preparation (Fig 4.15E). Correcting the Core Complex III 
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immunoreactivity for sample loading relative to Core Complex III band intensity in 
the PNS input determined >90 % mitochondrial recovery by this purification method, 
comparable to purification recovery obtained with SHSY5Y cells (Fig 4.15A, C). Weak 
3514-1 280 kDa immunoreactivity was detected by Western blot analysis of 
lymphoblast PNS input, however, 3514-1 immunoreactivity could not be clearly 
identified in affinity purified mitochondrial preparations (Fig 4.15E).  In an attempt 
to increase the sensitivity of endogenous LRRK2 detection, LRRK2 was 
immunoprecipitated from the PNS input and affinity purified mitochondria. A clear 
280 kDa 3514-1 immunoreactive band was identified in the lymphoblast PNS input 
(Fig 4.15E). LRRK2 immunoprecipitation from mitochondrial isolates containing 10 
times the volume of the PNS input detected a faint 3514-1 immunoreactive band co-
migrating with the band identified in the PNS input consistent with low levels 
mitochondrial LRRK2 in lymphoblasts. The background noise did not allow for 
quantification of the relative LRRK2 mitochondrial abundance in lymphoblasts.  
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4.5.2.1 Sub-fractionation of mitochondrial enriched fractions from SHSY5Y LRRK2-
V5 over-expressing SHSY5Y cells 
To determine the intra mitochondrial distribution of LRRK2, mitochondrial 
fractionation was carried out in wild type LRRK2-V5 over-expressing SHSY5Y cells. 
Mitochondrial sub-fractionation was initially carried out on mitochondria isolated by 
differential centrifugation before extending the studies to affinity purified 
mitochondria. The outer mitochondrial membrane of mitochondria was selectively 
removed by digitonin treatment. Following treatment, mitochondrial enriched 
fractions were separated into soluble and pellet components by centrifugation and 
the corresponding extracts analysed by Western blotting. Western blot analysis of 
untreated MEFs identified porin (outer mitochondrial membrane marker) and Core 
Complex III (inner mitochondrial membrane marker) immunoreactivities in the 
pelleted mitochondrial compartment absent in the corresponding soluble fraction 
(Fig 4.16A). V5 immunoreactivity was also detected in the untreated pellet of MEFs 
in line with our previous findings (Fig 4.15B).  
MEFs isolated from wild type LRRK2-V5 over-expressing SHSY5Y cells treated 
with 2 mg/ml digitonin revealed 20 % of the total porin immunoreactivity in the 
soluble fraction with 80 % retained in the mitochondrial pellet. At 3 mg/ml porin 
immunoreactivity in the soluble fraction was comparable to the band intensity 
detected in the mitochondrial pellet consistent with the removal of 50 % of the 
outer mitochondrial membrane. Core Complex III immunoreactivity was absent in 
the soluble fraction following 2 mg/ml digitonin treatment but 50 % of the total Core 
Comlex III immunoreactivity was found in the soluble compartment at 3 mg/ml 
digitonin, consistent with the increased solubilisation of the inner mitochondrial 
membrane at this digitonin concentration. At 3 mg/ml, when the inner 
mitochondrial membrane of MEF preparations was detected in the soluble fraction 
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60 % of total porin immunoreactivity was retained in the MEF pellet suggesting a 
portion of the outer membrane was still associated with the inner membrane even 
though the integrity of the inner membrane was compromised.  
Western blot analysis of untreated MEFs showed that V5 immunoreactivity 
was absent in the soluble fraction while MEFs treated with 1 mg/ml digitonin had 50 
% of the total V5 immunoreactivity in the soluble fraction consistent with 
solubilisation of half of the mitochondrial LRRK2 pool. Mitochondria treated with 2 
mg/ml digitonin revealed 60 % and 40 % V5 immunoreactivities in the soluble and 
mitochondrial pellet fractions while at 3 mg/ml digitonin the V5 immunoreactive 
signal was equally distributed between the two fractions. Although we have 
previously demonstrated 90 % of the LRRK2 immunoreactivity in mitochondria 
isolated by differential centrifugation potentially represents signal contamination 
from other cellular fractions, data shown suggests LRRK2 response to digitonin 
mimics that of porin consistent with LRRK2 localization to the outer mitochondrial 
membrane of MEFs.  
4.5.2.2 Sub-fractionation of affinity purified mitochondria from SHSY5Y LRRK2-V5 
over-expressing SHSY5Y cells 
To determine LRRK2 localization in affinity purified mitochondria from wild 
type LRRK2-V5 over-expressing SHSY5Y cells, affinity purified mitochondrial 
preparations were subject to digitonin treatment. Western blot analysis of 
untreated affinity purified mitochondria identified 60 kDa porin and 39 kDa Core 
Complex III and V5 immunoreactivities in the mitochondrial pellet, absent in the 
soluble fraction, consistent with intact mitochondrial inner and outer membranes 
(Fig 4.16B). Digitonin at 1 mg/ml resulted in 10 % of total porin immunoreactivity in 
the soluble fraction while 2 mg/ml digitonin the soluble pool was estimated to 
contain approximately 20 % porin immunoreactivity. Higher concentrations, 3 and 4 
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mg/ml produced 40 % porin immunoreactivity in the soluble fraction with 60 % 
immunoreactivity retained in the mitochondrial pellet consistent with a dose 
dependent solubilisation of the outer mitochondrial membrane. 
Western blot analysis of affinity purified mitochondria treated with digitonin 
at 1 mg/ml detected 5 % of total Core Complex III immunoreactivity in the soluble 
fraction (Fig 4.16B).  Digitonin at 2 mg/ml resulted in 20 % of the Core Complex III 
signal intensity present in the soluble fraction, while 3 and 4 mg/ml increased the 
soluble Core Complex III signal intensity to 50 % consistent with a dose dependent 
solubilization of the inner mitochondrial membrane. Similar to the data obtained for 
sub-cellular fractionation of mitochondria isolated by differential centrifugation, the 
digitonin titration did not appear to selectively target the outer mitochondrial 
membrane in highly purified mitochondrial preparations as the inner membrane was 
solubilised while a large portion of the outer membrane appeared intact. Despite 
the unpredictable inner and outer mitochondrial membrane marker behaviour, 
LRRK2 V5 immunoreactivity signal reflected the pattern of porin immunoreactive 
distribution with 10 %, 10 % and 20 % of the total V5 signal intensity identified in the 
soluble fraction for 1, 2 and 3 mg/ml digitonin, consistent with an outer 
mitochondrial membrane localisation in affinity purified mitochondrial preparations 
from wild type LRRK2-V5 over-expressing SHSY5Y cells.  
Attempts to sub-fractionate mitochondrial preparations with digitonin did 
not give the predicted data even after numerous attempts hence an alternative 
approach was tested. Affinity purified mitochondria were digested with proteinase k 
(5 and 10 µg/ml) for increasing incubation periods (0-20 min) following which 
mitochondria were pelleted by centrifugation and assessed by Western blot analysis. 
At 5 µg/ml proteinase, 39 kDa immunoreactivity for Core Complex III was 2 fold 
lower relative to untreated mitochondria for all the digestion times, consistent with 
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a partially digested inner mitochondrial membrane (Fig 4.16C). Increasing proteinase 
K to 10 µg/ml resulted in a 4 fold reduction of Core Complex III immunoreactivity for 
all time points analysed consistent with a correlation between enzyme 
concentration and the rate of mitochondrial inner membrane digestion by 
proteinase K. Porin immunoreactivity was present in untreated mitochondria but 
was absent in the presence of proteinase K for all concentrations and time points 
tested with a faint immunoreactive band detected following 20 minute treatment 
with 5 µg/ml proteinase K. The absence of a porin immunoreactive signal suggested 
the outer mitochondrial membrane was completely digested even after 5 minutes of 
proteinase K incubation at 5 µg/ml. An additional 15 kDa immunoreactive porin 
species was identified in affinity purified mitochondria treated with 5 and 10 µg/ml 
proteinase K for all time points (0-20 min) analysed. The 15 kDa porin 
immunoreactivity in the presence of the proteinase K was 3 fold greater relative to 
the band intensity in untreated mitochondrial preparations, suggesting the band 
could represent a porin degradation product.  
4.5.3.1 Sub-fractionation of mitochondria to determine LRRK2 membrane 
association 
Existing data suggests LRRK2 is more abundant in a membrane associated 
form, preferentially binding to cholesterol rich membranes such as those present in 
lipid rafts. To determine whether mitochondrial LRRK2 in wild type LRRK2 over-
expressing SHSY5Y cells is associated with mitochondrial membranes mitochondria 
were fractionated in hypotonic and sodium carbonate buffers. Initially, 
mitochondrial sub-fractionation was carried out on MEFs isolated by differential 
centrifugation. Following treatment, MEFs were separated into soluble and pellet 
components by centrifugation and the corresponding extracts analysed by Western 
blotting. Western blot analysis of mitochondria isolated by differential 
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centrifugation identified an immunoreactive signal for the inner membrane marker, 
SDHA, in the pelleted MEF while cytochtome C immunoreactivity, representing a 
soluble protein in the intermembrane space, was detected in both soluble fraction 
(20 %) and pellet (80 %) MEFs (Fig 4.16D). The presence of cytochrome C in the 
soluble compartment prior to fractionation suggested the integrity of mitochondria 
isolated by differential centrifugation may be partially compromised. LRRK2 was 
detected in the mitochondrial pellet as determined by 280 kDa V5 immunoreactivity.  
MEFs subject to treatment in hypotonic buffer resulted in a 3 fold increase in 
cytochrome C immunoreactivity in the soluble fraction relative to untreated MEFs 
consistent with cytochrome C release from the mitochondrial inter membrane space 
(Fig 4.16D). The distribution and relative intensity of the SDHA immunoreactivity in 
MEFs after the hypotonic treatment resembled that of untreated MEFs suggesting 
SDHA remained associated with the mitochondria and the inner mitochondrial 
membrane retained intact. V5 immunoreactivity following hypotonic treatment of 
MEFs was comparable to that of untreated cells and SHDA suggesting LRRK2 was not 
readily released from the mitochondria in hypotonic conditions.  
MEFs subject to sodium carbonate treatment resulted in a 4 fold decrease in 
the pellet SDHA immunoreactivity with the appearance of an immunoreactive band 
in the soluble fraction consistent with the release of the integral mitochondrial 
membrane protein in alkaline conditions. LRRK2 immunoreactive distribution in the 
presence of sodium carbonate resembled that of SDHA with approximately 30 % of 
the V5 signal identified in the soluble fraction characteristic of a membrane 
associated protein. 
Mitochondrial membrane sub-fractionation of affinity purified mitochondria 
was also investigated. V5, SDHA and cytochrome C immunoreactive bands were 
identified in the pellet of the untreated affinity purified mitochondria, absent in the 
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soluble fraction consistent with a better preserved mitochondrial integrity relative 
to the MEF isolated by differential centrifugation (Fig 4.16E). Cytochrome C was 
readily released from the mitochondria under hypotonic conditions as determined 
by the appearance of a cytochrome C immunoreactive signal in the soluble fraction 
with a corresponding 60 % decrease in the cytochrome C band intensity of the pellet 
relative to untreated mitochondria. Mitochondrial SDHA and V5 immunoreactivities 
resembled those of untreated mitochondria in hypotonic conditions as shown by the 
presence of immunoreactive bands in the pellet extracts only, suggesting both 
proteins were still associated with the mitochondria. A weak SDHA and V5 
immunoreactive band was detected following sodium carbonate treatment of 
mitochondria in the soluble extracts suggesting SDHA and LRRK2 were partially 
solubilised from the affinity purified mitochondria in alkaline conditions consistent 
with the characteristics of membrane associated proteins.  
A large portion of the SDHA and V5 immunoreactive signals were retained in 
the pellet fraction. In addition cytochrome C was not fully solubilized with hypotonic 
treatment for both affinity purified mitochondria and MEF preparations (Fig 4.16D, 
E) as determined by the immunoreactive band in the pelleted fraction suggesting 
some mitochondria were still intact. The incomplete solubilisation of membrane 
proteins under alkaline conditions and intact mitochondrial membranes made it 
difficult to definitively map LRRK2 to mitochondrial membranes. 
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Chapter 5: Results 
LRRK2 regulation of mitochondrial uncoupling: mechanisms  
Mitochondrial permeability to protons can be influenced by the opening of 
the mitochondrial transition pore coupled with the release of free radicals [311] or 
through reduced integrity of the mitochondrial membrane [312]. Free radical 
involvement, mitochondrial morphology and LRRK2 mitochondrial association in 
G2019S cells were assessed in Chapter 4. Mitochondrial uncoupling can also occur 
through the action of mitochondrial uncoupling proteins [313] which can be 
regulated transcriptionally and in the mitochondria by post translational 
modification. The PD associated DJ1 protein has been implicated in UCP 
transcriptional regulation [168], a pathway which could potentially involve LRRK2. In 
addition, mitochondrial bioenergetics have previously been shown to be influenced 
by the DLP1 protein, a putative LRRK2 interacting partner [280], suggesting LRRK2 
mitochondrial DLP1 association could contribute to the regulation of mitochondrial 
uncoupling reported in fibroblasts and SHSY5Y cells. This chapter explores the 
potential involvement of UCPs, DJ1 and DLP1 in the regulation of mitochondrial 
bioenergetics by LRRK2 in fibroblasts and SHSY5Y cells. 
5.1.1 The analysis of SHSY5Y cells over-expressing murine GFP-UCP2 
To determine how increased UCP2 expression influences mitochondrial 
bioenergetics in SHSY5Y cells, a GFP tagged murine UCP2 construct was transiently 
transfected into the cells. Confocal microscopy detected GFP fluorescence in 
transfected cells (Fig 5.1A) consistent with GFP-UCP2 protein expression. Co-staining 
the cells with the mitochondrial dye, TMRM, confirmed GFP expression in all cells 
and the superimposed GFP/TMRM fluorescence showed complete co-localization of 
the two fluorophores consistent with mitochondrial localization of the GFP tagged 
UCP2 molecule. The pattern of TMRM fluorescence resembled that of untransfected 
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SHSY5Y cells (Fig 5.1B) with no obvious change in mitochondrial morphology 
associated with GFP-UCP2 over-expression. Quantification of the TMRM intensity 
relative to control cells identified a 20 % (p<0.0001) reduction in GFP-UCP2 
expressing cells (Fig 5.1C).  
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5.1.2.1 The analysis of relative UCP mRNA expression in fibroblasts and SHSY5Y 
cells 
Having identified changes in the mitochondrial membrane potential in 
response to UCP2 over-expression, the G2019S expressing fibroblast and SHSY5Y cell 
models were screened to quantify relative levels of UCP mRNA and protein. mRNA 
was extracted from control SHSY5Y cells and fibroblasts cultured under normal 
growth conditions, reverse transcribed to cDNA and UCP expression quantified by 
real time PCR analysis as the cycle threshold (CT) value relative to GAPDH CT. Sizes 
of all UCP PCR products were confirmed by agarose gel electrophoresis (Appendix 
Fig A2). In control fibroblasts UCP1 mRNA was not readily detected while UCP2 and 
3 mRNA expression was approximately 5 and 10 fold lower relative to UCP4 and 
UCP5 mRNA levels (Fig 5.2A) suggesting UCP5 is the abundant mRNA isoform. In 
contrast, UCP2 was the most abundant mRNA isoform in control SHSY5Y cells (Fig 
5.2B). UCP3 levels were approximately 6 fold lower when compared to UCP2 
expression (Fig 5.2B). UCP4 mRNA abundance was 10 and 3 fold lower relative to 
UCP2 and 3. Expression of UCP5 mRNA was 5 and 1.5 fold lower relative to UCP2 
and 3 and 2 fold higher relative to UCP4. Our data confirmed UCP2, 3, 4 and 5 
expression in both fibroblasts and SHSY5Y cells and showed a cell specific pattern of 
UCP mRNA isoform distribution.  
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5.1.2.2 The analysis of relative UCP mRNA expression in G2019S fibroblasts and 
SHSY5Y cells 
To determine whether UCP2, 3, 4, 5 mRNA expression was altered in cells 
expressing G2019S LRRK2, mRNA levels were quantified and compared between 
control and G2019S fibroblasts and control, wild type and G2019S LRRK2-V5 
expressing SHSY5Y cells. Data was expressed as percentage CT value relative to 
control cells. UCP mRNA abundance was higher in the G2019S fibroblasts relative to 
control cells (Fig 5.3A) with 300 %, 200 %, 20 % and 15 % increases in the levels of 
isoforms 2, 3, 4 and 5 respectively. However, only the UCP2 mRNA increase was 
statistically significant. SHSY5Y cells over-expressing wild type LRRK2-V5 had 
comparable levels of UCP mRNA to control SHSY5Y cells for all UCP isoforms 
analysed (Fig 5.3B), suggesting wild type LRRK2-V5 over-expression did not influence 
UCP mRNA levels. However, G2019S LRRK2-V5 over-expressing SHSY5Y cells showed 
a 300 % increase in the mRNA levels of the UCP4 isoform with transcript levels of 
UCPs 2, 3, 5 expressed at similar abundances relative to control and wild type LRRK2 
over-expressing cells (Fig 5.3B) consistent with increased UCP4 mRNA expression. 
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5.1.3 Western blot analysis of UCP2 protein in fibroblasts and SHSY5Y cells 
To determine whether increased UCP mRNA expression correlated with UCP 
protein, Western blot analysis was carried out on whole cell lysates of fibroblasts 
and SHSY5Y cells. UCP2 antibody validation was initially preformed on GFP-UCP2 
over-expressing SHSY5Y cells. A UCP2 immunoreactive band of approximately 120 
kDa (i) was identified in the UCP2 GFP transfected cells absent in untransfected 
control SHSY5Y cells (Fig 5.4A) potentially corresponding to a GFP tagged UCP2 
dimer (predicted UCP monomer 33 kDa, GFP 30 kDa). In addition, a 60 kDa (ii) 
immunoreactive band of four fold weaker intensity was detected in both the GFP-
UCP2 transfected and control SHSY5Y cells equivalent to the molecular weight of an 
untagged UCP2 dimer (Fig 5.4A, B). Additional higher and lower molecular bands at 
20 kDa, 55 kDa, 80 kDa and 150 kDa were also present. These bands could not 
definitively be assigned to a particular UCP2 species and may represent truncated 
 187 
 
endogenous protein, post-translationally modified UCP2, oligomeric forms or other 
UCP isoforms as has previously been reported for this antibody [158].  
The 66 kDa (ii) immunoreactive species previously assigned to the 
endogenous untagged UCP2 dimer was detected in GFP UCP2, wild type and G2019S 
LRRK2-V5 SHSY5Y cell extracts in similar abundance with the equivalent band 3 fold 
lower in control SHSY5Y cells (Fig 5.4B). The level of the 66 kDa immunoreactive 
species was three fold lower for both control and G2019S LRRK2 patient fibroblasts 
relative to control SHSY5Y cells consistent with lower UCP2 mRNA expression in 
these cell lines. An additional band, common to both cell types, was detected at 
approximately 60 kDa (iv) with 2-4 fold higher immunoreactivity in fibroblasts 
relative to SHSY5Y cells. A UCP2 immunoreactive band at 125 kDa (iii) was identified 
in all fibroblast extracts potentially represented the endogenous UCP2 tetramer 
[314]. In addition, fibroblast extracts were immunoreactive for 75 kDa and 90 kDa 
UCP2 species, while SHSY5Y cells produced additional 70 kDa and 73 kDa UCP2 
immunoreactive bands. As we were unable to definitively characterise the UCP2 
species in UCP2-GFP over-expressing SHSY5Y cells it was not possible to quantify 
UCP2 levels in fibroblasts and SHSY5Y cells. 
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5.1.4.1 Evaluation of the influence of genipin on UCP induced mitochondrial 
depolarization in SHSY5Y cells 
To further investigate the potential role of UCP protein acting downstream 
of LRRK2 G2019S, the effects on mitochondrial bioenergetics by the previously 
characterized UCP inhibitor, genipin were tested [315]. The optimal concentration 
for this compound in SHSY5Y cells was determined by titrating increasing amounts of 
genipin (1.375-5.5 nM) into control and GFP-UCP2 over-expressing cells, monitoring 
the change in TMRM intensity over the course of 30 minutes (Fig 5.5A). 
Untransfected control SHSY5Y cells treated with genipin (1.375 nM) showed a mild, 
5 % increase in TMRM intensity potentially due to the influence on endogenous 
UCPs. Genipin (1.375 nM) increased the TMRM fluorescent intensity in GFP-UCP2 
cells by 20 % after 5 minutes of drug addition to levels comparable to those of 
untransfected control SHSY5Y cells consistent with a rescue of the reduced 
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mitochondrial membrane potential in GFP-UCP2 cells. The increase in the TMRM 
intensity was maintained for the remainder of the 30 minute time course. There was 
no obvious change in the TMRM or GFP distribution with cell morphology 
unperturbed at the lower dose of the drug (Fig 5.5B). GFP-UCP2 over-expressing 
SHSY5Y cells treated with 2.75 nM genipin showed a linear increase in TMRM 
intensity over the 30 minutes of the measurement with a 45 % increase in TMRM 
fluorescence recorded at the last time point (Fig 5.5A). Higher genipin 
concentrations (5.5 nM) caused a more rapid increase in TMRM intensity but made 
it difficult to image the cells as the genipin treatment resulted in cell mobility and 
nuclear shrinkage indicative of toxic side effects (Fig 5.5C, cells marked □).  
Control, wild type and G2019S LRRK2-V5 over-expressing SHSY5Y cells were 
treated with 1.375 nM genipin, the concentration of the drug which restored the 
mitochondrial membrane potential in UCP2-GFP expressing cells, and the 
mitochondrial membrane potential monitored by TMRM staining over 20 minutes. 
Consistent with previous measurements, TMRM intensity in control cells increased 
by approximately 5 % (Fig 5.5D) 5 minutes following genipin (1.375 nM) treatment 
with a stable TMRM signal intensity maintained for the duration of the time course. 
The TMRM intensity of wild type LRRK2-V5 over-expressing cells was not affected by 
genipin treatment while the TMRM intensity of G2019S LRRK2-V5 over-expressing 
SHSY5Y cells gradually increased in response to genipin, with a 5-10 % increase in 
TMRM fluorescence after 5 minutes and a 20 % increase after 10 minutes following 
treatment relative to untreated cells consistent with a restoration of the 
mitochondrial membrane potential to values resembling those observed for control 
and wild type LRRK2-V5 over-expressing SHSY5Y cells (Fig 5.5D).  
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5.1.4.2 Evaluation of the influence of genipin on UCP induced mitochondrial 
depolarization in fibroblasts 
Two cell lines of control (c1, c7) and three G2019S (p1, p2, p7) patient 
fibroblast lines were treated with genipin (1.375 nM) and the mitochondrial 
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membrane potential monitored by the intensity of TMRM staining over the course 
of 30 minutes. In control cells an increase in TMRM fluorescence was recorded over 
the course of the measurement with the TMRM signal measured to 110 % at 30 
minutes relative to that of untreated fibroblasts (Fig 5.6A). However, 30 minutes 
after genipin addition, a 20 % drop in the TMRM intensity was observed for both cell 
lines accompanied by nuclear shrinkage and excessive mobility (cells marked □ in Fig 
5.6B) in some of the treated control fibroblasts. Three lines of G2019S LRRK2 
fibroblasts showed a more pronounced increase in TMRM intensity with a linear 
increase in TMRM fluorescence from the basal 80 % to 130 % for two of the G2019S 
lines and to 100 % (Fig 5.6A) for the third G2019S line when compared to untreated 
control fibroblasts. In contrast to the control fibroblasts, there was no detectable 
TMRM intensity drop observed for the G2019S cells over the course of the 
measurement and the cellular morphology remained unchanged following genipin 
treatment (Fig 5.6C).  
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5.1.5 LRRK2 kinase activity assays with recombinant UCP2 protein 
UCP activity has previously been shown to be regulated by phosphorylation 
[159] and the mitochondrial fractionation experiments carried out in Chapter 4 
identified LRRK2 associated with mitochondrial membranes. To determine whether 
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LRRK2 could mediate UCP activity directly, in vitro LRRK2 kinase activity assays were 
carried out on wild type GST-LRRK2 immunoprecipitated from HEK293 cells and 
recombinant GST-UCP2 protein. Recombinant proteins were generated and LRRK2 
kinase assays carried out by Francisco Inesta-Vaquera (Dundee). SDS PAGE and 
coomassie stain of the components of the kinase activity reaction identified wild 
type GST-LRRK2 (residues 1326-2527) as the 164 kDa coomassie stained band, 
absent in control reactions where LRRK2 was omitted (Fig 5.7). GST-moesin, a 
previously characterised substrate for the LRRK2 kinase was detected as the 110 kDa 
coomassie stained species absent in GST-UCP2 containing reactions. LRRK2 kinase 
activity reactions contained increasing GST-UCP2 (2-10 µM) substrate 
concentrations, as shown by the increase in 54 kDa coomassie band intensity 
corresponding to GST tagged UCP2 monomer. Additional higher and lower 
molecular weight species were identified in GST-UCP2 containing reactions, absent 
in the GST-Moesin lanes (*), however the identity of these species was not 
investigated. 
Autoradiography analysis of LRRK2 kinase activity assays containing wild 
type GST-LRRK2, GST-Moesin or GST-UCP2 detected a 164 kDa band corresponding 
to the truncated LRRK2 protein consistent with LRRK2 autophosphorylation. In 
addition, in LRRK2 kinase activity assays containing GST-Moesin, autoradiography 
detected a 110 kDa band corresponding to radiolabelled GST-Moesin consistent with 
phosphorylation by GST-LRRK2. In contrast, no clear bands were detected in LRRK2 
kinase activity reactions containing GST-UCP2 protein by autoradiography, 
suggesting LRRK2 was not phosphorylating UCP2 in vitro under the conditions 
tested.  
 
 194 
 
 
 
5.1.6 The impact of UCP4 knockdown upon UCP4 mRNA levels and mitochondrial 
membrane potential in SHSY5Y cells 
To examine the role of UCP4 up-regulation in G2019S LRRK2-V5 over-
expressing SHSY5Y cells we investigated the influence of UCP4 knockdown. Control 
SHSY5Y cells were treated with UCP4 siRNA or scrambled siRNA for 3 days following 
which mRNA was extracted, reverse transcribed to cDNA and evaluated by real time 
PCR analysis. Control SHSY5Y cells treated with 10 nM and 5 nM UCP4 siRNA had 42 
% and 46 % UCP4 mRNA levels relative to untreated cells when corrected for GAPDH 
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expression consistent with a marked reduction in UCP4 mRNA levels. Control SHSY5Y 
cells treated with scrambled siRNA had 21 % higher UCP4 mRNA transcript levels 
relative to untreated cells (Fig 5.8C).  
 
 
 
UCP4 mRNA levels in wild type and G2019S LRRK2-V5 over-expressing 
SHSY5Y cells treated with UCP4 siRNA (5 nM) were 53 % and 75 % relative to the 
corresponding untreated clones consistent with a lower efficiency of UCP4 mRNA 
silencing relative to that achieved in control SHSY5Y cells (Fig 5.9A).  
As commercial UCP4 antibodies were not available at the time of the study 
we were unable to quantify levels of UCP4 protein in UCP4 siRNA treated SHSY5Y 
cells. However, UCPs have previously been reported to have relatively short half 
lives [160] hence we investigated whether the reduction in UCP4 mRNA expression 
was sufficient to alter the mitochondrial membrane potential in these cells. 
Mitochondrial membrane potential was assessed in untreated and UCP4 siRNA (5 
nM) treated control, wild type and G2019S LRRK2 V5 over-expressing SHSY5Y cells in 
glucose rich respiration buffer by TMRM staining and confocal microscopy. TMRM 
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intensities of control SHSY5Y cells treated with UCP4 siRNA were comparable to 
those of untreated SHSY5Y cells (Fig 5.9B). UCP4 siRNA treated wild type LRRK2-V5 
SHSY5Y cells had 10 % (p<0.0001) lower TMRM fluorescence relative to untreated 
cells, indicative of a reduced mitochondrial membrane potential. The reason for this 
decrease is not known. G2019S LRRK2-V5 over-expressing SHSY5Y cells treated with 
UCP4 siRNA had 6 % (p<0.0001) higher TMRM intensities when compared to 
untreated cells, consistent with a higher mitochondrial membrane potential (Fig 
5.9B) potentially due to lower UCP4 mRNA expression. However due to the low 
UCP4 siRNA knockdown efficiency in wild type and G2019S expressing cells and the 
effect of UCP4 siRNA treatment on the mitochondrial membrane potential in wild 
type LRRK2 over-expressing SHSY5Y cells, we could not fully evaluate the effect of 
UCP4 knockdown in the SHSY5Y system. 
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5.1.7 The influence of LRRK2 kinase inhibition upon UCP mRNA expression in 
SHSY5Y cells 
Bioenergetic assessment of wild type and G2019S LRRK2-V5 over-expressing 
SHSY5Y cells in Chapter 4 indicated the mitochondrial membrane potential and 
oxygen consumption abnormalities associated with G2019S expression could be 
partially reversed upon LRRK2 kinase inhibition. To determine whether these 
changes correlated with UCP mRNA transcript levels mRNA was extracted from 
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control, wild type and G2019S LRRK2-V5 over-expressing SHSY5Y cells following 
treatment with LRRK2 IN1 (1µM, 90 min), reverse transcribed to cDNA and UCP4 
mRNA expression quantified by real time PCR. Data was expressed as the 
percentage change in UCP4 CT values relative to untreated control SHSY5Y cells. 
UCPs 2, 4 and 5 were reduced by 15-30 % in control SHSY5Y cells treated with LRRK2 
IN1 (Fig 5.10). Wild type LRRK2-V5 over-expressing SHSY5Y cells treated with LRRK2-
IN1 showed a 10 % decrease in UCP2 mRNA levels but expression of UCP mRNA for 
isoforms 3-5 showed a considerable amount of variability between experiments 
making it difficult to evaluate the effect of LRRK2-IN1 treatment on the levels of 
these UCP isoforms (Fig 5.10). G2019S LRRK2-V5 expressing SHSY5Y cells treated 
with LRRK2-IN1 had similar UCP abundance for isoforms 2, 3 and 5 relative to 
untreated control cells. Basal UCP4 mRNA levels were 700 % higher in G2019S 
LRRK2-V5 over-expressing SHSY5Y cells when compared to control cells but were 
reduced to 150 % in cells treated with LRRK2 IN1 consistent with lower UCP4 mRNA 
abundance following LRRK2 kinase inhibition. The reduction in UCP4 mRNA 
expression in G2019S expressing SHSY5Y cells upon LRRK2 kinase inhibition 
correlated with a reduced rate of mitochondrial respiration and increased 
mitochondrial membrane potential (Fig  4.14 A,C).  
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5.1.8 The impact of LRRK2 knockdown upon UCP4 mRNA levels and mitochondrial 
membrane potential in SHSY5Y cells 
To investigate the influence of endogenous LRRK2 on the regulation of UCP 
expression, UCP4 mRNA levels were evaluated in the SHSY5Y LRRK2 siRNA 
knockdown model. mRNA was extracted from SHSY5Y cells treated with LRRK2 
siRNA for 6 days, reverse transcribed to cDNA and assessed for UCP4 mRNA levels by 
quantitative real time PCR. SHSY5Y cells treated with LRRK2 siRNA showed a 53 % 
decrease in UCP4 transcript levels relative to untreated cells (Fig 5.11A) supporting a 
role for endogenous LRRK2 in influencing UCP4 mRNA abundance. Mitochondrial 
membrane potential was assessed in control and LRRK2 siRNA treated SHSY5Y cells 
in glucose rich respiration buffer by TMRM staining and confocal microscopy. The 53 
% reduction in UCP4 mRNA expression in siRNA treated SHSY5Y cells correlated with 
a 10 % increase in TMRM intensity consistent a higher mitochondrial membrane 
potential relative to untreated cells (Fig 5.11B).  
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5.2.1 Characterization of DJ1 knockdown SHSY5Y cells 
Having shown UCP mRNA transcript levels are affected by changes in LRRK2 
kinase activity as well as levels of endogenous protein, we set out to investigate 
potential upstream events which may contribute to the UCP mRNA expressional 
changes. DJ1 has previously been implicated in the UCP mRNA regulatory pathway in 
dopaminergic neurons [168]. To determine whether DJ1 plays a role in regulating 
UCP mRNA expression in SHSY5Y cells, 2 clones of SHSY5Y cells stably expressing DJ1 
shRNA and 1 clone expressing scrambled shRNA were generated by Zhi Yao (UCL). 
mRNA was extracted from control, DJ1 shRNA and scrambled shRNA expressing 
SHSY5Y cells, reverse transcribed to cDNA and evaluated for DJ1 mRNA expression 
by quantitative real time PCR analysis. DJ1 mRNA levels were similar between 
control and scrambled shRNA treated SHSY5Y cells while DJ1 shRNA expression 
correlated with 85 % (clone x) and 95 % (clone y) lower DJ1 mRNA transcript levels 
relative to control SHSY5Y cells (Fig 5.12A). Western blot analysis of whole cell 
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lysates of control, DJ1 shRNA and scrambled shRNA expressing SHSY5Y cells showed 
comparable 30 kDa DJ1 immunoreactivities in control and scrambled shRNA treated 
cells (Fig 5.12 B, C) while an 80 % (clone x) and 90 % (clone y) decrease in the 30 kDa 
immunoreactivity was determined for DJ1 shRNA expressing cells relative to control 
cells consistent with reduced levels of DJ1 protein (Fig 5.12B, C).  
 
 
 
 
5.2.2 The analysis of UCP mRNA expression in DJ1 knockdown SHSY5Y cells 
To determine if DJ1 could play a role in the G2019S LRRK2 up regulation of 
UCP4 in SHSY5Y cells, DJ1 knockdown cells were screened for UCP2-5 mRNA 
expression. mRNA was extracted from SHSY5Y cells, reverse transcribed to cDNA and 
UCP expression evaluated by quantitative real time PCR analysis. UCP2 mRNA levels 
were comparable between control and DJ1 shRNA expressing SHSY5Y cells and 
reduced by 40 % in the scrambled shRNA expressing cells relative to control cells, 
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although this value was not statistically significant (Fig 5.13A). UCP3 mRNA 
expression was significantly lower in DJ1 shRNA expressing SHSY5Y cells (40-50 %, 
p<0.05) relative to untreated cells suggesting the loss of DJ1 is affecting the 
expression of the UCP3 isoform (Fig 5.13B). UCP4 mRNA expression was comparable 
between control cells and DJ1 shRNA clone x while a 56 % increase in UCP4 mRNA 
expression was identified for DJ1 shRNA clone y (Fig 5.13C). UCP4 mRNA levels were 
147 % more abundant in scrambled shRNA cells relative to control SHSY5Y cells, 
although this value was not statistically significant. UCP5 mRNA transcript levels 
were comparable between control, scrambled shRNA and DJ1 shRNA clone x cells 
with a 20 % reduction in UCP5 mRNA levels determined for DJ1 shRNA expressing 
clone y (Fig 5.13D). Due to the lack of a clear role for DJ1 in the regulation of UCP4 
mRNA levels we did not pursue with knocking DJ1 down in G2019S LRRK2-V5 
expressing SHSY5Y cells.  
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5.3 The influence of LRRK2 expression upon PGC1α, SOD2 and catalase mRNA in 
SHSY5Y cells  
UCP mRNA expression has previously been shown to be regulated by 
PGC1α/PPARγ mediated transcriptional activation by increased PGC1α levels [316]. 
PGC1α mRNA expression was quantified by real time PCR in control, wild type and 
G2019S LRRK2-V5 over-expressing SHSY5Y cells. PGC1α mRNA levels were 
comparable between control and wild type LRRK2-V5 over-expressing SHSY5Y cells 
while a 70 % increase in PGC1α mRNA was identified for the G2019S LRRK2-V5 cells 
consistent with increased PGC1α expression (Fig 5.14A). As PGC1α levels have also 
been shown to regulate expression of antioxidant defence genes including SOD2 and 
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catalase, we evaluated the mRNA levels of SOD2 and catalase in these cells. SOD2 
(Fig 5.14C) and catalase (Fig 5.14B) mRNA levels were comparable between the 
control, wild type and G2019S LRRK2-V5 over-expressing cells.  
 
 
 
5.4.1 The analysis of HDAC5 cellular distribution by immunohistochemistry in 
SHSY5Y cells 
HDAC5 involvement in PGC1α regulation was investigated by measuring 
nuclear and cytosolic HDAC5 protein by immunocytochemistry. Control SHSY5Y cells 
were fixed in paraformaldehyde and permeabilised in 0.1 % Triton X100. Titrating 
HDAC5 antibody concentrations (50-200 nM) revealed a dose dependent increase in 
the green fluorescence in SHSY5Y cells (Fig 5.15A). This increase in fluorescence was 
observed for large nuclear punctate structures (nuclear HDAC5 pool), diffuse 
cytosolic staining (cytoplasmic HDAC5 pool) and punctate cytosolic structures 
potentially representing HDAC5 polymers (complexes). Concentrations (200 µM) 
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where the nuclear HDAC5 punctate structures were best resolved were chosen for 
subsequent experiments.  
Phorbol myristate acetate (PMA) has previously been shown to induce HDAC 
nuclear export [317] and was used to test the HDAC5 antibody specificity in SHSY5Y 
cells monitoring the nuclear to cytosolic HDAC5 redistribution. The PMA dose (100 
nM) was chosen based on concentrations previously shown to induce HDAC5 
nuclear export in SHSY5Y cells [317]. Control SHSY5Y cells treated with PMA (100 
nM, 90 min) resulted in a decrease in HDAC5 immunofluorescent intensity of nuclear 
immunoreactive punctae with a weak increase in cytosolic HDAC5 immunoreactivity 
consistent with a partial redistribution of the HDAC5 molecule from the nucleus into 
the cytosolic compartment. Cells subject to prolonged PMA treatment (3 hours) 
showed a further reduction in the intensity of the nuclear HDAC5 signal with the 
nuclear punctate structures appearing less well defined to the ones observed in the 
untreated SHSY5Y cells (Fig 5.15B). The intensity and frequency of the cytosolic 
punctate structures were comparable between untreated and PMA treated cells. As 
we did not observe gross changes in cellular HDAC5 distribution in response to PMA 
we did not extend the immunohistochemical analysis to wild type and G2019S 
LRRK2-V5 over-expressing SHSY5Y cells. 
 
 206 
 
 
 
5.4.2 The analysis of HDAC5 by Western blot in SHSY5Y cells  
HDAC5 protein levels were evaluated in SHSY5Y cells by Western blot 
analysis of whole cell lysates. The HDAC5 antibody showed strong immunoreactivity 
for the 100 kDa species on Western blot of control SHSY5Y cells corresponding to 
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the predicted full length HDAC5 protein (Fig 5.16). Comparable 100 kDa HDAC5 
immunoreactivities were identified following PMA treatment (100 nM, 90 min) 
suggesting PMA does not influence cellular HDAC5 levels (Fig 5.16). Comparison of 
HDAC5 immunoreactivity between control, wild type and G2019S LRRK2-V5 over-
expressing SHSY5Y cells revealed similar HDAC5 band intensities relative to GAPDH 
immunoreactivity correcting for equivalent protein loading, in the absence and 
presence of PMA consistent with equivalent levels of cellular HDAC5 protein.  
 
 
 
5.4.3 The analysis of HDAC5 and LRRK2 interaction  
HDAC5 immunoprecipitations were carried out on 1 % Triton X100 extracts 
of LRRK2 over-expressing SHSY5Y cells, control and LRRK2 knockout mouse brain 
cortex to investigate whether LRRK2 interacts with HDAC5. In addition, HDAC5 
immunoprecipitations were carried out on LRRK2 over-expressing SHSY5Y cells 
treated with PMA in an attempt to enhance the cytosolic HDAC5 levels. Western 
blot analysis of HDAC5 immunoprecipitates from wild type and LRRK2 knockout 
mouse brains detected a HDAC5 immunoreactive species of approximately 100 kDa 
in all brain IPs, absent in IPs where HDAC5 antibodies were omitted (Fig 5.17A). The 
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100 kDa band co-migrated with the HDAC5 immunoreactivity detected in brain IP 
input lysate consistent with a successful pull-down of a full length HDAC5. Western 
blot analysis of HDAC immunoprecipitates revealed 3514-1 weak 280 kDa 
immunoreactivity detected in the wild type brains absent in LRRK2 knockout brain 
samples. 3514-1 280 kDa immunoreactivity could not be detected in the brain IP 
input lysate due to low LRRK2 levels, as has previously been shown in Chapter 3. An 
additional band of 170 kDa (*) was detected by the 3514-1 antibody in HDAC5 IP 
from mouse brains as well as a weaker intensity signal in the input fraction. As the 
signal was present in both control and LRRK2 knockout brains it was possible to 
assume non specific binding of the antibody. The co-IP of LRRK2 with HDAC5 
suggested LRRK2 interacted with full length HDAC5 in the mouse brain. 
To determine whether the LRRK2 HDAC5 association occurs in SHSY5Y cells, 
HDAC5 was immunoprecipitated from 1 % Triton X100 extracts of control, wild type 
and G2019S LRRK2-V5 over-expressing SHSY5Y cells. Positive immunoreactivity for 
the HDAC5 antibody was detected in the IP input sample of SHSY5Y cells, consistent 
with full length HDAC5 protein (Fig 5.17B). Equivalent HDAC5 100 kDa 
immunoreactive bands were detected in immunoprecipitates from control, wild type 
and G2019S LRRK2-V5 over-expressing SHSY5Y cells consistent with comparable 
efficiencies in the HDAC5 IP (Fig 5.17B). An additional lower molecular weight 
species immunoreactive for HDAC5 was detected at approximately 90-95 kDa in the 
IP samples, absent in the IP input lysate (Fig 5.17B), control and LRRK2 knockout 
mouse brains (Fig 5.17A). The nature of this species was not evaluated. Probing the 
IP Western blot for V5 immunoreactivity detected a weak immunoreactive band in 
the wild type LRRK2-V5 over-expressing samples and a 280 kDa species of 
approximately two fold greater intensity in the G2019S LRRK2-V5 co-IP. No 
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equivalent bands were detected in untransfected control SHSY5Y cells or PMA 
treated samples suggesting PMA influenced the LRRK2 HDAC5 association.  
The G2019S LRRK2-V5 protein appeared to be more associated with HDAC5 
when compared to wild type LRRK2 as shown by the increase in the V5 band 
intensity of HDAC5 co-IPs (Fig 5.17B), suggesting LRRK2 kinase activity may play a 
role in HDAC5 association. To investigate the effects of LRRK2 kinase inhibition on 
the LRRK2 HDAC5 co-IP, immunoprecipitation was carried out following treatment of 
wild type and G2019S LRRK2-V5 over-expressing SHSY5Y cells with LRRK2 kinase 
inhibitors (LRRK2-IN1 (1 µM, 90 min) and CZC25146 (0.3 µM, 60 min)). LRRK2 kinase 
inhibition by LRRK2-IN1 and CZC25146 and potentially PMA was evaluated by 
immunoprecipitating LRRK2 from 1 % Triton X100 lysates and probing for 
phosphorylation at Serine 935 by Western blot. LRRK2 Serine 935 phosphorylation 
was reduced by 80-90 % in both wild type and G2019S LRRK2-V5 over-expressing 
SHSY5Y cells following LRRK2-IN1 and CZC25146 treatment as determined by the 
band intensity of phospho Serine 935 relative to total LRRK2 (3514-1 antibody) 
consistent with the inhibition of the LRRK2 kinase activity (Fig 5.17C). In contrast, the 
phospho Serine 935 immunoreactive LRRK2 band from PMA treated wild type and 
G2019S LRRK2-V5 SHSY5Y cells was of comparable intensity relative to untreated 
cells suggesting PMA did not influence the LRRK2 Serine 935 phosphorylation status 
(Fig 5.17C).  
HDAC5 was immunoprecipitated from 1 % Triton X100 lysates of untreated, 
LRRK2 IN1 or CZC25146 treated wild type or G2019S LRRK2-V5 over-expressing 
SHSY5Y cells. Western blot analysis of HDAC5 immunoprecipitates revealed 
comparable immunoreactivities in the presence and absence of LRRK2 kinase 
inhibition consistent with equivalent HDAC5 IP efficiencies (Fig 5.17D). Probing 
HDAC5 IP Western blots for V5 immunoreactivity revealed an immunoreactive band 
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of approximately 2 fold greater intensity for the untreated G2019S LRRK2-V5 cell 
line relative to untreated wild type LRRK2-V5 SHSY5Y cells, in line with the previous 
experiment (Fig 5.17B). The 280 kDa V5 immunoreactive signal was of comparable 
intensity for wild type and G2019S LRRK2-V5 over-expressing SHSY5Y cells treated 
with both LRRK2-IN1 and CZC25146 LRRK2 kinase inhibitors relative to untreated 
cells suggesting LRRK2 kinase inhibition does not influence the LRRK2 HDAC5 
interaction (Fig 5.17D) as detected by co-IP. An additional 300 kDa band 
immunoreactive for the 3514-1 antibody (*) was detected in the IP input lysates of 
both wild type and G2019S LRRK2 over-expressing SHSY5Y cells, the identity of this 
band was not investigated. 
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5.5.1 The analysis of DLP1 protein in SHSY5Y cells 
A LRRK2 DLP1 interaction has recently been described [280, 281] correlating 
with changes in mitochondrial function described for wild type and G2019S 
expressing SHSY5Y cells. To evaluate the potential role of DLP1 in the regulation of 
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mitochondrial uncoupling in G2019S expressing fibroblasts and SHSY5Y cells, DLP1 
levels were assessed in whole cell lysates of control and G2019S LRRK2 fibroblasts by 
Western blot analysis. 90 kDa DLP1 immunoreactivity was detected in fibroblast 
extracts corresponding to the predicted molecular weight of the monomeric full 
length DLP1 (Fig 5.18A). Quantification of the DLP1 immunoreactivity relative to 
GAPDH confirmed equivalent levels of DLP1 abundance in control and G2019S 
fibroblasts (Fig 5.18B). Furthermore, DLP1 protein levels were also comparable 
between control, wild type and G2019S LRRK2-V5 over-expressing SHSY5Y cells as 
determined by DLP1 90 kDa immunoreactivity relative to GAPDH in whole cell 
extracts (Fig 5.18C).  
Mitochondrial levels of DLP1 were evaluated by Western blot analysis of 
affinity purified mitochondria isolated from wild type and G2019S LRRK2-V5 over-
expressing SHSY5Y cells. The band intensity of Core Complex III markers was 
comparable for wild type and G2019S LRRK2-V5 mitochondrial isolations suggesting 
similar mitochondrial loading (Fig 5.18D). DLP1 90 kDa immunoreactive bands in 
extracts of purified mitochondria were of similar intensities for wild type and 
G2019S LRRK2-V5 expressing cells with comparable DLP1/Core Complex III ratios 
suggesting similar mitochondrial DLP1 levels. Furthermore, affinity purified 
mitochondria from wild type and G2019S LRRK2-V5 over-expressing cells treated 
with LRRK2-IN1 (1 µM, 90 min) revealed comparable DLP1 Core Complex III 
immunoreactivities. Although mitochondrial DLP1 quantifications were only carried 
out once (n=1) our data suggested LRRK2 G2019S and LRRK2 kinase inhibition did 
not impact on steady state mitochondrial DLP1 abundance (Fig 5.18E). 
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5.5.2 The analysis of LRRK2 and DLP1 interaction in SHSY5Y cells 
To determine whether LRRK2 interacts with DLP1 in SHSY5Y cells LRRK2 was 
immunoprecipitated from 1 % Triton X100 extracts of wild type and G2019S LRRK2-
V5 over-expressing SHSY5Y cells. Western blot analysis of immunoprecipitates 
revealed a 3514-1 immunoreactive 280 kDa band corresponding to the approximate 
molecular weight of the full length LRRK2 protein, co-migrating with the 280 kDa 
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immunoreactive species in the input fraction and absent in immunoprecipitates of 
samples where the primary antibody was omitted (Fig 5.19). Western blot analysis 
of LRRK2 immunoprecipitates detected a 90 kDa DLP1 immunoreactive band 
corresponding to the full length protein in the input sample, representing 
approximately 5 % of the total IP input. DLP1 immunoreactivity was not clearly 
detected in immunoprecipitates where the LRRK2 antibody was omitted, control, 
wild type or G2019S LRRK2-V5 IP samples at the equivalent exposure times. 
However, longer exposures detected a faint 90 kDa immunoreactive band 
corresponding to the molecular weight of the full length DLP1 protein in 
immunoprecipitates of G2019S LRRK2-V5 expressing SHSY5Y cells absent in control, 
wild type LRRK2-V5 immunoprecipitates and IPs where DLP1 antibodies were 
omitted consistent with a small portion of the LRRK2 G2019S mutant pool 
interacting with the DLP1 molecule.  
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Chapter 6: Discussion 
6.1 LRRK2 tissue distribution 
Idiopathic PD is characterized by the loss of dopaminergic neurons in the 
SNpc while the Braak hypothesis of the pathological spread in PD suggests 
progressive disease transmission from the lower brain stem regions, midbrain and to 
the neocortex. The motor dysfunction and cognitive decline associated with the 
deterioration of these tissues suggests the function of neurons in these brain regions 
may play an important role in the disease pathogenesis. As LRRK2 mutations are 
clinically and pathologically indistinguishable from idiopathic PD, LRRK2 tissue 
distribution may provide an insight into the function of the protein in the context of 
PD pathology. 
Previous studies have demonstrated ubiquitous LRRK2 expression, with low 
levels of LRRK2 mRNA and protein detected in the rodent brain relative to peripheral 
tissues such as the kidneys lungs and lymph nodes [245]. High LRRK2 expression in 
peripheral tissues has been linked to cell specific processes such as microbial 
elimination in bone derived macrophages and RAW264.7 cell lines [241, 243], 
antibody secretion in B lymphocytes [242] and autophagic control of lung and kidney 
homeostasis [238, 240]. Although similar processes may be relevant in the brain 
potentially playing a role in PD pathogenesis, lower levels of LRRK2 mRNA imply 
neurons are less dependent on these LRRK2 regulated mechanisms, supported by a 
lack of a neuronal phenotype in LRRK2 knockout animals where kidney atrophy and 
poor immune responses have been noted [238, 240, 271]. Furthermore, the G2019S 
mutation does not appear to have an aberrant effect on the LRRK2 functions 
described in peripheral tissues. The immune response in T cells [271] and microbial 
elimination by macrophages [241] were unaffected by G2019S transgene expression. 
Mice expressing bacterial artificial chromosome (BAC) derived wild type and G2019S 
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LRRK2 constructs had normal kidney and lung function [238] suggesting the 
mutation does not functionally impair these cell types.  
Proposed brain specific functions for LRRK2 include maintenance of 
dopamine homeostasis which relies on the function of dopaminergic cells while the 
dysregulation of this pathway is linked to PD pathogenesis [234]. Striatal dopamine 
release in mice was enhanced by wild type LRRK2 over-expression and reduced in 
G2019S transgenic animals, however, dopaminergic cell loss was not observed 
questioning the suitability of the LRRK2 mouse model in the study of PD [234]. 
Although LRRK2 expression has been noted in dopaminergic brain areas, with 
immunohistochemical analysis detecting LRRK2 in the striatum, hippocampus and 
cortex of rodent and non human primates, substantially lower LRRK2 protein levels 
were detected in the substantia nigra [244, 249, 250, 318]. The G2019S mutation 
appears to be linked to the death of dopaminergic neurons in substantia nigra of PD 
patients which seems to correlate with low SNpc LRRK2 expression suggesting a 
specific functional role for LRRK2 in this cell type or the preferential vulnerability of 
these cells to a G2019S LRRK2 associated insult.  
Our analysis of LRRK2 mouse, rat and marmoset brain distribution by the 
combined immunoprecipitation and Western blot approach supported previous 
reports describing the LRRK2 brain expression pattern, detecting greatest LRRK2 
levels in the striatum, cortex and cerebellum with lower LRRK2 abundance in the 
midbrain, olfactory lobe and brain stem. Comparing LRRK2 striatal and cortical 
expression to that of lymphoblasts detected 50 fold higher LRRK2 levels in the 
immune cells in support of the expressional differences between peripheral cells and 
brain tissue. 
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6.2 LRRK2 detection 
6.2.1 LRRK2 detection by Immunohistochemistry 
Methods for LRRK2 protein detection in rodent and primate brains have 
previously included Western blotting, BN PAGE and immunohistochemistry using in 
house and commercially available polyclonal LRRK2 antibodies. Although generally a 
common distribution pattern has been noted (described in section 6.1), 
discrepancies between groups exist, most pronounced in immunohistochemical 
studies where LRRK2 expression in neuronal sub populations and glial cells has been 
debated. In particular immunohistochemical analysis of LRRK2 expression in Purkinje 
cerebellar granular cells have yielded mixed reports in both human and rodent 
tissues. Three studies reported positive LRRK2 immunoreactivity [206, 319, 320] 
while two others failed to detect LRRK2 in this cell subtype [246, 247]. Our 
characterization of the 3514-1 antibody in wild type mouse cerebellar sections 
revealed positive staining in this cell subtype absent in the equivalent LRRK2 
knockout brain regions. Utilizing the same protocol we were able to detect LRRK2 
immunoreactivity in human purkinje neurons of the cerebellum suggesting LRRK2 is 
indeed present in this cell type in the human brain. LRRK2 expression in brain 
microglia has also been debated with some reports suggesting glial cells do not 
express LRRK2 [249] while other studies using the 3514-1 and NB300-268 antibodies 
detected strong immunoreactivity in activated mouse microglia, human microglia 
and astrocytes [320, 321]. LRRK2 glial staining was not observed in control mouse or 
human cerebellar sections described here potentially due to the young age of the 
animals and absence of immunoinfiltration in the human cerebellum, a point that 
was not addressed. Considering the emerging literature on the role of LRRK2 in 
activated macrophages [241] and adhesive monocytes [322], it is possible that 
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LRRK2 does indeed have a role in brain immunoprotection which may be relevant to 
PD.  
Although immunohistochemical assessment can distinguish between cell 
populations in different brain regions, this technique is semi quantitative and cannot 
be used to compare LRRK2 brain expression between cell types, brain regions and 
species. In addition, although the specificity of the antibody can be validated by 
LRRK2 knockout tissue, the size of the immunoreactive LRRK2 species detected 
cannot be defined. Western blotting on the other hand is quantitative and provides 
molecular weight estimations for the immunoreactive species.  
6.2.2 LRRK2 detection by Western blotting 
Western blot analysis for LRRK2 detection has been limited by the 
availability of antibodies that can detect low levels of endogenous LRRK2 protein 
and poor characterization of the <280 kDa LRRK2 immunoreactive species detected 
by these antibodies. Biskup et al, [237] [251] screened 8 in house and commercially 
available LRRK2 antibodies in SHSY5Y cells, M17, PC12, HEK293 cells and brain 
tissue. All of the antibodies detected multiple bands in both wild type and LRRK2 
knockout mouse brains including a 280 kDa band corresponding to the full length 
LRRK2. The lack of specificity questioned the use of these antibodies [237, 251]. 280 
kDa LRRK2 immunoreactivity in HEK293 cells was observed for two of the 8 
antibodies and although the data was not shown, the authors stated that they had 
difficulty detecting endogenous LRRK2 in SHSY5Y, M17 and PC12 cells. The antibody 
screen described in this report detected 280 kDa LRRK2 immunoreactive species by 
Western blot in SHSY5Y cells over-expressing LRRK2 absent in control cells 
corresponding to the predicted molecular weight of the full length protein for all 
four antibodies analyzed. However, the four antibodies could not definitively 
identify endogenous 280 kDa LRRK2 in SHSY5Y cells, fibroblasts or brain extracts. In 
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addition to the 280 kDa LRRK2 immunoreactive species, lower molecular weight 
immunoreactive bands were also detected in all cells and tissues analysed in line 
with previous observations [237]. Similar to the <280 kDa LRRK2 immunoreactive 
species in the Biskup et al report, these bands could represent non specific binding 
of the antibodies however truncated versions of the protein and splice variants of 
endogenous LRRK2 cannot be ruled out.  
A number of studies validated in house antibodies for detection of 
endogenous full length LRRK2 species by siRNA knockdown of the protein in cell 
culture systems [224, 239, 243]. siRNA knockdown of LRRK2 confirmed endogenous 
LRRK2 detection in Hela cells [239] and Raw264.7 macrophages [243] potentially 
reflecting higher LRRK2 abundance in these cell types or improved antibody 
specificity for conditions used in the study involving HEK293 cells [224]. In all cases, 
the intensity of the 280 kDa band was reduced in siRNA treated cells consistent with 
reduced LRRK2 abundance. However, the effect of siRNA on the band intensity of 
<280 kDa immunoreactive LRRK2 species was not provided with the published data 
making it difficult to address the nature of these species. 
Analysis of the LRRK2 coding sequence derived from human SNpc predicted 
the 280 kDa size of the multidomain protein. When cloned in carcinoma cells, the 
LRRK2 immunoreactive band resolved at 280 kDa on SDS PAGE consistent with the 
expression of full length monomeric LRRK2 [203]. As cDNA was cloned into the 
HEK293 expression system, potential LRRK2 splice isoforms were not investigated. 
The possibility of tissue specific regulation required to initiate transcription or 
generate spliced and truncated forms of LRRK2 cannot be ruled out. In particular, 
BAC LRRK2 derived transcripts (containing the complete LRRK2 gene) appear to 
undergo post transcriptional or post-translational processing in mouse kidneys to 
generate a lower molecular weight protein observed by SDS PAGE absent in 
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equivalent extracts of brain or lung tissues and LRRK2 knockout controls [238]. 
Characterization by mass spectrometry to identify the exact nature of the lower 
molecular weight species confirmed the 160 kDa band as N terminally truncated 
LRRK2 [238]. Western blot analysis of LRRK2 protein expression described in this 
thesis revealed 160 kDa immunoreactivity for the 100-500 and 3514-1 antibodies in 
lymphoblasts and human brain tissue. As the 100-500 antibody was raised against 
the LRRK2 N terminus, the 160 kDa N terminally truncated LRRK2 would not bind 
this antibody, hence the 100-500 160 kDa immunoreactive bands are likely to be 
non specific. However, the 3514-1 antibody epitope spans the core domain of LRRK2 
suggesting the 160 kDa LRRK2 and 3514-1 160 kDa immunoreactivity in 
lymphoblasts and human brain tissue could represent the LRRK2 N terminally 
truncated species. In addition, 160 kDa immunoreactivity was identified by 100-500 
and 3514-1 antibodies in SHSY5Y cells over-expressing LRRK2, absent in control cells. 
Alternative LRRK2 splicing was ruled out in this cDNA expressing system, however 
post translational cleavage of full length LRRK2 may account for these 
immunoreactive species. LRRK2 Immunoreactive bands >280 kDa have been 
assigned to SDS stable dimers [244]. These > 280 kDa species were not detected in 
our analyses and were absent in a range of other antibody screens [237, 249] under 
a variety of solubilisation conditions tested questioning the reproducibility of these 
findings. Although phosphorylation of LRRK2 has been confirmed by mass 
spectrometry the species to size correlation has not yet been fully clarified [202, 
211].  
6.2.3 LRRK2 detection by BN PAGE 
LRRK2 detection by BN PAGE has previously been used to look at the native 
structure of the protein. In lymphoblasts and HEK293 cells over-expressing LRRK2, 
LRRK2 was shown to exist predominantly as a dimer and in higher molecular weight 
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oligomeric forms while monomeric LRRK2 could not be detected in these systems 
under native conditions [228, 323]. The lack of native monomeric LRRK2 was 
challenged by Berger et al, [252] who demonstrated the 280 kDa as the predominant 
native species in mouse brain, lymphoblasts and HEK293 over-expressing cells. We 
investigated the native state of LRRK2 and the specificity of the 3514-1 LRRK2 
antibody in over-expressing SHSY5Y cells and endogenous brain tissue using this 
methodology.  
LRRK2 V5 immunoreactivity confirmed the equivalent species detected by 
the 3514-1 antibody represented over-expressed LRRK2 in SHSY5Y cells. A 280 kDa 
species was the dominant form of LRRK2 detected in over-expressing SHSY5Y cells, 
human and rodent brains by BN PAGE electrophoresis in line with reports by Berger 
et al. This may in part be due to the preferential extraction of the soluble pool of 
LRRK2 using the extraction conditions for BN PAGE, as LRRK2 dimers have previously 
been shown to be enriched in the membrane fraction [252]. In support of this, 
inclusion of DDM and Triton X100 detergents during solubilisation of SHSY5Y cells 
over-expressing LRRK2 increased the recovery of the higher molecular weight LRRK2 
species. Although detergents appeared to improve recovery of LRRK2, the resolution 
and LRRK2 migration on BN PAGE resulted in the formation of immunoreactive 
smears, previously assigned to higher molecular weight LRRK2 species [228, 323]. 
Both the V5 and 3514-1 antibodies showed comparable specificities for the 
monomeric and oligomeric forms of LRRK2 in contrast to SDS PAGE and Western 
blot analysis where multiple lower molecular weight species were detected by 3514-
1, potentially due to improved specificity of the 3514-1 antibody for LRRK2 under 
native conditions. 
Assessment of human and rodent samples by BN PAGE produced a range of 
LRRK2 immunoreactive species not resolved in the over-expressing SHSY5Y cells 
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potentially due to low levels of tissue soluble LRRK2, supported by the higher ratio 
of membrane versus soluble LRRK2 in rodent tissue relative to lymphoblasts and 
LRRK2 over-expressing HEK293 cells [252]. In addition, a 280 kDa immunoreactive 
band was detected in LRRK2 knockout brain extracts suggesting non specific binding 
of the antibody may occur under these solubilisation conditions. As mouse LRRK2 
knockout tissue has not previously been evaluated by BN PAGE, the true nature of 
the bands observed in lymphoblasts and brain tissue warrants further analysis. The 
poor recovery and resolution on Western blot of the LRRK2 immunoreactive species 
in mouse and human brain extracts did not allow for quantitative comparison of 
LRRK2 protein levels between different regions of human and rodent brain samples.  
6.2.4 LRRK2 detection by immunoprecipitation and Western blotting 
The immunoprecipitation protocol utilized throughout this study 
demonstrated specificity and improved sensitivity of antibody detection when 
compared to Western blot analysis and BN PAGE. The combination of two LRRK2 
antibodies consistently produced a 280 kDa species in all cells, rodent and non 
human primate brain tissue. The LRRK2 immunoreactive band could not be detected 
in knockout mouse brain tissue and the signal intensity was markedly reduced in 
SHSY5Y cells upon siRNA treatment. Solubilization conditions producing efficient >90 
% LRRK2 recovery and the linear correlation for the LRRK2 signal intensity change 
relative to protein input made it comparable to the quantitative assessment of 
whole cell lysates by SDS PAGE [244]. IP assessment suggested the 280 kDa species 
was the dominant isoform in all models analyzed and that the truncated LRRK2 
protein previously validated by mass spectrometry [238] was not detected by this 
methodology. As the 100-500 antibody was raised against the N terminus of LRRK2, 
N terminally truncated 160 kDa LRRK2 would not bind the 100-500 antibody. The 
absence of additional bands implied enhanced specificity for the 250-300 kDa 
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protein or reduced sensitivity for the lower molecular weight species suggesting the 
combination of IP and Western blot preferentially detects the full length LRRK2.  
In contrast to the immunohistochemical analyses where LRRK2 was readily 
detected in both human and mouse cerebellum [248, 251, 319, 320], 
immunoreactivity was either absent or extremely weak in Western blot analysis of 
immunoprecipitates from human brain lysates of the frontal cortex, amygdala, 
caudate nucleus and cerebellum. Even when analysing samples with post mortem 
delay times as short as 1h30. Due to the lack of a suitable control for the human 
tissue, the weak intensity identified as LRRK2 immunoreactivity in 
immunoprecipitates from one human cerebellum extract cannot be definitively 
confirmed as a true LRRK2 species, an issue which has been encountered in other 
studies [318]. Analysis of LRRK2 recovery from fibroblast lysates in the presence of 
human brain samples revealed a reduction in the signal intensity suggesting the 
human brain sample was interfering with the IP procedure. This phenomenon was 
not observed in the presence of mouse brain extracts suggesting quantifications of 
LRRK2 distribution in the rodent brain are not underestimated and the problem with 
LRRK2 detection in immunoprecipitates from human brain extracts is likely to be 
influenced by the contents of the human brain lysate. 
Based on our evaluation of immunohistochemistry, Western blotting, BN 
PAGE and immunoprecipitation in combination with Western blot analysis as 
methods for LRRK2 detection and quantification of protein expression, the 
combined immunoprecipitation and Western blot approach was chosen for 
quantitative comparison of the relative LRRK2 expression in fibroblast, lymphoblast, 
SHSY5Y cell lines and dopaminergic mouse brain areas in an attempt to evaluate the 
suitability of our cell systems as models to study LRRK2 function and the effects of 
the G2019S mutation in relation to PD pathogenesis. 
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6.3 Evaluation of LRRK2 protein expression in cell models and brain tissue 
LRRK2 protein was detected in fibroblasts, lymphoblasts, SHSY5Y cells and 
mouse brain tissue with the greatest expression reported in SHSY5Y LRRK2 over-
expressing cells. Although fibroblasts have previously been shown to express LRRK2 
mRNA [324], LRRK2 protein expression in this cell type was not demonstrated. Using 
the combined immunoprecipitation and Western blot approach, LRRK2 protein was 
detected in control human fibroblasts at 10 and 20 fold lower abundances relative 
to lymphoblasts and over-expressing SHSY5Y cells respectively. LRRK2 expression in 
fibroblasts was quantified as 10 fold higher relative to the striatal and cortical mouse 
brain regions as well as endogenous protein in SHSY5Y cells. Considering fibroblasts 
express low levels of endogenous LRRK2 and the availability of 8 cell lines from PD 
patients harbouring the G2019S mutation this cell model was determined as an 
attractive system to study the generic cellular consequences of G2019S LRRK2 in 
relation to PD pathogenesis. 
Lymphoblasts and B lymphocytes, cells from which the lymphoblasts were 
derived have previously been shown to express high levels of endogenous LRRK2 
protein [242, 244] detectable by Western blot analysis of whole cell lysates. 
However, LRRK2 expression was reported as variable when 5 lymphoblast cell lines 
were evaluated [228]. We detected endogenous LRRK2 in lymphoblasts by Western 
blot (NT2, NB300-268 antibodies) and confirmed LRRK2 expression by the combined 
immunoprecipitation and Western blot approach. Western blot analysis detected 
variability in LRRK2 expression in 6 lines from control and 8 lines from G2019S LRRK2 
PD patients, in line with previous observations [228]. Endogenous expression of 
LRRK2 protein in the highest expressing lymphoblast cell line was comparable to 
LRRK2 levels detected in primary PMBCs suggesting LRRK2 expression in 
lymphoblasts was physiologically relevant. PMBC fractionation revealed high LRRK2 
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expression in B cells and lower abundance in the T cell sub-types consistent with 
previous observations [242, 325]. Although LRRK2 protein levels were comparable 
between lymphoblasts and primary PMBCs, the variability in LRRK2 levels between 
cell lines would complicate the interpretation of the effect of LRRK2 function in 
relation to PD. However, the ability to detect endogenous LRRK2 by Western blot in 
lymphoblasts prompted us to study endogenous LRRK2 sub-cellular distribution in 
this cell type. 
SHSY5Y cells were chosen as a neuronal cell model to investigate LRRK2 
function. Although endogenous LRRK2 expression in SHSY5Y cells was similar to 
protein levels detected in mouse striatum and cortex, we were limited to 
endogenous wild type LRRK2 expression in this cell type and were unable to 
investigate the effects of endogenous G2019S LRRK2. Hence SHSY5Y cells were 
utilized as a system to look at LRRK2 knockdown. LRRK2 has previously been shown 
to have a long half life 24-36 hours [201] in HEK293 cells and 3 day LRRK2 siRNA 
silencing of endogenous protein in RAW264.7 cells reduced the levels of the 280 kDa 
species by >90 % [241]. SHSY5Y cells described here treated with LRRK2 siRNA for a 
period of 3 days were shown to have 60 % less endogenous LRRK2 protein as 
determined by the combined immunoprecipitation and Western blot approach. 
Extending the LRRK2 siRNA treatment to 6 days achieved an 85 % reduction in 
endogenous LRRK2 protein in SHSY5Y cells. Although previous reports [257, 326, 
327] have used 3 day silencing protocols, the greater knockdown efficiency following 
6 days of LRRK2 silencing convinced us to utilize the 6 day silencing protocol to 
address the functional relevance of the loss of LRRK2 protein in the context of 
molecular pathways implicated in Parkinson’s disease.  
The LRRK2 over-expressing SHSY5Y model was generated to address the 
effects of the G2019S mutation on LRRK2 function in a neuronal system. The relative 
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level of LRRK2 expression in the over-expressing SHSY5Y cells was 2-3 fold greater 
than levels detected in the highest expressing lymphoblast lines. Considering LRRK2 
protein levels in RAW624.7 cells and B lymphocytes have been shown to respond to 
IFNγ and LPS rising to 10 fold levels of magnitude relative to basal LRRK2 expression 
[241, 243], the level of LRRK2 over-expression in SHSY5Y cells can be considered high 
but within the physiological range.  
Using the combined immunoprecipitation and Western blot approach 
quantification of endogenous LRRK2 expression in control SHSY5Y cells and rodent 
striatum determined wild type LRRK2 over-expression in SHSY5Y cells to be 100 fold 
greater relative to endogenous levels of LRRK2 in the striatum and control SHSY5Y 
cells. Wild type and mutant LRRK2 over-expression has previously been associated 
with induction of apoptosis in HEK293 and HeLa cells [254]. Furthermore, over-
expression of both the wild type and mutant LRRK2 protein has previously been 
shown to compromise cell viability in SHSY5Y cells [227] suggesting increased levels 
of LRRK2 are potentially toxic and questioning the suitability of a LRRK2 over-
expressing cell model system. Although dopaminergic cell death is observed in SNpc 
of PD patients there is no evidence to suggest LRRK2 levels are altered in the PD 
brain [328]. Furthermore there was no evidence of cell death in brains or peripheral 
tissues of wild type and mutant LRRK2 transgenic mice suggesting LRRK2 over-
expression in animal tissues does not result in apoptosis [240, 329, 330]. In addition, 
induction of LRRK2 protein expression in peripheral tissues leading to increased 
LRRK2 protein levels have been linked to functional roles of microbial elimination 
[243], T cell activation and cytokine secretion [271] with no correlation to apoptosis.  
Cell viability was not directly assessed in the SHSY5Y over-expressing cells 
however there was no obvious evidence of cell death or differences in growth rates 
between control, wild type and G2019S LRRK2 over-expressing cells. The 
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discrepancy between the SHSY5Y system described here and by Iaccarino et al may 
be due to the differences in the level of over-expression. LRRK2 over-expression in 
SHSY5Y cells described by Iaccarino et al was under the control of a CMV promoter 
potentially driving higher levels of over-expression.  As the SHSY5Y cells over-
expressing LRRK2 presented here have comparable LRRK2 protein levels to those 
detected in lymphoblasts, greater LRRK2 expression may be required to induce 
toxicity.  
A number of studies have reported cellular phenotypes associated with 
induced or over-expressed wild type LRRK2 protein suggesting functions governed 
by increased LRRK2 levels which may be independent of G2019S associated 
processes and relevant to the SHSY5Y LRRK2 over-expressing model. Microbial 
elimination by bone marrow derived macrophages involved the up-regulation of 
endogenous wild type LRRK2 protein [241]. Synaptic vesicle endocytosis was 
impaired by wild type LRRK2 over-expression and LRRK2 siRNA knockdown in 
primary neuronal cultures [255]. LRRK2 over-expression appeared to deplete the 
soluble β-tubulin pool in wild type and G2019S transgenic mouse brains consistent 
with enhanced tubulin polymerization [262]. To help identify artefacts associated 
with LRRK2 over-expression, the SHSY5Y over-expressing model and fibroblasts 
expressing endogenous wild type and G2019S LRRK2 were assessed in parallel. 
6.4 Evaluation of LRRK2 G2019S protein and mRNA expression 
As previously described (section 6.3) LRRK2 function can be regulated by 
induction of expression by LPS, IFNγ and microbial infiltration with subsequent 
changes in steady state LRRK2 mRNA and protein levels. We set out to determine 
whether the G2019S mutation correlated with altered LRRK2 expression. LRRK2 
mRNA levels have previously been assessed as part of a microarray analysis carried 
out on the same 6 control and 8 G2019S fibroblast cell lines used in this study, 
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finding comparable LRRK2 mRNA levels in control and G2019S cells [324]. 
Quantitative real time PCR analysis described here confirmed comparable levels of 
endogenous LRRK2 mRNA for wild type and mutant fibroblast cell lines. In addition, 
similar levels of LRRK2 mRNA have been described for control and G2019S LRRK2 PD 
brains as noted in the amygdala, putamen, cerebellum and frontal cortex regions 
further suggesting the pathogenic mutation does not correlate with differential 
LRRK2 mRNA expression  [331].  
LRRK2 polymorphisms have previously been shown to affect the stability of 
the LRRK2 protein. The T2397M polymorphism prevalent in patients suffering from 
inflammatory bowel disease has been demonstrated to result in lower levels of 
LRRK2 protein in B lymphocytes without affecting LRRK2 mRNA expression [271] 
suggesting single base amino acid substitutions can affect the half life of the 
molecule. In addition, engineered kinase dead forms of the LRRK2 protein (D1994S 
mutant) have consistently been shown to be present at lower levels despite 
comparable mRNA expression [238], suggesting the protein is less stable. LRRK2 
G2019S has been demonstrated to have a half life comparable to the wild type 
molecule in HEK293 LRRK2 over-expressing cells [201] suggesting the G2019S 
mutation does not impact on LRRK2 stability. Furthermore, there is no evidence of 
altered LRRK2 protein levels in G2019S LRRK2 PD brain tissue, although this 
evaluation has been limited to semi quantitative immunohistochemical analysis of 
amygdala, putamen, cerebellum and frontal cortex regions [331]. In support of these 
immunohistochemical findings, the combined immunoprecipitation and Western 
blot approach determined similar LRRK2 protein levels in control and G2019S 
fibroblast lines. Although the level of LRRK2 expression was found to be two fold 
lower in the G2019S LRRK2 over-expressing SHSY5Y cells relative to wild type LRRK2 
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levels, this difference is most likely due to clone to clone variation rather than the 
processing of the mutant protein.  
6.5 LRRK2 cellular localization 
6.5.1 Wild type and G2019S LRRK2 cellular distribution 
As well as having a broad tissue distribution, LRRK2 appears to have a broad 
sub-cellular localization. Sub-cellular fractionation studies have detected LRRK2 in 
mitochondria, lysosomal, ER and Golgi enriched compartments with greatest 
proportion of cellular LRRK2 in the cytosolic and vesicular fraction as described for 
ectopic LRRK2 in SHSY5Y cells [239], HEK293 cells and endogenous protein in rat 
whole brain tissue homogenates [201, 251]. The proposed LRRK2 cellular 
distribution is in line with the data obtained here where LRRK2 was detected in all 
sub-cellular fractions with the greatest levels identified in the cytosolic and vesicle 
enriched compartments of SHSY5Y over-expressing cells. Endogenous LRRK2 protein 
in lymphoblasts had a comparable distribution pattern suggesting LRRK2 over-
expression does not lead to gross changes in the localization of the protein. LRRK2 
has been identified in synaptosomal isolations from mouse brain tissue with a 
proposed role in vesicle handling [239, 254]. Identification of LRRK2 in the vesicle 
enriched fraction in SHSY5Y cells provides a potential link between LRRK2 
localization in the brain and synaptic function. Analysis by immunogold labelling and 
electron microscopy of endogenous LRRK2 in rat basal ganglia identified LRRK2 
immunoreactivity in mitochondria, autophagosomes, endosomal and Golgi transport 
vesicles [251] supported by immunocytochemical analysis of over-expressed LRRK2 
co-localization with ER, Golgi, lysosomal and mitochondrial markers in HEK293 and 
SHSY5Y cells [218, 227, 239, 251]. However, the immunogold analysis was 
performed without the corresponding LRRK2 knockout controls hence the specificity 
of the antibody labelling is questionable. Immunohistochemical evaluation of wild 
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type LRRK2-V5 over-expression in SHSY5Y cells described in this report identified a 
comparable pattern of diffuse antibody staining. Co-localization studies were not 
carried out, however lysosomal, mitochondrial and ER localization was supported by 
differential centrifugation analysis identifying 5 % of LRRK2 in cellular compartments 
containing these organelle markers. In line with these observations, the direct 
interaction of LRRK2 with multi vesicular bodies and mitochondria has been linked 
to autophagic regulation of the endocytic lysosomal pathway in BAC-LRRK2 
transfected HEK293 cells, as well as mediating mitochondrial function and 
morphology in SHSY5Y cells and primary neurons [280, 332].  
Pathological forms of LRRK2, including kinase domain (G2019S, I2020T) and 
GTPase (R1441G, R1441C) mutants have previously been linked to the formation of 
LRRK2 aggregates in HEK293 [215, 228, 298, 333] and SHSY5Y cells [224] over-
expressing the protein. Aggregates in wild type LRRK2 over-expressing HEK293 and 
SHSY5Y cells have also been noted albeit at lower levels. LRRK2 aggregation has 
been linked to reduced cell viability [333] suggesting aberrant LRRK2 cellular 
localization may be a feature of G2019S LRRK2 PD. Cellular fractionation 
experiments identified similar LRRK2 localization for wild type and G2019S LRRK2 in 
HEK293 and SHSY5Y cells [201, 239]) comparable to the data obtained in our study 
comparing cellular distribution of wild type and G2019S LRRK2 by differential 
centrifugation. In addition, although limited to analysis of the wild type protein, our 
immunocytochemical evaluation of LRRK2 cellular localization did not reveal any 
LRRK2 positive aggregates in SHSY5Y over-expressing cells. Aggregated LRRK2 
structures have not yet been described in PD brains or cell models expressing 
physiologically relevant levels of LRRK2 suggesting the observed aggregates could 
occur as a result of LRRK2 over-expression above a certain threshold. The level of 
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LRRK2 over-expression relative to endogenous LRRK2 was not evaluated in any of 
the studies reporting LRRK2 aggregates [215, 224, 228, 298, 333]. 
6.5.2 Wild type and G2019S LRRK2 mitochondrial localization 
Previously, it has been estimated that 10 % of endogenous LRRK2 can be found 
in the mitochondrial enriched fraction of rat brain mitochondria isolated by glycerol 
density gradient [251]. LRRK2 mitochondrial localization has also been evaluated in 
affinity purified mitochondrial preparations [280, 281] however estimations of 
LRRK2 mitochondrial abundance were not carried out in these studies. In addition, 
an accurate comparison of wild type and G2019S LRRK2 mitochondrial levels has not 
yet been described. 10 % of total cellular LRRK2 was identified in the mitochondrial 
enriched compartment in the sub-cellular fractionation experiments. Although 
affinity purification and removal of lysosomal and ER contaminants confirmed that 
LRRK2 was present in highly purified mitochondria, the level of mitochondrial LRRK2 
may well be very low. As a large portion of cytochrome C was lost during the 
mitochondrial affinity isolation, it is possible that the integrity of affinity purified 
mitochondria was compromised and a fraction of the outer membrane bound LRRK2 
[251] was lost. Nonetheless comparing levels of wild type and G2019S LRRK2 in 
affinity purified preparations identified similar portions (1-2 %) of the total LRRK2 
pool in the mitochondrial fraction further in support of comparable LRRK2 
intracellular distribution for the wild type and G2019S protein.  
ER and lysosomal contamination was not investigated in mitochondria isolated 
from rat brain and may therefore contribute to the estimated 10 % of the LRRK2 
mitochondrial pool [251]. However, mitochondrial LRRK2 levels in the rat brain may 
also be different to the level of mitochondrial LRRK2 in the over-expressing SHSY5Y 
cells. Cell specific LRRK2 mitochondrial localization is supported by the barely 
detectable levels of endogenous LRRK2 in the mitochondrial enriched fractions 
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isolated from lymphoblasts. The presence of LRRK2 in highly purified mitochondria 
from over-expressing SHSY5Y cells could relate to high LRRK2 levels, however these 
were only 2-3 fold higher than endogenous expression in lymphoblasts, comparable 
to the difference in LRRK2 cellular levels between wild type and G2019S over-
expressing cells where similar levels of mitochondrial LRRK2 were identified. The 
differences in mitochondrial LRRK2 levels between lymphoblasts and LRRK2 over-
expressing SHSY5Y cells are probably not due to antibody sensitivity problems as the 
combined immunoprecipitation and Western blot approach could detect LRRK2 
immunoreactivity in diluted (1:10) fibroblast lysates containing 100 fold lower levels 
of LRRK2 protein relative to the equivalent amount of undiluted lymphoblast input. 
Rather the differences in mitochondrial LRRK2 abundance between the cell types 
could indicate a cell specific functional regulation.  
LRRK2 lacks an obvious mitochondrial localization sequence as has been 
described for the PINK1 protein [46]. The mechanism of LRRK2 mitochondrial 
targeting has not been investigated. Interactions with 14-3-3 proteins are recognized 
mechanisms regulating the mitochondrial localization of certain proteins including 
Bax [334]. LRRK2 is known to interact with 14-3-3 which is disrupted when LRRK2 
kinase is inhibited [216]. However, inhibition of LRRK2 kinase activity disrupts 14-3-3 
binding but did not influence mitochondrial LRRK2 levels suggesting 14-3-3 binding 
was not regulating its mitochondrial localization. 
6.5.3 LRRK2 localization in the mitochondria 
25-50 % of the total LRRK2 pool is believed to be membrane associated 
suggesting membrane association could play a role in the LRRK2 mitochondrial 
interaction [252]. LRRK2 association with the outer mitochondrial membrane in 
isolated rat brain mitochondria has previously been described [251]. In support of 
this LRRK2 was shown to behave like a mitochondrial membrane bound protein as 
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determined by the partial release of LRRK2 from the mitochondria under alkaline 
conditions. Hypotonic conditions did not appear to affect mitochondrial LRRK2 
abundance further suggesting that mitochondrial LRRK2 was membrane associated 
as the membrane unbound protein cytochrome C was released under these 
conditions.  
Sterically, an interaction between LRRK2 and the outer mitochondrial 
membrane is most plausible. In addition, the full length 280 kDa molecule is too 
large for import through transmembrane channels [335]. Our limited data supported 
the LRRK2 association with the outer mitochondrial membrane however attempts to 
accurately map the LRRK2 mitochondrial localization were hampered by a number of 
technical issues. The shift of the inner membrane markers to the soluble fraction 
while the outer membrane markers were present in the pellet suggested the outer 
membrane was still intact when the inner membrane was already compromised, 
observed for both crude and pure preparation. We also experienced problems with 
the proteinase K digestion and the preferential removal of the outer membrane. 
Loss of mitochondrial integrity, as determined by cytochrome C release during 
mitochondrial affinity purifications and MEF isolations may have prematurely 
exposed the inner membrane to digitonin and proteinase K. As both methods have 
previously been successfully carried out on SHSY5Y cells [336, 337], additional 
optimization of the technique may be required focusing on preserving the integrity 
of mitochondrial isolations.  
6.6 Wild type and G2019S LRRK2 kinase activity  
LRRK2 has previously been demonstrated as an active kinase in in vitro 
assays utilizing full length immunoprecipitated LRRK2 protein from HEK293 cells and 
lymphoblasts as well as a truncated version of LRRK2 lacking the N terminus purified 
from HEK293 cells (GST-LRRK2 1362-2527) [202], monitoring the incorporation of 32P 
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ATP into artificial substrates (LRRKtide) and LRRK2 interacting partners MBP [202]. In 
the same assays the pathological G2019S LRRK2 mutant has consistently been 
shown to have higher kinase activity when compared to the wild type protein [338] 
while inhibition of LRRK2 kinase activity by LRRK2-IN1, CZC25146 and TAE-684 has 
been shown to correlate with dephosphorylation of LRRK2 at Serine 910 and 935 
[214, 215, 339]. LRRK2tide phosphorylation was detected in in vitro kinase assays of 
LRRK2 immunoprecipitated from lymphoblasts and over-expressing SHSY5Y cells, 
confirming these cell models expressed an active LRRK2 molecule. LRRK2 specific 
activity was 3-5 times lower for LRRK2 immunoprecipitated from over-expressing 
SHSY5Y cells relative to lymphoblasts suggesting LRRK2 is less active in this cell type. 
Although the discrepancy may be due to cell specific differences, the C terminal V5 
tag may have impacted on the kinase activity of the protein. In relation to this, 
truncations of 7 C terminal residues in the LRRK2 WD40 domain have previously 
been shown to ablate the kinase activity of LRRK2 suggesting the C terminus is 
potentially involved in enzymatic regulation of the protein [202]. However, Serine 
935 phosphorylation in wild type and G2019S LRRK2 over-expressing SHSY5Y cells 
was sensitive to LRRK2 kinase inhibition as determined by Western blot analysis of 
the immunoprecipitated protein further suggesting the tagged enzyme was active in 
this cell type. In addition, the inhibitor doses that were required to reduce LRRK2 
Serine phosphorylation by >90 % were comparable to those shown for enzymatically 
active, N-terminally tagged LRRK2 immunoprecipitated from HEK293 cells [215] 
suggesting LRRK2 kinase activities were similar in the two systems.  
The kinase activity of G2019S LRRK2 immunoprecipitated from SHSY5Y over-
expressing cells was 2 fold greater relative to the wild type protein in line with 
previous observations [338]. The potency of LRRK2 IN1 was greater for G2019S 
relative to wild type LRRK2 immunoprecipitated from SHSY5Y cells, implying G2019S 
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LRRK2 has greater affinity for ATP as LRRK2 IN1 is an ATP competitive inhibitor, 
consistent with enzymatic hyperactivation associated with the pathogenic mutant. 
The kinase activity of LRRK2 expressed in control and G2019S patient fibroblasts was 
not evaluated due to the low level of LRRK2 expression in this cell type. LRRK2 kinase 
activity in fibroblasts has not been reported in the literature, however the effects of 
the G2019S mutation on LRRK2 kinase activity have been described for kidney and 
immune cells lines [215] for endogenous and over-expressed LRRK2 suggesting the 
increased kinase activity associated with the mutant protein is not dependent on the 
cell type and G2019S fibroblasts are likely to have increased LRRK2 kinase activity 
relative to control cells. 
6.7 LRRK2 and mitochondrial function 
Mitochondrial respiratory chain abnormalities are a common feature of 
idiopathic, genetic PD and experimental models of the disease; reduced Complex I 
activity has been described for idiopathic PD substantia nigra, platelets and skeletal 
muscle [99, 340] suggesting respiratory function was compromised. The 
parkinsonian phenotype induced by systemic MPTP injections in mice correlated 
with a reduction in mitochondrial respiration [341, 342]. Various genetic causes of 
PD have compromised mitochondrial function; Complex I defects have been noted in 
fibroblasts harbouring PD associated PINK1 mutations [343] while reduced 
mitochondrial respiration and mitochondrial membrane potential correlated with 
the loss of PINK1 in mouse embryonic fibroblasts [344]. Parkin deficiency in 
Drosophila melanogaster and PD patient derived parkin mutant fibroblasts were 
associated with reduced oxygen consumption rates [345, 346]. α-synuclein over-
expression in primary cells was shown to inhibit Complex I activity [123]. 
Mitochondrial membrane potential and ATP levels were reduced in SHSY5Y cells, 
primary cortical cultures [280, 281] and fibroblasts [285] expressing G2019S LRRK2 
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consistent with abnormal respiratory chain function, suggesting respiratory chain 
dysfunction may be a common feature in different forms of PD and potentially 
involved in the disease pathogenesis. 
Although variability was detected in ATP measurements for control and 
G2019S fibroblasts described in this report, as a group G2019S cells had reduced ATP 
levels, consistent with the previous observations [280, 281, 285].  In addition, 
G2019S LRRK2 expression correlated with a 20 % reduction in mitochondrial 
membrane potential in SHSY5Y and fibroblast cell models. The reduction in 
mitochondrial membrane potential in SHSY5Y cells was comparable to what has 
previously been described [280, 281], while fibroblast showed a more modest defect 
in comparison to the 60 % decrease determined in the previous report [285]. Of 
note, Mortiboys et al, determined an 85 % reduction in the mitochondrial 
membrane potential in control fibroblasts treated with parkin siRNA [347], a 
decrease much greater than those generally reported for viable cells. Reductions of 
15-20 % in the mitochondrial membrane potential have previously been observed 
for fibroblasts derived from patients with PINK1 mutations and PINK1 deficient 
mouse embryonic fibroblasts [172, 348] consistent with the magnitude of changes 
reported for our G2019S expressing fibroblasts. In addition, fibroblasts have 
previously been shown to adjust to gross mitochondrial defect such as complex I 
enzymatic deficiency by reversing the mitochondrial ATPase [310]. We have 
modelled this in control fibroblasts exposed to rotenone and demonstrated ATPase 
reversal by the response of the rotenone treated cells to oligomycin which led to the 
dissipation of the mitochondrial membrane potential. Hence a 60 and 85 % decrease 
in mitochondrial membrane potential is physiologically unlikely as the fibroblasts 
would most likely attempt to adjust to such a massive perturbation in the 
mitochondrial proton gradient. The discrepancy in the mitochondrial membrane 
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potential measurements is therefore likely due to an over-estimation of the 
magnitude of the defect. Nonetheless a common trend was observed among all the 
LRRK2 studies detecting a reduction in the mitochondrial membrane potential and 
ATP levels associated with G2019S LRRK2.  
Oxygen consumption measurements detected a 1.5-2 fold increase in 
cellular respiration rates in G2019S expressing fibroblasts and SHSY5Y cells. The 
increase in cellular respiration in G2019S expressing cells opposed the respiratory 
deficiencies reported for PINK1 deficient mouse embryonic fibroblasts [348], MPTP 
and rotenone treated mice [342] and parkin deficient Drosophila melanogaster 
[345].  
The reduction in basal ATP levels and mitochondrial membrane potential 
have previously been assigned to a mitochondrial defect associated with G2019S 
LRRK2 expression consistent with the respiratory chain abnormalities linked with the 
genetic and experimental PD models [280, 281, 285]. Although the decrease in ATP 
levels and mitochondrial membrane potential detected in G2019S expressing 
fibroblasts and SHSY5Y cells mirrored the characteristics of bioenergetically 
compromised cells, increased oxygen utilization argued against a respiratory chain 
defect. Measurements of chemically uncoupled respiration revealed comparable 
cellular respiratory capacities for control and G2019S fibroblasts, further arguing 
against a mitochondrial dysfunction. 
Mitochondrial respiration of fibroblasts cultured under substrate limiting 
conditions was comparable to those observed in G2019S expressing cells suggesting 
mutant LRRK2 expressing cells could suffer from deficient glycolytic input, as has 
previously been shown for PINK1 deficient neuroblastoma cells and mouse primary 
dopaminergic neurons [172]. However, mitochondrial membrane potential was 
increased in fibroblasts cultured on galactose consistent with an increased flux 
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though the mitochondrial respiratory chain, different to the effect on the 
mitochondrial membrane potential observed in G2019S expressing fibroblasts and 
SHSY5Y cells. In addition, the respiratory chain defect described in PINK1 and parkin 
deficient cells has been associated with mitochondrial ATPase reversal in primary 
cortical neurons and SHSY5Y cells [172] as determined by the dissipation of the 
mitochondrial membrane potential in the presence of oligomycin. Oligomycin 
treatment produced comparable effects on the mitochondrial membrane potential 
in control and G2019S fibroblasts consistent with a normal functioning ATPase. As 
there was no evidence for limitation in glycolytic substrate supply or mitochondrial 
ATPase reversal in G2019S LRRK2 expressing fibroblasts and SHSY5Y cells these 
systems are likely to have a different underlying cause to the mitochondrial 
bioenergetic changes associated with mutant LRRK2. In fact, the combination of 
reduced mitochondrial membrane potential and enhanced respiration supported 
the presence of a mitochondrial proton leak [349]. 
Bioenergetically, a mitochondrial proton leak has previously been 
characterized by oxygen utilization measurements in the presence of oligomycin; a 
respiration rate was detected in oligomycin treated thymocytes over-expressing 
UCP2 [350] absent in control cells. Oligomycin inhibited respiration rates have also 
been shown to contribute to skeletal contractions in mice [351]. In support of a 
mitochondrial proton leak, oxygen utilization was taking place in G2019S expressing 
fibroblasts in the presence of oligomycin, absent in control cells.   
6.8 LRRK2 and mitochondrial permeability 
The decrease in mitochondrial membrane potential combined with 
increased oxygen utilization rates associated with G2019S expression implied an 
increased permeability of the mitochondrial inner membrane to protons. This may 
involve opening of the mitochondrial permeability pore [352], the presence of 
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proteins on mitochondrial forming a pore [353] or the up-regulation and activation 
of uncoupling proteins [354].  
Opening of the mitochondrial permeability pore is associated with increased 
reactive oxygen species (ROS), increased mitochondrial calcium levels and apoptosis 
[352]. Respiratory chain Complex I defects, a prominent feature in PD patient brains 
and skeletal muscle [99] as well as PINK1 deficient fibroblasts [343], have correlated 
with increased oxidative stress, apoptosis and mitochondrial permeability pore 
opening [348]. Wild type and mutant LRRK2 over-expression in SHSY5Y cells has 
previously been shown to promote PTP opening through the interaction between 
adenine nucleotide translocator (ANT) and porin [286]. In addition, SHSY5Y cells 
over-expressing the G2019S LRRK2 protein showed increased cytochrome C release, 
the activation of the caspase cascade and increased cell death [227]. However, there 
was no evidence of cell death in our G2019S expressing fibroblasts or SHSY5Y cells. 
In agreement with this thesis, oxidative stress levels were comparable between wild 
type and G2019S over-expressing SHSY5Y cells in one report [280] but in another 
study greater for G2019S expressing SHSY5Y cells [281]. Oxidative stress was also 
reported in G2019S expressing fibroblasts relative to control cells [285] however the 
rate of ROS generation in G2019S fibroblasts described in this report were lower 
relative to control cells. Hence the effects of G2019S expression on ROS generation 
are not consistent and may vary depending on cell type and assay conditions. The 
absence of cell death and increased ROS levels suggested the mitochondrial 
permeability transition pore was unlikely to cause the mitochondrial uncoupling in 
G2019S expressing fibroblasts and SHSY5Y cells. 
Regarding any direct interaction of LRRK2 with mitochondria leading to 
increased proton permeability of the inner membrane, we confirmed that a small 
proportion of LRRK2 was present in highly purified mitochondria. Further 
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mitochondrial sub-fractionation suggested LRRK2 associated with mitochondrial 
membranes, however, we were not able to restrict this to either the outer or inner 
membranes. The mitochondrial uncoupling in G2019S SHSY5Y cells was not likely to 
be an artefact of over-expressed LRRK2 localizing to the mitochondria as uncoupling 
was also observed in fibroblasts expressing endogenous G2019S LRRK2 and absent 
in SHSY5Y cells over-expressing the wild type protein. 
The mitochondrial uncoupling associated with G2019S mutant fibroblasts 
and SHSY5Y cells closely resemble what has previously been described for cells and 
tissues with increased uncoupling protein expression. Increased oxygen 
consumption rates, reduced mitochondrial membrane potential and ROS production 
have been reported for mitochondrial isolations from mouse brains, livers and 
kidneys of UCP2 transgenic mice [355] as well as CHO cells over expressing UCP1 
[356]. Reduced membrane potential has been demonstrated for mitochondria in 
UCP4 over-expressing cells [357] and UCP4/5 reconstituted in liposomes [358]. In 
line with these observations, we observed a reduced mitochondrial membrane 
potential in SHSY5Y cells over-expressing the UCP2-GFP protein.   
6.9 LRRK2 regulation of mitochondrial uncoupling proteins  
6.9.1.1 LRRK2 regulation of UCP mRNA expression 
Mitochondrial uncoupling has been demonstrated to be regulated by 
specific UCP isoforms in different cell types; UCP1 is the dominant isoform in brown 
fat reported to regulate thermogenesis [359], while the UCP2 isoform is found in 
pancreatic β-cells and mediates insulin secretion through ATP mediated opening of 
potassium channels [360]. Expression of four UCP isoforms (UCP2-5) was detected in 
control fibroblasts and SHSY5Y cells, suggesting these proteins may have a functional 
role in these cell lines. UCP2, 4 and 5 mRNA expression has been reported in 
fibroblasts, although UCP3 mRNA expression was not investigated [361]. UCP2 has 
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previously been identified as the abundant UCP isoform in the rodent brain, 
expression of UCP4 and 5 was also described consistent with the pattern of UCP 
expression detected in SHSY5Y cells [362].  
The LRRK2 G2019S mutation correlated with an increase in UCP2-5 mRNA in 
fibroblasts and increased UCP4 expression in SHSY5Y cells. The UCP mRNA changes 
observed in G2019S expressing fibroblasts and SHSY5Y cells suggested the LRRK2 
associated mitochondrial uncoupling was regulated at the transcriptional level. 
Increased UCP4 mRNA expression has previously been demonstrated in SHSY5Y cells 
[363] and brain in experimental stroke models [364] while UCP2 expressional 
changes in response to PGC1α over-expression have been described in myotubes, 
confirming that these isoforms can be transcriptionally regulated. Of note, increased 
UCP4 levels in G2019S LRRK2 SHSY5Y cells suggested the artificial UCP2 over-
expressing system used in this study may not be an accurate model of uncoupling 
for this cell type. 
The fold changes in UCP4 mRNA expression were comparable to 5 fold 
changes reported for UCP1 expression in brown fat comparing tissue isolated from 
warm acclimated mice to those exposed to cold temperatures [365]. A similar 2-3 
fold induction in UCP3 mRNA has been described in adipocytes and skeletal muscle 
associated with reduced body weight in mice suggesting small changes in UCP mRNA 
levels are sufficient to induce phenotypic changes [366].  
6.9.1.2 LRRK2 regulation of UCP protein  
Changes in UCP2 and 3 mRNA have previously been shown to affect UCP 
protein levels in pancreatic β cells [367]. While ectopic UCP2 expression in the UCP2-
GFP SHSY5Y model was confirmed by confocal microscopy and Western blot, 
Western blot analysis detected additional higher and lower molecular weight 
immunoreactive species making it difficult to identify and quantitively evaluate 
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endogenous UCP2 protein in wild type and G2019S fibroblasts and SHSY5Y cells. 
Cross reactive bands of 28 and 50 kDa have previously been described for UCP2 
over-expressing insulinoma cells [368] and in a variety of mouse and rodent tissues 
[368] suggesting antibody specificity may not be reliable enough to distinguish 
between true endogenous species.  
To determine the potential contribution of UCP protein to the mitochondrial 
uncoupling observed in G2019S fibroblasts and SHSY5Y cells, UCP activity was 
inhibited by genipin. Although genipin is often described as a general UCP inhibitor, 
the characterization of the drug has been limited to in vitro studies involving UCP2 
protein [315] and its selectivity profile for the other UCP family members has not 
been fully elucidated. Studies of pancreatic islet cells have previously shown genipin 
to increase the mitochondrial membrane potential, ATP levels and promote insulin 
secretion, a function governed by UCP3 [315] while inhibition of mitochondrial 
proton leak in leukemic MX2 cells correlated with lower ROS levels and reduced 
drug resistance of the cancer cells [369] linking UCP2 protein activity and inhibition 
to respiratory chain function. 
Consistent with UCP mRNA expression in control SHSY5Y cells and 
fibroblasts, a mild 10 % increase in mitochondrial membrane potential was observed 
upon genipin treatment suggesting a role for UCP proteins in the regulation of 
respiratory chain function. In addition, restoration of the mitochondrial membrane 
potential in UCP2-GFP cells with genipin suggested the drug could counteract the 
phenotype of UCP2 protein over-expression. The specificity of genipin for the UCP2 
isoform was questioned by the effects of the compound on the G2019S LRRK2 over-
expressing SHSY5Y cells, where the UCP4 mRNA expression was preferentially 
induced. As UCP3 and 5 were found to be expressed in SHSY5Y cells and UCP2 mRNA 
was expressed at greater levels relative to UCP4 mRNA, the observed effect could be 
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due to genipin inhibition of all the UCPs in SHSY5Y cells. UCP2 mRNA levels were 
comparable for control, wild type and G2019S over-expressing clones however, we 
cannot rule out the possibility of increased UCP2 protein in SHSY5Y cells expressing 
G2019S LRRK2. Although it was not possible to specifically inhibit UCP2 and UCP4 in 
fibroblasts and SHSY5Y cells respectively, restoration of the mitochondrial 
membrane potential in G2019S expressing cells upon genipin treatment supported 
the role of UCP protein in the mitochondrial uncoupling associated with mutant 
LRRK2. 
Of note, effective genipin concentrations reported here were considerably 
lower with respect to ranges described in the literature. Genipin at 5 µM was 
required to restore the UCP dependent contractile response in cardiac myocytes 
[370]. Genipin at 10 µM was determined as the effective dose for toxicity in 
leukemic cells [369] while 200 µM genipin induced toxicity in hepatoma cells [371]. 
Although toxicity was not apparent in our short term genipin incubations for SHSY5Y 
cells, the mitochondrial membrane potential in control fibroblasts was reduced by 
20 % in prolonged treatments (30 min) suggesting this cell type is more sensitive to 
the drug. The cell toxicity associated with genipin treatment is likely due to the off 
target effects associated with the drug. In support of this, there is no evidence to 
suggest siRNA knockdown of UCPs 2 and 4 lead to reduced cell viability [363, 372]. 
Effective genipin dose requirements for UCP inhibition in different cell types could 
potentially correlate with the levels of expression of the different UCP isoforms. 
6.9.1.3 LRRK2 regulation of PGC1α expression  
The difference in the relative mRNA abundance between the UCP isoforms 
in SHSY5Y cells and fibroblasts as well as induction of specific UCPs (2 and 4) in these 
cells may reflect cell specific regulatory roles such as those described for adipose 
tissue and the regulation of thermogenesis by UCP1 and pancreatic β cells in the 
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modulation of insulin secretion by UCP2 [359, 360]. Tissue specific UCP4 and 5 
regulation has also been described for dopaminergic neurons in the SNpc, required 
for the regulation of pacemaking activity [168]. Therefore LRRK2 regulation of 
different UCP isoforms in fibroblasts and SHSY5Y cells may be required for cell 
specific mitochondrial uncoupling mediated functions. 
Cell specific UCP mRNA expression has previously been linked to PGC1α 
mediated transcriptional regulation. Stimulation of PGC1α expression was described 
for brown adipocytes undergoing differentiation and developing muscle, processes 
requiring induction of UCP1 and UCP2 transcription [373, 374]. In these studies 
UCP1-3 expression was detected in both cell types however only UCP1 or 2 mRNA 
was preferentially stimulated in the two studies [373, 374]. Increased UCP4 mRNA 
levels correlated with a two fold increase in PGC1α expression in G2019S LRRK2 
over-expressing cells suggesting PGC1α may play a role in the specific regulation of 
UCP4 expression.  
PGC1α mediated UCP2 regulation has previously correlated with an increase 
in catalase and SOD2 mRNA in endothelial cells undergoing oxidative stress [141]. In 
addition, increased mitochondrial densities in white adipose tissue [375] and muscle 
cells [376, 377] correlated with PGC1α mediated UCP1, 2, TFAM and Nrf1, 2 
expression in line with stimulation of mitochondrial biogenesis suggesting the 
increase in UCP2 and UCP4 expression could be a part of a biosynthetic or 
antioxidant gene response. The relative expression of antioxidant enzymes SOD2 
and catalase were comparable between control, wild type and G2019S expressing 
cells suggesting the increased UCP4 expression associated with the G2019S 
mutation was not a part of a global antioxidant response. Furthermore comparable 
abundance of mitochondrial proteins, TFAM and mitochondrial structures in control 
and mutant fibroblasts and SHSY5Y cells implied rates of mitochondrial biogenesis 
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were not perturbed. The absence of an oxidative stress response and changes to 
mitochondrial abundance implies the induction of UCP expression in the presence of 
G2019S is unlikely a stress response and selectively targets the UCP gene.  
The selectivity for UCP4 induction could potentially be accounted for by 
PGC1α interacting molecules in the relevant cell types. PGC1α mediated UCP 
response in skeletal and cardiac muscle as well as brown adipose tissue has 
previously been shown to be dependent on the isoform of its interacting gene 
regulator PPAR. UCP3 expression in skeletal muscle is more responsive to the PPARδ 
than PPARα isoform [378, 379] and UCP3 mRNA induction in cardiac muscle requires 
PPARα [380]. While induction of UCP2 expression in skeletal muscle and heart is 
responsive to PPAR related stimuli in a similar manner to UCP3, additional 
regulatory mechanisms exist [381]. PGC1α in muscle cells requires co-activators 
MyoD and p300 for UCP2 gene stimulation [382]. In this study, the direct regulation 
of the UCP promoter by PGC1α was not investigated and warrants further analysis to 
determine whether a specific PPAR isoform and additional regulators are involved. 
The selective changes in UCP4 mRNA further emphasise the importance of UCP 
regulated mitochondrial uncoupling in G2019S LRRK2 expressing fibroblasts and 
SHSY5Y cells. 
6.9.1.4 LRRK2 regulation of HDAC5  
Based on the sub-cellular localization data for both endogenous and over-
expressed LRRK2, a large portion of the full length protein pool appeared to exist in 
the cytosolic compartment. The multiple structural domains of LRRK2 implicate a 
scaffold function in signalling cascades and the reported association with 14-3-3 
[215, 216, 383] suggested LRRK2 may potentially be involved in compartmental 
targeting of 14-3-3 interacting molecules while 14-3-3 could in turn regulate LRRK2 
function. LRRK2 mediated regulation of nuclear to cytosolic shuttling has been 
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described for the nuclear factor of activated T cells (NFAT) in T cells where LRRK2 
was identified as a crucial component of the NRON complex maintaining NFAT in its 
inactive state in the cytosol [271]. Loss of LRRK2 was linked to the translocation of 
NFAT to the nucleus and hyperactivation of transcription. HDAC5 mediated PGC1α 
transcription has previously been shown to also involve nuclear translocation in 
response to protein kinase A (PKA) and protein kinase C (PKC) [317]. Hypothesising a 
mechanistic conservation, LRRK2 association with HDAC5 was investigated to 
determine what effect LRRK2 kinase activity has on the cellular localization and 
integrity of this complex and how the potential LRRK2 HDAC5 interaction could be 
involved in PGC1α transcription and UCP expression.  
In an attempt to determine what effect LRRK2 G2019S has on HDAC5 
nuclear translocation, HDAC5 subcellular localization was investigated. Under basal 
conditions HDAC5 has been shown to localize to the nucleus and cytoplasm with the 
relative nuclear to cytosolic ratios depending on the cell system in question [317, 
384]. HEK293 and HeLa cell lines have nuclear HDAC5 abundance while the 
localization of HDAC5 in H9C2 rat heart cell line was shown to vary depending on the 
differentiation status [385]. In addition, PMA treatment of cells in these studies has 
been shown to mobilize the HDAC5 pool and result in the complete redistribution of 
HDAC5 to the cytoplasm. HDAC5 nuclear export in response to PMA has been 
demonstrated in Cos7 cells [317, 384]. The antibodies used for 
immunocytochemistry have been limited to HDAC5 over-expressing systems with no 
reports of endogenous HDAC5 localization in SHSY5Y cells yet described [317, 384]. 
We detected endogenous HDAC5 in the nucleus and cytosol of SHSY5Y cells by 
immunocytochemistry, however PMA treatment of wild type cells did not grossly 
affect the nuclear HDAC5 pool suggesting antibody specificity may be an issue as the 
same PMA conditions have consistently been shown to lead to HDAC5 nuclear 
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export in SHSY5Y cells [317]. As we did not have a suitable HDAC5 knockout system 
to validate the HDAC5 antibody for immunohistochemistry, analysis of HDAC5 
cellular distribution in wild type and G2019S LRRK2 over-expressing SHSY5Y cells was 
not carried out. 
Immunoprecipitation of the HDAC5 protein has previously been carried out 
on Flag tagged, over-expressed species in COS7 cells [386] and GFP tagged HDAC5 in 
SHSY5Y cells [387], detecting 120 kDa immunoreactive bands corresponding to the 
full length tagged molecule. Although the relative molecular mass of the HDAC5 
immunoreactive band detected in HDAC5 immunoprecipatates matched the 
molecular weight of the predicted and previously described full length HDAC5, an 
additional lower molecular weight species was also detected which has not 
previously been reported for IPs of the HDAC5 protein. To determine whether the 
80 kDa species detected here is an artefact associated with the HDAC5 antibody, 
additional characterization of the antibody should be carried out on HDAC5 
knockout tissue. Nevertheless LRRK2 was detected in HDAC5 immunoprecipitated 
from wild type and G2019S LRRK2 over-expressing SHSY5Y cells and wild type but 
not LRRK2 knockout mouse brain cortex.  
Immunoprecipitation of LRRK2 has previously identified NFAT in T cells 
[271], Ago2 in the aged fly brain [273], 14-3-3 in HEK293 cells and lymphoblasts 
[216], DLP1 in SHSY5Y cells and primary cortical neurons [280, 281] as potential 
LRRK2 interacting molecules. LRRK2 interaction with DLP1 was enhanced for the 
G2019S LRRK2 mutant in SHSY5Y cells [280], the human Ago2 protein pulled down 
more of the G2019S LRRK2 than the wild type [273], LRRK2 kinase inhibition has 
previously been shown to correlate with the amount of bound 14-3-3 [215, 216] 
suggesting LRRK2 kinase activity may play a role in complex formation. However, 
although 14-3-3 binding to LRRK2 was affected by LRRK2 kinase inhibition, the 
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G2019S mutation did not impact on the amount of 14-3-3 associated with LRRK2 
[215] suggesting additional regulatory factors may be involved in this interaction and 
the regulation of downstream signalling cascades. Association of NFAT with the 
NRON complex required the LRRK2 protein but the affinity of the interaction did not 
seem to be affected by the G2019S mutation [271] suggesting the integrity of 
complexes involving LRRK2 may not always depend on LRRK2 kinase status. The 
intensity of the LRRK2 immunoreactive species detected in the HDAC5 pulldowns 
was consistently stronger in G2019S LRRK2 over-expressing SHSY5Y lysates relative 
to wild type LRRK2. The efficiency of HDAC5 pulldown was similar between control, 
wild type and G2019S LRRK2 over-expressing suggesting that the G2019S LRRK2 
protein was more associated with HDAC5, similar to the effects described for 
G2019S LRRK2 association with Ago2 and DLP1 proteins. Although not investigated 
in the studies involving Ago2 and DLP1, LRRK2 kinase inhibition did not seem to 
affect the integrity of the HDAC5 interaction, in contrast to what has previously been 
shown for 14-3-3 suggesting Serine 910 and 935 phosphorylation is not required for 
HDAC5 binding to LRRK2.  
We reasoned that any potential interaction with LRRK2 could be enhanced 
by enriching the cytosolic pool of HDAC5. PMA treatment of wild type and G2019S 
LRRK2 over-expressing SHSY5Y cells failed to detectibly enhance cytosolic HDAC5 as 
determined by Western blot analysis of IP input lysates, further questioning the 
antibody specificity. PMA treatment of wild type and G2019S LRRK2 over-expressing 
cells resulted in the loss of LRRK2 immunoreactivity in the HDAC IPs suggesting a 
dissociation of the HDAC5 LRRK2 complex. LRRK2 interaction with 14-3-3 has 
previously been shown to be disrupted upon de-phosphorylation of Serine residues 
[215, 216] in a PKA dependent mechanism [383]. As PMA activates a number of 
intracellular kinases and phosphatases including PKA [388], it is possible that the 
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intrinsic phosphorylation status of LRKR2 could be affected in the presence of the 
drug. Although LRRK2 phosphorylation at Serine 935 was not affected by PMA 
treatment, dephosphorylation of other serine residues [202, 383] cannot be ruled 
out. Identification of LRRK2 specific phosphatases and determination of their 
mechanism of action may provide a better understanding of LRRK2 interacting 
partners and the associated complex formation.   
LRRK2 association with HDAC5 suggested a potential role for LRRK2 in 
HDAC5 mediated transcriptional regulation of PGC1α and UCP4 in SHSY5Y cells. 
Increased association between G2019S LRRK2 and HDAC5 could potentially account 
for increased PGC1α and UCP4 mRNA in SHSY5Y cells. Although LRRK2 kinase 
inhibition did not influence the HDAC5 association, UCP4 expression was reduced in 
G2019S expressing SHSY5Y cells suggesting UCP4 transcription was altered while the 
LRRK2 HDAC5 association was still intact. An additional level of HDAC5 regulation 
could involve post translational modification [384] as has been previously described 
for NFAT and DLP1 proteins [389, 390]. Although DLP1 phosphorylation was 
comparable for HeLa cells transfected with wild type and G2019S LRRK2, specific 
phospho residues were not examined and site specific modification by G2019S 
LRRK2 cannot be ruled out. Furthermore, the contribution of LRRK2 GTPase activity 
could also contribute to the regulation of the HDAC5 interaction. 
6.9.1.5 LRRK2 GTPase mutations and mitochondrial function 
LRRK2 GTPase mutations have been described in North American, Basque, 
English and Italian cohorts with the clinical features and pathology resembling that 
of idiopathic and G2019S LRRK2 linked PD [28, 29, 391]. Similar to the LRRK2 G2019S 
mutation, transgenic mice expressing R1441C do not have a neurodegenerative or 
kidney phenotype [233, 240]. Studies investigating the interplay between the two 
enzymatic domains are inconsistent with some groups describing GTPase LRRK2 
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mutations to decrease LRRK2 kinase activity in HEK293 and neuro2A cells [203, 204] 
while studies carried out in HEK293 cells in two other studies suggest GTPase 
mutations have no effect on the kinase activity of the protein [201, 202]. GTPase and 
kinase mutations have been shown to increase LRRK2 affinity for GTP in HEK293 
cells [203], however kinase deficient LRRK2 has normal GTPase activity [204]. The 
effect of LRRK2 kinase inhibition on GTPase function has not besn studied. In 
addition the Serine 935 phosphorylation status of LRRK2 is reduced in GTPase but 
not LRRK2 G2019S mutants [215]. The enzymatic crosstalk between the kinase and 
GTPase domains as well as the pathological and clinical similarities associated with 
GTPase and kinse LRRK2 mutant proteins suggest the existence of converging 
pathways in the disease pathogenesis. 
Although over-expression of mutant kinase and GTPase LRRK2 proteins in 
SHSY5Y, HEK293 cells and rodent primary neurons is associated with increased 
toxicity [222] [203, 227, 260], functional studies have often struggled to identify a 
common converging phenotype; reduced complexity of dopaminergic midbrain 
neurons was described for G2019S but not R1441C transgenic mice [233], GTPase 
mutations enhanced filament formation and promoted association with 
microtubules in HEK293 cells, an effect not observed for LRRK2 G2019S [333], kinase 
but not GTPase mutations increased Tau phosphorylation [263]. These studies 
implicated the existence of pathways which are kinase independent but require 
LRRK2 GTPase activity and visa versa, questioning their contribution to the common 
PD pathology observed for the kinase and GTPase mutations.  
Mitochondrial fragmentation and the reduced mitochondrial membrane 
potential described [280, 281] was extended to the R1441C GTPase mutation 
suggesting mitochondrial function is affected by kinase and GTPase mutant LRRK2 
proteins. In addition, GTPase LRRK2 mutants showed increased affinity for the DLP1 
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protein at the mitochondrial membrane of SHSY5Y cells [280] suggesting the GTPase 
mutation can affect the affinity of complex formation in a similar manner to G2019S 
LRRK2. Mitochondrial uncoupling associated with G2019S LRRK2 and the increase in 
UCP4 mRNA expression was described as a LRRK2 kinase dependent mechanism 
based on in vitro kinase activity assays characterizing G2019S LRRK2 as a hyperactive 
kinase and the effects of LRRK2 kinase inhibitors on UCP4 levels in SHSY5Y cells. 
Whether LRRK2 GTPase activity contributes to the regulation of UCP expression was 
not investigated. However, the proposed mechanism of HDAC5 contribution to the 
regulation of PGC1α and UCP4 mRNA levels by LRRK2 demonstrated increased 
affinity of G2019S LRRK2 for HDAC5 suggesting a structural modulation of the 
complex, comparable to the effects of G2019S and R1441C on the DLP1 interaction. 
LRRK2 kinase inhibition did not seem to disrupt the LRRK2 HDAC5 association. As 
LRRK2 kinase deficient mutants retain GTPase activity [204]  GTPase function may be 
sufficient to maintain the interaction. As the PD associated GTPase R1441C mutation 
has been shown to contribute to mitochondrial abnormalities in cell models of PD, 
the effects of GTPase mutants on the regulation of the UCP4 transcription, PGC1α 
expression and HDAC5 association warrants further investigation. 
6.9.2 LRRK2 regulation of DJ1  
Mitochondrial uncoupling is believed to mediate the pacemaker activity of 
SNpc dopaminergic neurons while the loss of the PD associated DJ1 protein results 
in the dysregulation of pacemaking in mouse SNpc [168]. The proposed mechanism 
of regulation of the pacemaker activity was shown to involve UCP4 and 5. The level 
of these isoforms correlated with oscillations in the mitochondrial membrane 
potential. UCP4 and 5 levels were reduced in DJ1 knockout mice while the oscillatory 
activity of pacemaking was inhibited in these animals. As LRRK2 was shown to 
increase UCP2 and 4 in fibroblasts and SHSY5Y cells, it was possible to speculate that 
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LRRK2 regulated UCP mRNA through a genetic interaction with DJ1 potentially 
contributing to the regulation of pacemaking in SNpc. In addition to UCP mRNA 
regulation, DJ1 has also been shown to be involved in PGC1α mediated transcription 
by binding to upstream regulatory elements of PGC1α target genes [145] in line with 
PGC1α involvement in UCP4 regulation in G2019S LRRK2 SHSY5Y cells. Similar to the 
UCP transcriptional changes in G2019S expressing SHSY5Y cells, UCP gene regulation 
by DJ1 appeared specific as SOD2 and catalase expression was unperturbed in the 
SNpc of DJ1 knockout mice, [168], further implicating LRRK2, DJ1 and PGC1α in a 
common regulatory pathway involving UCP transcription. 
To investigate whether the regulation of UCP4 expression in SHSY5Y cells 
was mediated by DJ1, DJ1 knockdown cell lines were studied. Genetic knockdown of 
DJ1 in SHSY5Y cells did not affect UCP4 or 5 expression in contrast to what has 
previously been described for SNpc of DJ1 knockout animals [168] suggesting LRRK2 
regulation of UCP4 in SHSY5Y cells is unlikely to be DJ1 dependent. As the functional 
role of UCP4 and 5 was assigned to the regulation of the pacemaker activity in SNpc 
neurons, the absence of pacemaking in SHSY5Y cells could eliminate the need for 
this regulatory process. In support of this UCP4 and 5 expression in the neighbouring 
ventral tegmental neurons lacking intrinsic pacemaker function was not affected by 
the loss of DJ1 in mice [168].  
UCP3 levels were reduced by 50 % in both lines of DJ1 knockdown SHSY5Y 
cells suggesting a potential regulatory role of DJ1 for this UCP isoform in the 
neuroblastoma cells. UCP3 specific regulation implies a specific functional response 
as has previously been described for UCP3 expression in cardiac muscle cells 
mediating contractile responses and adipose tissue regulating body mass [359, 392]. 
As the G2019S mutation was associated with changes in UCP4 expression, we did 
not pursue with UCP transcriptional rescue experiments involving DJ1 and LRRK2 in 
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the SHSY5Y cells. However, a converging pathway of UCP mRNA regulation by LRRK2 
and DJ1 in SNpc neurons should not be ruled out and warrant further investigation.  
6.9.3 LRRK2 regulation of NFκB  
As well as transcriptional regulation of UCP mRNA through the PGC1α 
pathway, UCP mRNA expression has been demonstrated to be regulated through 
activation of the NFκB pathway. NFκB mediated UCP4 regulation has been shown in 
SHSY5Y cells in response to oxidative stress [357] suggesting UCP levels can be 
mediated by NFκB. In support of this an NFκB response element has been described 
on the UCP gene [357]. NFκB activation of UCP4 transcription in SHSY5Y cells occurs 
in parallel with SOD2 [393, 394] as a mechanism to protect against increased levels 
of cellular ROS [357, 393, 394]. LRRK2 has been demonstrated to regulate NFκB 
mediated transcription; over-expression of LRRK2 in HEK293 cells increased NFκB 
dependent transcription [243], shRNA knockdown of LRRK2 reduced NFκB mediated 
transcription [395] while wild type, and G2019S LRRK2 equally enhanced NFκB 
mediated transcription [395]. Although NFκB regulation of UCP4 was not 
investigated in SHSY5Y cells, SOD2 levels between control, wild type and G2019S 
LRRK2 over-expressing cells were similar suggesting NFκB mediated regulation was 
not involved. However UCP4 gene regulation by NFκB independent of SOD2 cannot 
be ruled out.  
6.9.4 UCP4 knockdown and LRRK2 regulation of Argonate 2 
In an attempt to reduce UCP4 levels in SHSY5Y, UCP4 siRNA knockdown was 
carried out. UCP4 knockdown has previously been linked to perturbations in calcium 
homeostasis in SHSY5Y cells [363] suggesting reduced UCP4 levels can affect the 
coupling state of mitochondria, in line with what was reported in SHSY5Y cells 
treated with LRRK2 siRNA. A similar efficiency of UCP4 siRNA knockdown (60%) in 
SHSY5Y cells was described here correlating with an increase in TMRM intensity 
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suggesting a potential link between UCP4 mRNA expression and the mitochondrial 
membrane potential. UCP4 protein levels were not evaluated in either study due to 
the lack of effective antibodies. Although the stability of the UCP4 protein has not 
been investigated, the UCP2 and 3 homologues have been reported to have a short 
half life of 1-4 hours [354, 396, 397] suggesting short term silencing protocols reduce 
UCP protein and affect cellular functions mediated by UCP levels. In support of this, 
a 55 % reduction in UCP2 mRNA in islet cells correlated with a 25 % decrease in 
mitochondrial membrane potential, 30 % reduction in respiration rates and a 20 % 
increase in ATP levels [372] suggesting small changes in UCP mRNA expression can 
have pronounced effects on respiratory chain function.  
The G2019S mutation has previously been shown to impact on LRRK2 
regulation of the Ago2 containing RNA-induced silencing complex (RISC) mediating 
microRNA regulation of mRNA translation [273]. As this complex is also required for 
the siRNA interaction with its target genes it is possible to speculate that the 
efficiency of knockdown in the LRRK2 over-expressing cells is affected by LRRK2 
involvement in the transcriptional regulation pathway. Similar LRRK2 siRNA 
conditions resulted in a knockdown of lower efficiency in wild type (40 %) and 
G2019S (25 %) LRRK2 over-expressing SHSY5Y cells. siRNA knockdown efficiencies in 
G2019S LRRK2 cell culture models have not previously been described and warrant 
further investigation. LRRK2 association with the Ago2/RISC complex and the 
proposed effects of G2019S on microRNA regulation could also potentially be 
involved in microRNA mediated regulation of UCP mRNA levels. In support of this, 
microRNA regulation of UCP2 mRNA expression has been described in cardiac and 
skeletal muscle required for muscle development [398]. However, the influence of 
this pathway on UCP expression in fibroblasts and SHSY5Y cells was not investigated. 
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6.9.5 LRRK2 regulation of UCP phosphorylation 
As well as regulation through transcription, UCP activity can be regulated at 
the protein level; increased mitochondrial uncoupling has correlated with increased 
phosphorylation of UCP1 in brown adipose tissues of cold acclimatised animals [159] 
while glutathionylation of cysteine residues in UCP2 and 3 has been shown to 
regulate mitochondrial respiration in thymocytes [399]. Although phosphorylation 
mediated regulation has been described for the UCP1 isoform, the serine residue is 
conserved among the family members [159] suggesting other UCP isoforms could 
potentially be regulated in a similar fashion. The kinase associated with UCP 
phosphorylation has not yet been described. LRRK2 has previously been shown to 
phosphorylate tau and 4E-BP functionally linked to mediating tubulin polymerization 
and induction of autophagy [231, 261]. Identification of LRRK2 in the mitochondrial 
enriched fraction of SHSY5Y cells suggested the protein could potentially mediate 
UCP activity by post translational regulation. To directly test LRRK2 phosphorylation 
of UCP2 in vitro kinase assays were carried out using recombinant proteins but failed 
to produce any detectable UCP2 phosphorylation. However, as UCP functional 
activity in vitro is enhanced by protein incorporation into liposomes [358, 400], it is 
also possible that the crude assay conditions presented in this study require 
modification. 
6.10 LRRK2 regulation of mitochondrial morphology 
Changes in mitochondrial bioenergetics associated with LRRK2 G2019S 
expression in fibroblasts and SHSY5Y cells have previously been shown to correlate 
with mitochondrial morphological changes; mitochondria in LRRK2 G2019S patient 
derived fibroblasts were described as elongated although no quantitative 
assessment was carried out in the study [285]. In contrast mitochondrial 
fragmentation was reported for primary neurons and SHSY5Y cells over-expressing 
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wild type and more so mutant LRRK2 [280, 281] where quantifications were limited 
to neuronal processes with no calibration for the methodology. Visually, 
mitochondria in cell bodies appeared un-fragmented when compared to stress 
induced fragmentation in a number of other studies [135, 401]. Mitochondrial 
fragmentation in the neuronal processes reported for LRRK2 mutants could 
potentially relate to the mutant effects on neurite length and branching [259] more 
so than the bioenergetic changes, an issue not addressed by either of the studies. 
Although bioenergetic alterations were reported for both G2019S mutant 
fibroblasts and SHSY5Y cells, mitochondrial uncoupling did not appear to perturb the 
mitochondrial morphology. Intact mitochondrial networks described in patient 
fibroblasts reported here and by Mortiboys et al suggest LRRK2 associated 
mitochondrial fragmentation could result from LRRK2 over-expression or be limited 
to neuronal models as fragmented structures were reported for both wild type and 
mutant LRRK2 over-expressing SHSY5Y cells and primary cultures [280, 281]. 
Although difficult to assess without a direct comparison, the level of ectopic 
expression of LRRK2 in the SHSY5Y model presented here may not be sufficient to 
fragment the network.  
In terms of a cell specific phenotype, comparable discrepancies have been 
reported for studies involving PINK1. Mitochondrial fragmentation was reported in 
fibroblasts derived from patients with familial PINK1 mutations, suggesting primary 
skin cells are capable of this phenomenon [119]. In contrast genetic ablation of 
PINK1 in Cos7 cells increased mitochondrial size through tubulation [402] while HeLa 
and SHSY5Y PINK1 knockdown models presented with fragmented mitochondria 
[119, 121]. Swollen mitochondria were described in human dopaminergic neurons 
and primary mouse neuronal cultures from PINK1 knockout animals [403]. Electron 
microscopy studies of recessive PD animal models revealed additional 
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inconsistencies where flies lacking PINK1 were reported to have swollen 
mitochondria with disrupted cristae [404, 405] while genetic ablation in mice 
produced only a mild mitochondrial phenotype with no obvious morphological 
defects. Condensed and aggregated mitochondrial structures were also observed in 
G2019S LRRK2 transgenic mice [233]. While Lin et al, reported mitochondria with 
denser mitochondrial cristae in their G2019S LRRK2 transgenic mouse [235]. Animal 
studies investigating mitochondrial morphology in PINK1 and LRRK2 PD associated 
mutant did not reflect fragmented structures observed in the SHSY5Y cell models 
[280, 281]. 
Although chemical uncouplers can induce mitochondrial fragmentation 
[406], there is no evidence to suggest mild mitochondrial uncoupling correlates with 
mitochondrial fragmentation. Uncoupled HtrA2 deficient mouse embryonic 
fibroblasts and HeLa cells treated with HtrA2 siRNA showed elongated mitochondria 
suggesting mitochondrial uncoupling in these cells correlated with mitochondrial 
fusion [407]. UCP2-GFP over-expression in SHSY5Y cells did not appear to impact on 
the mitochondrial morphology while mitochondrial uncoupling in G2019S expressing 
fibroblasts and SHSY5Y cells did not correlate with mitochondrial fragmentation. In 
addition to chemical uncouplers mitochondrial fragmentation can be induced by a 
variety of cellular stressors such as nitric oxide (NO), FeSo4, N-methy-D-aspartic acid 
(NMDA) agonists, extracellular β-amyloid aggregates [408] suggesting this process 
may be a general feature of stressed cells. In support of this a genetic screen in 
C.elegans showed that individual gene ablation of 80 % of all genes leads to 
mitochondrial fragmentation [409]. Hence mitochondrial fragmentation is unlikely 
to correlate with specific respiratory chain alterations or contribute to mitochondrial 
uncoupling observed in G2019S expressing fibroblasts and SHSY5Y cells. 
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The bioenergetic changes and mitochondrial fragmentation associated with 
mutant LRRK2 over-expression have been linked to increased cellular and 
mitochondrial DLP1 levels [280, 281]. DLP1 mediated fragmentation has also been 
described in the PINK1 and parkin PD models as well as for fragmented neuronal 
cells following treatment with rotenone [410] suggesting defects in mitophagy and 
Complex I inhibition can influence the fission/fusion machinery. The trigger for 
mitochondrial DLP1 recruitment in mitochondrial toxin studies has been proposed to 
be the defective electron transport chain. However, whether the mechanism is 
membrane potential dependent or requires an enzyme stimulus has not been 
addressed. A direct interaction between DLP1 and LRRK2 has been described [280, 
281]. This association was enhanced for the G2019S mutant LRRK2 suggesting 
mitochondrial LRRK2 could be the trigger for the DLP1 recruitment. A weak 
association was detected for G2019S LRRK2 immunoprecipitated from SHSY5Y cells 
absent for the wild type protein, potentially demonstrating enhanced mitochondrial 
DLP1 recruitment by the mitochondrial G2019S LRRK2 pool. However, mitochondrial 
LRRK2 and DLP1 abundance was comparable between control and G2019S 
expressing SHSY5Y cells, in contrast to previous observations, suggesting increased 
affinity for the G2019S LRRK2 DLP1 interaction which could take place in the cytosol, 
a point not addressed in any of the studies. Kinase inhibition did not appear to affect 
mitochondrial DLP1 recruitment further suggesting mitochondrial LRRK2 levels or 
kinase activity did not influence DLP1 translocation in SHSY5Y cells. Our data 
suggests that mitochondrial fragmentation and DLP1 levels are unlikely to contribute 
to the mitochondrial uncoupling described in G2019S expressing fibroblasts and 
SHSY5Y cells.  
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6.11 LRRK2, mitochondrial uncoupling and cellular disturbances implicated in PD 
6.11.1 ATP, mitochondrial biogenesis and calcium 
ATP depletion and bioenergetic insufficiency have been proposed to 
contribute to cellular dysfunction and the death of dopaminergic neurons in PD. 
Reduced ATP levels have been reported for PINK1 deficient mouse embryonic 
fibroblasts [411], fibroblasts from patients with parkin mutations [346] and α-
synuclein over-expression in HEK293 cells [412], correlating with respiratory chain 
defects. Reduced ATP levels were also described in the HtrA2 deficient mouse 
embryonic fibroblasts where mitochondrial uncoupling was described [413]. 
Reduced ATP levels have been described for G2019S expressing SHSY5Y cells [280] 
and G2019S LRRK2 mutant fibroblasts [285]. Consistent with these observations, a 
15 % reduction in basal ATP levels was reported for G2019S patient fibroblasts 
relative to control cells described in this study suggesting reduced ATP levels are a 
common feature of uncoupled cells and cells with respiratory chain defects, 
potentially explaining some of the over-lapping pathology and clinical features 
observed in genetically linked PD cases.  
UCP levels have been shown to correlate with changes in cellular ATP and 
mitochondrial biogenesis, a pathway associated with the recessively linked PD genes 
suggesting dysregulated mitochondrial biogenesis may play a role in PD. 
Downregulation of parkin correlated with reduced mitochondrial content [122] 
while parkin over-expression was linked to enhanced mitochondrial biogenesis 
[140]. Increased cellular ATP correlated with UCP1 expression in brown adipocytes 
[414] correlating with increased mitochondrial biogenesis [415] while reduced 
mitochondrial DNA content was linked to lower levels of UCP1 expression [416]. 
Increased UCP2 expression in muscle cells also enhanced mitochondrial biogenesis 
and increased the cellular ATP content [373]. However, other studies have identified 
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mitochondrial uncoupling independent of mitochondrial biogenesis in UCP over-
expressing systems; UCP2 over-expression resulted in mitochondrial uncoupling and 
reduced basal ATP levels in pancreatic β-cells [417]. ATP levels were reduced in 
skeletal muscle expressing high levels of UCP1 protein, relative to mice with lower 
UCP1 expression [418]. As mitochondrial mass, respiratory chain subunit and TFAM 
levels were comparable between control and G2019S LRRK2 expressing fibroblasts 
we ruled out the potential contribution of mitochondrial biogenesis to mitochondrial 
uncoupling in these cells. 
As well as UCP regulation of the mitochondrial membrane potential and ATP 
levels described in G2019S expressing fibroblasts and SHSY5Y cells, UCPs have a role 
in the regulation of cellular calcium homeostasis. Calcium dysregulation is a noted 
feature in PD; the loss of PINK1 protein has previously been shown to affect 
mitochondrial calcium handling resulting in a decreased threshold for calcium 
dependent cell death in primary neurons and neuroblastoma cells [172]. The 
influence of UCPs on the mitochondrial membrane potential has previously been 
related to their action as calcium uniporters, in line with the mechanism proposed to 
regulate SNpc pacemaking [168]. In support of this, UCP2 and UCP3 over-expression 
in human endothelial cells was associated with increased concentrations of free 
mitochondrial calcium [419]. LRRK2 influence on UCP mRNA expression in fibroblasts 
and SHSY5Y cells suggests that it is likely to play a role in the regulation of 
mitochondrial calcium homeostasis which in turn may contribute to PD 
pathogenesis. 
6.11.2 LRRK2 regulation of autophagy and mitophagy 
LRRK2 regulation of autophagy has been linked to the regulation of steady 
state levels of misfolded proteins such as α-synuclein with the deregulation of this 
pathway in G2019S expressing induced pluripotent dopaminergic stem cells 
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resulting in increased α-synuclein levels [420], potentially providing the link to the 
pathological Lewy bodies observed in PD. However the mechanism of LRRK2 
autophagic regulation is still under debate. Induced pluripotent stem cells generated 
from PD patients with LRRK2 G2019S mutations were compromised at the level of 
autophagic clearance [421] while autophagic flux was enhanced in G2019S patient 
fibroblasts [422]. An increase in autophagic vacuoles was observed in differentiated 
G2019S SHSY5Y cells [259] but whether these changes occurred as a result of 
increased autophagic activation or reduced autophagic clearance was not 
investigated. Tong et al, [240] reported a bi-phasic effect on autophagy in kidneys of 
knockout animals where autophagic flux was enhanced at 7 months and perturbed 
at 20 months suggesting age may contribute to the LRRK2 regulation of the 
autophagy pathway and account for some of the discrepancies observed in the 
experimental cell models. A number of studies emphasise unperturbed autophagic 
flux associated with G2019S [271] and LRRK2 siRNA knockdown in T lymphocytes 
and bone marrow derived macrophages [241]. The discrepancy may occur at the 
tissue or cell source as differentiated neuronal cells, proliferating fibroblasts and 
phagocytic immune cells have variable autophagic demands correlating with their 
respective functional roles [423, 424]. A recent study has demonstrated that UCP2 
over-expression in pancreatic adrenocarcinoma cells correlated with reduced 
autophagy suggesting a potential link between mitochondrial uncoupling and the 
autophagy cascade [425]. Whether these findings can be replicated in the SHSY5Y 
system and extend to the UCP4 isoform warrants further investigation. 
Although LRRK2 regulation of autophagy was not evaluated in G2019S 
fibroblasts and SHSY5Y cells, mitochondrial removal by mitophagy was explored in 
the context of LRRK2. Mitochondrial depolarization is thought to act as the trigger 
for PINK1 mediated Parkin recruitment and stimulate mitophagy [426]. As the 
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mitochondrial membrane potential was reduced in G2019S expressing fibroblasts 
and SHSY5Y cells, it was possible to speculate that excessive mitophagy may occur in 
these cells. Although the process of mitochondrial turnover was not directly 
evaluated, mitochondrial content and levels of respiratory chain subunits were 
comparable between control and G2019S LRRK2 fibroblasts suggesting mitochondria 
were not depleted. The levels of mitochondrial transcription factor, SOD2 and 
catalase, genes that are part of the mitochondrial biosynthetic pathway were 
comparable between control, wild type and G2019S expressing SHSY5Y cells 
suggesting mitochondrial biosynthesis was not taking place. As mitochondrial 
synthesis and number were comparable between control and G2019S cells, 
excessive mitochondrial removal is unlikely to contribute to the mitochondrial 
uncoupling observed in mutant fibroblasts and SHSY5Y cells. 
6.11.3 LRRK2 regulation of synaptic function and tubulin dynamics 
As well as mitochondrial morphology and autophagy, LRRK2 has been 
implicated in the regulation of synaptic function [254, 255] and tubulin dynamics 
[262, 427]. Mitochondria play a central role in meeting the demands of synapses for 
ATP and regulating calcium homeostasis which in turn controls synaptic vesicle 
endocytosis. UCP4 has previously been demonstrated to regulate calcium 
homeostasis at synapses [428]. siRNA knockdown of LRRK2 in SHSY5Y correlated 
with a 50 % reduction of UCP4 levels while LRRK2 silencing in presynaptic primary 
cortical mouse neurons reduced synaptic transmission [254] and enhanced synaptic 
vesicle recycling [255], both calcium dependent mechanisms [429, 430]. Over-
expression of wild type LRRK2 impaired synaptic vesicle recycling in primary rat 
hippocampal neurons, while the effect was more pronounced for the G2019S 
mutant protein. The 5 fold increase in UCP4 mRNA in G2019S expressing SHSY5Y 
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cells is likely to result in reduced cytosolic calcium concentrations [419], which could 
potentially account for the impaired vesicle recycling at the synapse [430]. 
Mitochondrial trafficking to and from the synapse requires the interaction 
between glycogen synthase kinase 3β (GSK3β) and the Tau protein, forming 
microtubules [431]. The speed of this process is dependent on GSK3β levels and the 
subsequent phosphorylation of its Tau substrate [431]. Microtubule destabilization 
correlates with reduced mitochondrial membrane potential and visa versa [432]. 
Hence UCP4 over-expression and the reduced mitochondrial membrane potential in 
G2019S expressing SHSY5Y cells could impact on the mitochondrial association with 
tubulin. In addition, the cellular and mitochondrial G2019S LRRK2 pools could 
directly affect the phosphorylation status of tubulin which would in turn result in 
reduced affinity of tubulin for mitochondria. In support of this LRRK2 has been 
implicated in the regulation of microtubule assembly in mouse brain [262] with 
interactions between LRRK2 and tubulin reported in mouse brain and HEK293 cells 
[262]. Microtubule destabilization results in reduced mitochondrial trafficking to 
synaptic terminals [433] reflecting how functional changes in the mitochondria could 
affect mitochondrial delivery to the synapse and alter synaptic function in G2019S 
expressing neuronal systems. In support of this, reduced mitochondrial numbers 
have been noted in neuronal processes of G2019S expressing primary cortical 
cultures and SHSY5Y cells [280, 281].  
6.12 Mitochondrial uncoupling proteins and disease 
Mitochondrial uncoupling has been associated with the loss of function of 
the PD linked HtrA2 protein. Mouse embryonic fibroblasts generated from HtrA2 
knockout animals had greater basal and oligomycin inhibited respiration rates 
relative to their respective wild type counterparts [413] consistent with the 
observations in G2019S LRRK2 expressing fibroblasts. The study reporting 
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mitochondrial uncoupling in HtrA2 knockout animals investigated the involvement 
of UCP2 protein. Although the data was not shown, the authors claimed no changes 
in UCP2 levels. The involvement of other UCP isoforms was not described hence the 
involvement of these UCP family members in the regulation of HtrA2 knockout 
mitochondrial phenotype cannot be ruled out. Alternative mechanisms for HtrA2 
mediated mitochondrial uncoupling were not investigated. Although mitochondrial 
uncoupling in disease is not common, increased respiration has also been described 
for Luft’s disease. Although the etiology of the disorder is unknown the muscle 
atrophy associated with the disease has been linked to hypermetabolism and 
mitochondrial uncoupling in skeletal muscle [434, 435], potentially involving the 
UCPs. HtrA2 linked PD and Luft’s disease emphasise the correlation between 
mitochondrial uncoupling, neurodegeneration and skeletal pathology. In addition, 
the genetic link between DJ1, recessively inherited PD and the UCP mediated 
regulation of pacemaking activity specifically in the SNpc where cell death is 
observed in PD patients further implicated the potential role of mitochondrial 
uncoupling and UCPs in PD pathogenesis [168]. In support of this, pacemaker activity 
involves the action of voltage dependent L type calcium channel with inhibitors 
targeting this channel demonstrated to have a protective effect against PD in a 
Danish cohort [436].  
Mechanistically, mitochondrial uncoupling proteins have previously been 
implicated in Parkinson’s disease as a protective mechanism against ROS [437-439]. 
Their protective effects have also been demonstrated on a background of 
respiratory chain dysfunction models but the effects of chronic UCP upregulation 
have not been investigated. In addition to protection from disease associated ROS, 
UCP have been proposed to play a general role in ageing; over-expression of UCP5 in 
Drosophila [440] correlated with increased lifespan, while UCP2 levels regulate 
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lifespan in mice [355]. However, the protective role of chronic UCP expression and 
activation correlating with increased lifespan has been challenged. UCP activation by 
fatty acids in fibroblasts was associated with premature senescence [441], as 
assessed by β-galactosidase staining. Over-expression of UCP2 in COS7 cells had no 
effect on lifespan but seemed to correlate with induction of apoptosis [167]. In 
addition, although transient transfections of UCPs are well tolerated, prolonged 
over-expression has been shown to result in death of HeLa, endothelial and 
fibroblast cell lines [166]. The potential link of mitochondrial uncoupling and cell 
death in PD has also been demonstrated by chronic exposure to low concentrations 
of FCCP correlating with reduced lifespan in cell culture models as a result of 
premature senescence [441]. Hepatic cells exposed to another uncoupler, 
dinitrophenol retarded proliferation [442]. Although LRRK2 G2019S expression has 
previously correlated with apoptotic induction [227, 286] senescence and cell death 
were not observed in G2019S fibroblasts and SHSY5Y cells described here, however 
compromised cell viability cannot be ruled out.  
6.13 Endogenous LRRK2 regulation of UCPs 
The G2019S mutation can either lead to a novel function or hyperactivate a 
pathway regulated by wild type LRRK2. Two studies support the latter hypothesis; 
siRNA knockdown of endogenous LRRK2 increased autophagic activity in HEK293 
cells while expression of a BAC G2019S construct impaired autophagy [257] 
suggesting this process is mediated by endogenous LRRK2 and dysregulated in the 
presence of the mutant protein. The effects of wild type BAC LRRK2 expression were 
not addressed. Ago2 mediated regulation of microRNA in Drosophila melanogaster 
appeared to involve endogenous LRRK2 as siRNA knockdown of LRRK2 correlated 
with reduced levels of dominant-negative dsRNA dependent protein kinase (DP1) 
and eukaryotic translation initiation factor 2 alpha (EIF2α) proteins, the steady state 
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levels of which are regulated in a microRNA mediated fashion [273]. While wild type 
LRRK2 over-expression in Drosophila melanogaster did not appear to grossly affect 
DP1 or EIF2α levels, G2019S LRRK2 expression increased the levels of both of these 
microRNA regulated proteins.  
In support of these findings G2019S over-expression in SHSY5Y cells led to 
mitochondrial uncoupling correlating with increased UCP4 levels. siRNA knockdown 
of LRRK2 was associated with increased mitochondrial membrane potential and 
reduced UCP4 expression suggesting endogenous LRRK2 in SHSY5Y cells may be 
required for UCP4 transcriptional regulation. In line with the report by Gehrke et al, 
wild type LRRK2 over-expression did not appear to impact on respiratory chain 
function or UCP levels. If both mechanisms are dependent on the levels of the 
associated LRRK2 substrate, increased levels of wild type protein would not affect 
downstream signalling, reduced LRRK2 levels would reduce the LRRK2 substrate 
interaction and downstream signalling while G2019S would compete with 
endogenous LRRK2 for the substrate and the effects of increased LRRK2 kinase 
activity could be implemented. This model is supported by LRRK2 kinase inhibitor 
effects in control SHSY5Y cells where a mild effect on UCP2, 4 and 5 mRNA 
expression was observed. UCP levels were unperturbed in wild type over-expressing 
cells (kinase inhibition was not 100 % effective suggesting some active LRRK2 
remained in the cells) while UCP4 levels in G2019S expressing cells were partially 
restored. Therefore the G2019S mutation is likely to perturb LRRK2 regulation of 
UCPs and impact on different aspects of cellular function, the cumulative effect of 
these disturbances could contribute to PD pathogenesis. 
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